0001493152-21-014308.txt : 20210614 0001493152-21-014308.hdr.sgml : 20210614 20210614160152 ACCESSION NUMBER: 0001493152-21-014308 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20210430 FILED AS OF DATE: 20210614 DATE AS OF CHANGE: 20210614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advaxis, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 211014578 BUSINESS ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2021

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 001-36138

ADVAXIS, INC.

(Exact name of registrant as specified in its charter)

Delaware		02-0563870
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ		08852
(Address of principal executive offices)		(Zip Code)

(609) 452-9813

(Registrant’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ADXS	Nasdaq Capital Market
Preferred Share Purchase Rights	-	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has fled all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	[ ]	Accelerated Filer	[ ]
Non-accelerated Filer	[X]	Smaller Reporting Company	[X]
Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The number of shares of the registrant’s Common Stock, $0.001 par value, outstanding as of June 7, 2021 was 145,638,459.

TABLE OF CONTENTS

		Page No.

PART I	FINANCIAL INFORMATION	5

Item 1.	Financial Statements (unaudited)	5

	Condensed Balance Sheets	5

	Condensed Statements of Operations	6

	Condensed Statements of Cash Flows	7

	Notes to the Condensed Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	25

PART II	OTHER INFORMATION	26

Item 1.	Legal Proceedings	26

Item 1A.	Risk Factors	26

Item 6.	Exhibits	26

SIGNATURES		27

CAUTIONARY NOTE REGARDING FORWARD LOOKING-STATEMENTS

This quarterly report on Form 10-Q (“Form 10-Q”) of Advaxis, Inc. (the “Company”) includes statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by the use of such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or the negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drug candidates, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, our available cash, liquidity, prospects, growth and strategies, impacts of the ongoing coronavirus (COVID-19) pandemic, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect our industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to the occurrence and timing of events or circumstances, many of which are beyond the control of the Company As a result of these, we cannot assure you that the forward-looking statements in this Form 10-Q will prove to be accurate. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent with the forward-looking statements contained in this Form 10-Q, they may not be predictive of results or developments in future periods.

Some of the material factors that we believe could cause actual results to differ from those anticipated or predicted include:

	●	the success and timing of our clinical trials, including patient accrual;

	●	our ability to obtain and maintain regulatory approval or reimbursement of our product candidates for marketing;

	●	our ability to obtain the appropriate labeling of our products under any regulatory approval;

	●	our ability to develop and commercialize our products;

	●	potential effects of the COVID-19 pandemic on our business, financial condition, liquidity and results of operations, and our ability to continue operations in the same manner as previously conducted prior to the macroeconomic effects of the COVID-19 pandemic;

	●	the successful development and implementation of our sales and marketing campaigns;

	●	the change of key scientific or management personnel;

	●	the size and growth of the potential markets for our product candidates and our ability to serve those markets;

	●	our ability to successfully compete in the potential markets for our product candidates, if commercialized;

	●	regulatory developments in the United States and other countries;

	●	the rate and degree of market acceptance of any of our product candidates;

	●	new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements;

	●	market conditions in the pharmaceutical and biotechnology sectors;

	●	our available cash;

	●	the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;

	●	our ability to obtain additional funding;

	●	our ability to obtain and maintain intellectual property protection for our product candidates;

	●	the success and timing of our preclinical studies, including IND enabling studies;

	●	the ability of our product candidates to successfully perform in clinical trials and to resolve any clinical holds that may occur;

	●	our ability to obtain and maintain approval of our product candidates for trial initiation;

	●	our ability to manufacture and the performance of third-party manufacturers;

	●	our ability to identify license and collaboration partners and to maintain existing relationships;

	●	the performance of our clinical research organizations, clinical trial sponsors, clinical trial investigators and collaboration partners for any clinical trials we conduct;

	●	any outcomes from our review of strategic transactions;

	●	our ability to successfully implement our strategy; and

	●	the factors described in the “Risk Factors” section of the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2020 (the “2020 Annual Report on Form 10-K”), as updated and amended in other filings by the Company with the Securities and Exchange Commission (the “SEC”).

You should also read carefully the factors described in the “Risk Factors” section of the 2020 Annual Report on Form 10-K. Any forward-looking statements that we make in this Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 10-Q except as required by the federal securities laws.

This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ADVAXIS, INC.

CONDENSED BALANCE SHEETS

(In thousands, except share and per share data)

	April 30, 2021 (Unaudited)			October 31, 2020
ASSETS
Current Assets:
Cash and cash equivalents	$	48,110		$	25,178
Deferred expenses		1,333			1,808
Accounts receivable		1,375			-
Prepaid expenses and other current assets		1,295			865
Total current assets		52,113			27,851

Property and equipment (net of accumulated depreciation)		333			2,393
Intangible assets (net of accumulated amortization)		3,325			3,261
Operating right-of-use asset (net of accumulated amortization)		-			4,839
Other assets		-			182
Total assets	$	55,771		$	38,526

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,156		$	410
Accrued expenses		2,133			1,737
Common stock warrant liability		4,931			17
Current portion of operating lease liability		-			962
Deferred revenue		-			165
Total current liabilities		8,220			3,291

Operating lease liability, net of current portion		-			5,055
Total liabilities		8,220			8,346

Commitments and contingencies – Note 9

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at April 30, 2021 and October 31, 2020; Liquidation preference of $0 at April 30, 2021 and October 31, 2020		-			-
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 and 78,074,023 shares issued and outstanding at April 30, 2021 and October 31, 2020, respectively		146			78
Additional paid-in capital		467,227			440,840
Accumulated deficit		(419,822	)		(410,738	)
Total stockholders’ equity		47,551			30,180
Total liabilities and stockholders’ equity	$	55,771		$	38,526

The accompanying notes should be read in conjunction with the financial statements.

ADVAXIS, INC.

CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except share and per share data)

	Three Months Ended April 30,						Six Months Ended April 30,
	2021			2020			2021			2020

Revenue	$	1,375		$	250		$	2,990		$	253

Operating expenses:
Research and development expenses		4,344			3,922			6,914			8,781
General and administrative expenses		3,352			2,649			6,360			5,679
Total operating expenses		7,696			6,571			13,274			14,460

Loss from operations		(6,321	)		(6,321	)		(10,284	)		(14,207	)

Other income (expense):
Interest income, net		2			35			3			101
Net changes in fair value of derivative liabilities		995			14			968			(23	)
Other income (expense)		217			(1	)		229			(1	)
Net loss before income taxes		(5,107	)		(6,273	)		(9,084	)		(14,130	)

Income tax expense		-			50			-			50

Net loss	$	(5,107	)	$	(6,323	)	$	(9,084	)	$	(14,180	)

Net loss per common share, basic and diluted	$	(0.04	)	$	(0.10	)	$	(0.08	)	$	(0.25	)

Weighted average number of common shares, basic and diluted		123,145,051			60,572,632			111,895,403			56,107,657

The accompanying notes should be read in conjunction with the financial statements.

ADVAXIS, INC.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

(In thousands)

	Six Months Ended April 30,
	2021			2020

OPERATING ACTIVITIES
Net loss	$	(9,084	)	$	(14,180	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation		451			452
Employee stock purchase plan expense		-			1
Loss (gain) on change in value of warrants		(968	)		23
Loss on disposal of property and equipment		1,530			-
Loss on write-down of intangible assets		69			-
Abandonment of intangible assets		-			603
Depreciation expense		316			457
Amortization expense of intangible assets		135			181
Amortization of right-of-use asset		327			365
Net gain on write off of right-of-use asset and lease liability		(1,116	)		-
Change in operating assets and liabilities:
Accounts receivable		(1,375	)		-
Prepaid expenses, other current assets and deferred expenses		45			235
Other assets		182			1
Accounts payable and accrued expenses		1,142			(1,161	)
Deferred revenue		(165	)		-
Operating lease liabilities		(389	)		(397	)
Net cash used in operating activities		(8,900	)		(13,420	)

INVESTING ACTIVITIES
Proceeds from disposal of property and equipment		214			-
Cost of intangible assets		(268	)		(358	)
Net cash used in investing activities		(54	)		(358	)

FINANCING ACTIVITIES
Net proceeds of issuance of common stock and warrants		28,115			9,628
Warrant exercises		3,771			-
Proceeds from employee stock purchase plan		-			4
Net cash provided by financing activities		31,886			9,632

Net increase in cash and cash equivalents		22,932			(4,146	)
Cash and cash equivalents at beginning of period		25,178			32,363
Cash and cash equivalents at end of period	$	48,110		$	28,217

SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes	$	-		$	50

SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Warrant liability reclassified into equity		-			2

The accompanying notes should be read in conjunction with the financial statements.

ADVAXIS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and
	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

Liquidity and Capital Resources

Liquidity and Management’s Plans

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

As of April 30, 2021, the Company had approximately $48.1 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least July 2022, the actual amount of cash that it will need to operate is subject to many factors. Over the past year, the Company has taken steps to obtain additional financing, including conducting sales of its common stock through its at-the-market (“ATM”) program through A.G.P./Alliance Global Partners, an equity line financing arrangement with Lincoln Park Capital and the completion of a registered direct offering and concurrent private placement with two healthcare-focused, institutional investors in April 2021, as further described below. The Company received aggregate proceeds of about $3.8 million during the six months ended April 30, 2021 upon the exercise of outstanding warrants, which were payable upon exercise.

On April 12, 2021, the Company entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock, (ii) 7,671,937 pre-funded warrants to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock ("Accompanying Warrants") in a registered direct offering (the “April 2021 Registered Direct Offering”). The Company also issued to the investors, in a concurrent private placement (the “April 2021 Private Placement” and together with the April 2021 Registered Direct Offering, the “April 2021 Offering”), unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock (the “Private Placement Warrants”).. The Company received gross proceeds of approximately $20 million, before deducting the fees and expenses payable by us in connection with the April 2021 Offering.

On November 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stock warrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”). On November 24, 2020, the underwriters notified us that they had exercised their option to purchase an additional 3,999,999 shares of common stock and 1,999,999 warrants in full. The Company received gross proceeds of approximately $9.2 million, before deducting the fees and expenses payable by us in connection with the November 2020 Offering. With these funds raised and a reduction in the operating expenses the Company believes that it has enough cash to fund its operations for one year from the date of filing.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-K/A filed on February 26, 2021.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.

	As of April 30,
	2021		2020
Warrants		30,225,397		5,398,226
Stock options		1,031,323		252,296
Restricted stock units		-		5,818
Total		31,256,720		5,946,322

Sequencing Policy

The Company adopted a sequencing policy under ASC 815-40-35, if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. Certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

Leases

At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. In accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases “ASC 842”), The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

3. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

	April 30, 2021			October 31, 2020

Leasehold improvements	$	-		$	2,335
Laboratory equipment		413			1,218
Furniture and fixtures		-			744
Computer equipment		409			409
Construction in progress		-			19
Total property and equipment		822			4,725
Accumulated depreciation and amortization		(489	)		(2,332	)
Net property and equipment	$	333		$	2,393

Depreciation expense for the three months ended April 30, 2021 and 2020 was $0.1 million and $0.2 million, respectively. Depreciation expense for the six months ended April 30, 2021 and 2020 was $0.3 million and $0.5 million, respectively. During the three months ended April 30, 2021, the Company incurred a loss on disposal of equipment of $1.5 million, $0.97 million of which is reflected in the research and development expenses and $0.53 million of which is reflected in the general and administrative expenses in the statement of operations.

4. INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

	April 30, 2021			October 31, 2020

Patents	$	4,674		$	4,479
Licenses		777			777
Software		117			117
Total intangibles		5,568			5,373
Accumulated amortization		(2,243	)		(2,112	)
Intangible assets	$	3,325		$	3,261

The expiration dates of the existing patents range from 2021 to 2040 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of $0.1 million and $0.4 million were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended April 30, 2021 and 2020, respectively. Patent applications having a net book value of $0.1 million and $0.6 million were abandoned and were charged to general and administrative expenses in the statement of operations for the six months ended April 30, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $0.1 million for each of the three months ended April 30, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.1 and $0.2 million for each of the six months ended April 30, 2021 and 2020, respectively.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2021 (Remaining)	$	136
2022		273
2023		273
2024		273
2025		273
Thereafter		2,097
Total	$	3,325

5. ACCRUED EXPENSES:

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):

	April 30, 2021		October 31, 2020

Salaries and other compensation	$	445	$	737
Vendors		1,357		671
Professional fees		331		329
Total accrued expenses	$	2,133	$	1,737

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of April 30, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 and 16,220,195 shares, respectively, of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.30		70,297	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		4,578,400	November 2025	November 2020 Public Offering
$	0.70		11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70		14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		30,225,397

As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data):

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		48,254,606			0.48		5.00
Exercised		(18,427,435	)		0.20
Outstanding and exercisable warrants at April 30, 2021		30,225,397		$	0.67		4.89	$	809,752

As of April 30, 2021, the Company had 18,910,965 of its total 30,225,397 outstanding warrants classified as equity (equity warrants). At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the condensed balance sheets.

Warrant Liability

As of April 30, 2021, the Company had 11,314,432 of its total 30,225,397 outstanding warrants from April 2021 Private Placement Offering and September 2018 Public Offering classified as liabilities (liability warrants). At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants).

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is fourteen (14) days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As a result, liability classification is warranted. For these liability warrants, the Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at April 30, 2021 and April 14, 2021 (issuance date), the Company used the following inputs in its Black Scholes model:

	April 30, 2021			April 14, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.49		$	0.57
Expected Term		5.00 years			5.00 years
Volatility %		106	%		106	%
Risk Free Rate		0.86	%		0.85	%

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of April 30, 2021, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.30. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	April 30, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.49		$	0.34
Expected Term		3.37 years			3.87 years
Volatility %		120	%		106	%
Risk Free Rate		0.35	%		0.29	%

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):

	Three Months Ended April 30,				Six Months Ended April 30,
		2021		2020		2021		2020
Research and development	$	56	$	62	$	113	$	153
General and administrative		159		148		338		299
Total	$	215	$	210	$	451	$	452

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows:

	Number of RSUs			Weighted-Average Grant Date Fair Value

Balance at October 31, 2020		5,556		$	24.32
Vested		(5,555	)
Cancelled		(1	)
Balance at April 30, 2021		-		$	-

As of April 30, 2021, there was no unrecognized compensation cost related to non-vested RSUs.

Employee Stock Awards

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 5,561 shares during the three months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the three months ended April 30, 2021 and 2020 was approximately $30,000 and $40,000, respectively.

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 8,608 shares during the six months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the six months ended April 30, 2021 and 2020 was approximately $0.1 million and $0.1 million, respectively.

Stock Options

A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Exercised		(333	)		0.30
Cancelled or expired		(30,112	)		10.57
Outstanding as of April 30, 2021		1,031,323		$	32.51		7.62	$	28
Vested and exercisable at April 30, 2021		352,747		$	93.53		4.87	$	8

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	.30-$10.00		777.385		8.95	$	1.04		100,404		8.27	$	3.02
$	10.01-$100.00		91,700		6.69	$	29.17		90,105		6.68	$	29.35
$	100.01-$200.00		92,847		2.26	$	166.04		92,847		2.26	$	166.04
$	200.01-$277.50		69,391		1.09	$	210.79		69,391		1.09	$	210.79

During the six months ended April 30, 2021, the Company granted options to purchase 50,000 shares of its common stock to an employee. The stock options have a ten-year term, vest over three years from the date of grant, and have an exercise price of $0.39.

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended April 30, 2021 and 2020 was approximately $0.2 million and $0.2 million, respectively. For the six months ended April 30, 2021 and 2020, compensation cost related to the Company’s outstanding stock options was approximately $0.4 million and $0.4 million, respectively

As of April 30, 2021, there was approximately $0.3 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.75 years.

As of April 30, 2021, the aggregate intrinsic value of vested and exercisable options was $8 thousand and the aggregate intrinsic value of non-vested options was approximately $28 thousand.

In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model:

	Six Months Ended April 30, 2021

Expected Term		6 years
Expected Volatility		103.27	%
Expected Dividends		0	%
Risk Free Interest Rate		0.53	%

Employee Stock Purchase Plan

During the six months ended April 30, 2021 and 2020, the Company issued 1,000 and 8,249 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

8. COLLABORATION AND LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

On April 26, 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans. The Company has a receivable due from OS Therapies of $1.375 million at April 30, 2021.

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

10. LEASES

Operating Leases

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $817,000. During the three months ended April 30, 2021, the Company wrote off of the remaining right-of-use asset of $4.5 million and lease liability of $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of $0.1 million.

On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one year term upon six months written notice to the landlord. This new lease is accounted for as a short-term lease and the Company has elected to not recognize the right-of-use asset and lease liability.

As a result of the termination of the Company's prior lease agreement pursuant to the Lease Termination and Surrender Agreement, the Company does not have an outstanding lease liability or operating right-of-use asset recorded as of April 30, 2021.

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended April 30, 2021		For the Six Months Ended April 30, 2021
Operating lease cost	General and administrative		1,011		1,301
Short-term lease cost	General and administrative		16		16
Variable lease cost	General and administrative	$	61		159
Total lease expense		$	1,088		1,476

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended April 30, 2020		For the Six Months Ended April 30, 2020
Operating lease cost	General and administrative		289		579
Short-term lease cost	General and administrative		85		169
Variable lease cost	General and administrative	$	129		270
Total lease expense		$	503		1,018

Supplemental cash flow information related to operating leases was as follows:

		For the Three Months Ended April 30, 2021				For the Six Months Ended April 30, 2021
Cash paid for operating lease liabilities		$	1,039				1,363

		For the Three Months Ended April 30, 2020				For the Six Months Ended April 30, 2020
Cash paid for operating lease liabilities		$	311				611

11. STOCKHOLDERS’ EQUITY

Public Offerings

On April 12, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors. The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 17,577,400 shares (the “Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”), at an offering price of $0.7921 per Share and 7,671,937 pre-funded warrants to certain purchasers whose purchase of additional Shares would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the Company’s outstanding Common Stock immediately following the consummation of the offering (the “Pre-Funded Warrants”). The Shares and Pre-Funded Warrants were sold together with warrants to purchase up to 11,244,135 shares of Common Stock (the “Accompanying Warrants” and together with the Shares and the Pre-Funded Warrants, the “Securities”). The Pre-Funded Warrants were sold for a purchase price of $0.7911 per share and have an exercise price of $0.001 per share. The Pre-Funded Warrants were immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Each Accompanying Warrant has an exercise price per share of $0.70, became exercisable immediately and will expire on the fifth anniversary of the original issuance date.

The Purchase Agreement also provided for a concurrent private placement (the “Private Placement”) of 14,005,202 warrants to purchase the Company’s Common Stock (the “Private Placement Warrants”) with the purchasers in the Registered Offering. The Private Placement Warrants will be exercisable for an aggregate of 14,005,202 shares of Common Stock at any time on or after such date, if ever, that is fourteen (14) days after the Company files an amendment (the “Authorized Shares Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares with the Delaware Secretary of State and on or prior to the date that is five years after such date. The Private Placement Warrants have an exercise price of $0.70 per share.

In March 2021, the Company sold 886,048 shares of its common stock via the at-the-market (“ATM”) program through A.G.P./Alliance Global Partners netting about $0.7 million in proceeds.

In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million.

During the six months ended April 30, 2021, warrant holders from the Company’s November 2020 offering exercised 10,754,932 warrants in exchange for 10,754,932 shares of the Company’s common stock and warrant holders from the Company’s April 2021 Offering exercised 7,671,937 pre-funded warrants in exchange for 7,671,937 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $3.8 million which were payable upon exercise.

A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2019		-	$	-		50,201,671	$	50	$	423,750	$	(384,269	)	$	39,531
Stock-based compensation		-		-		2,957		-		242		-			242
Advaxis public offerings, net of offering costs		-		-		10,000,000		10		9,618		-			9,628
Warrant exercises		-		-		26,416		-		2		-			2
Issuance of shares to employees under ESPP Plan		-		-		5,555		-		2		-			2
Net Loss		-		-		-		-		-		(7,857	)		(7,857	)
Balance at January 31, 2020		-	$	-		60,236,599	$	60	$	433,614	$	(392,126	)	$	41,548
Stock-based compensation		-		-		5,651		-		210		-			210
Warrant exercises		-		-		7,500		-		-		-			-
Issuance of shares to employees under ESPP Plan		-		-		2,694		-		2		-			2
Net Loss		-		-		-		-		-		(6,323	)		(6,323	)
Balance at April 30, 2020		-	$	-		60,252,444	$	60	$	433,826	$	(398,449	)	$	35,437

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575
Stock-based compensation		-		-		5,888		-		215		-			215
Advaxis public offerings, net of offering costs		-		-		18,463,448		19		13,664		-			13,683
Warrant exercises		-		-		11,037,435		11		1,174		-			1,185
Issuance of shares to employees under ESPP Plan		-		-		1,000		-		-		-			-
Net Loss		-		-		-		-		-		(5,107	)		(5,107	)
Balance at April 30, 2021		-	$	-		145,638,459	$	146	$	467,227	$	(419,822	)	$	47,551

12. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands):

April 30, 2021	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.30 through September 2024		-		-	$	29	$	29
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-	$	4,902	$	4,902
Total		-		-	$	4,931	$	4,931

October 31, 2020		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024			-				-			$	17			$	17

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):

	For the Six Months Ended April 30, 2021
Beginning balance	$	17
Warrants issued		5,882
Warrant exercises		-
Change in fair value		(968	)
Ending Balance	$	4,931

13. Subsequent Events

None.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results indicated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in Part I Item 1A. “Risk Factors” in our 2020 Annual Report on Form 10-K, below in Part II Item 1A. “Risk Factors” of this Form 10-Q. and in the “Cautionary Note Regarding Forward-Looking Statements” set forth at the beginning of this report.

You should read the following discussion and analysis in conjunction with the unaudited financial statements, and the related footnotes thereto, appearing elsewhere in this Form 10-Q, and in conjunction with management’s discussion and analysis and the audited financial statements included in our Annual Report on Form 10-K. In addition, we intend to use our media and investor relations website (www.advaxis.com/investor-relations), SEC filings, press releases, public conference calls and webcasts to communicate with the public about Advaxis, its services and other issues.

Overview

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment, or TME, to enable the T cells to attack tumor cells.

The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, our product candidates (i.e., ADXS-PSA and ADXS-503) have the potential to optimize checkpoint performance, while having a generally well-tolerated safety profile, and most of our product candidates have an expected low cost of goods. A new Investigator-Sponsored-Study with our FDA-approved IND is expected to start with ADXS-504-HOT construct in biochemically recurrent prostate cancer patients at a leading US Medical Institution in the first half of 2021.

Advaxis is currently winding down clinical studies of Lm Technology immunotherapies in three program areas:

	●	Human Papilloma Virus (“HPV”)-associated cancers
	●	Personalized neoantigen-directed therapies
	●	Human epidermal growth factor receptor-2 (HER-2) associated cancers

All these clinical program areas are anchored in the Company’s Lm Technology^TM, a unique platform designed for its ability to safely and effectively target various cancers in multiple ways. While we are currently winding down clinical studies of Lm Technology immunotherapies in these three program areas, our license agreements continue with OS Therapies, LLC for ADXS-HER2 and with Global BioPharma, or GBP, for the exclusive license for the development and commercialization of AXAL in Asia, Africa, and the former USSR territory, exclusive of India and certain other countries.

Recent Developments

On March 11, 2020, the World Health Organization declared the coronavirus (COVID-19) to be a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19. The pandemic has resulted in government-imposed quarantines, travel restrictions, business and school closures and other public health safety measures, many of which remain in effect to varying degrees. We continue to monitor the COVID-19 pandemic and take steps intended to mitigate the potential risks to our workforce and our operations. The COVID-19 pandemic has, and may continue to, directly or indirectly affect the pace of enrollment in our clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Nonetheless, thus far, the COVID-19 pandemic has not had a significant impact on our business or results of operations. However, we remain in contact with the clinical sites in our study and are in discussion with additional sites to combat any potential impact in enrollment. We are unable to determine or predict the extent, duration or scope of the overall impact of the COVID-19 pandemic on our business, operations, financial condition or liquidity.

Strategic Transactions

As a matter of course, we are reviewing strategic transactions and alternatives and there can be no assurance that we will be successful in identifying or completing any strategic transactions, that any such strategic transaction will result in additional value for our stockholders or that the process will not have an adverse impact on our business. These transactions could include, but are not limited to, collaboration agreements, co-development agreements, strategic mergers, reverse mergers, the issuance or buyback of public shares, or the purchase or sale of specific assets, in addition to other potential actions aimed at increasing stockholder value. There can be no assurance that the review of strategic transactions will result in the identification or consummation of any transaction. Our Board of Directors may also determine that our most effective strategy is to continue to effectuate our current business plan. Any potential transaction would be dependent upon a number of factors that may be beyond our control, including, but not limited to, market conditions, industry trends, the interest of third parties in our business and the availability of financing to potential buyers on reasonable terms. No decision has been made with respect to any transaction.

Results of Operations for the Three Months Ended April 30, 2021 and 2020

Revenue

Revenue increased by approximately $1.1 million to $1.4 million for the three months ended April 30, 2021 compared to $0.3 million for the three months ended April 30, 2020. In the current period, we recognized royalty payments from OST of $1.4 million.

Research and Development Expenses

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the three months ended April 30, 2021 and April 30, 2020 were categorized as follows (in thousands):

	Three Months Ended April 30,				Increase (Decrease)
	2021		2020		$			%

Hotspot/Off-the-Shelf therapies	$	786	$	909	$	(123	)		(14	)%
Prostate cancer		52		156		(104	)		(67	)%
HPV-associated cancers		914		789		125			16	%
Personalized neoantigen-directed therapies		260		558		(298	)		(53	)%
Other expenses		2,332		1,510		822			54	%
Total research & development expense	$	4,344	$	3,922	$	422			11	%
Stock-based compensation expense included in research and development expense	$	56	$	62	$	(6	)		(10	)%

General and Administrative Expenses

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the three months ended April 30, 2021 and April 30, 2020 were as follows (in thousands):

	Three Months Ended April 30,				Increase (Decrease)
	2021		2020		$		%

General and administrative expense	$	3,352	$	2,649	$	703		27	%

Stock-based compensation expense included in general and administrative expense	$	159	$	148	$	11		7	%

General and administrative expenses for the three months ended April 30, 2021 increased approximately $703 thousand, or 27%, compared to the same period in 2020. This increase primarily relates to increases in sublicense fees, amounts paid in settlement of a shareholder demand letter and losses on disposal of property and equipment in connection with the termination of our office lease at our former location.

Changes in Fair Values

For the three months ended April 30, 2021, we recorded non-cash income from changes in the fair value of the warrant liability of approximately $995 thousand. The decrease in the fair value of liability warrants resulted from this issuance of Private Placement Offering warrants during the three months ended April 30, 2021. The Private Placement Offering warrants had a decrease in fair value of approximately $980 thousand from date of issuance to April 30, 2021.

For the three months ended April 30, 2020, we recorded non-cash income from changes in the fair value of the warrant liability of approximately $14 thousand. The decrease in the fair value of liability warrants resulted from a decrease in our share price from $0.86 at January 31, 2020 to $0.67 at April 30, 2020.

Results of Operations for the Six Months Ended April 30, 2021 and 2020

Revenue

Revenue increased approximately $2.7 million for the six months ended April 30, 2021 compared to $0.3 million for the six months ended April 30, 2020. In the current period, we recognized royalty payments from OST.

Research and Development Expenses

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the six months ended April 30, 2021 and April 30, 2020 were categorized as follows (in thousands):

	Six Months Ended April 30,				Increase (Decrease)
	2021		2020		$			%

Hotspot/Off-the-Shelf therapies	$	1,986	$	1,462	$	524			36	%
Prostate cancer		95		534		(439	)		(82	)%
HPV-associated cancers		1,445		2,524		(1,079	)		(43	)%
Personalized neoantigen-directed therapies		392		908		(516	)		(57	)%
Other expenses		2,996		3,353		(357	)		(11	)%
Total research & development expense	$	6,914	$	8,781	$	(1,867	)		(21	)%
Stock-based compensation expense included in research and development expense	$	113	$	153	$	(40	)		(26	)%

General and Administrative Expenses

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the six months ended April 30, 2021 and April 30, 2020 were as follows (in thousands):

	Six Months Ended April 30,				Increase (Decrease)
	2021		2020		$		%

General and administrative expense	$	6,360	$	5,679	$	681		12	%

Stock-based compensation expense included in general and administrative expense	$	338	$	299	$	39		13	%

General and administrative expenses for the six months ended April 30, 2021 increased approximately $681 thousand, or 12%, compared to the same period in 2020. This increase primarily relates to increases in sublicense fees, amounts paid in settlement of a shareholder demand letter and losses on disposal of property and equipment in connection with the termination of our office lease at our former location.

Changes in Fair Values

For the six months ended April 30, 2021, we recorded non-cash income from changes in the fair value of the warrant liability of approximately $968 thousand. The decrease in the fair value of liability warrants resulted from this issuance of warrants in the April 2021 Private Placement during the three months ended April 30, 2021. The warrants issued in the April 2021 Private Placement had a decrease in fair value of approximately $980 thousand from date of issuance to April 30, 2021.

For the six months ended April 30, 2020, we recorded non-cash loss from changes in the fair value of the warrant liability of approximately $23 thousand. The increase in the fair value of liability warrants resulted from an increase in our share price from $0.32 at October 31, 2019 to $0.67 at April 30, 2020.

Liquidity and Capital Resources

Management’s Plans

Similar to other development stage biotechnology companies, our products that are being developed have not generated significant revenue. As a result, we have historically suffered recurring losses and we have required significant cash resources to execute our business plans. These losses are expected to continue for the foreseeable future.

Historically, the Company’s major sources of cash have comprised proceeds from various public and private offerings of its securities (including common stock), debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants, and interest income. From October 2013 through April 30, 2021, the Company raised approximately $338.5 million in gross proceeds ($29.1 million during the six months ended April 30, 2021) from various public and private offerings of our common stock. The Company has sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future. As of April 30, 2021 and October 31, 2020, the Company had an accumulated deficit of approximately $419.8 million and $410.7 million, respectively, and stockholders’ equity of approximately $47.6 million and $30.2 million, respectively.

The COVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption of financial markets. An extended period of economic disruption could negatively affect the Company’s business, financial condition, and access to sources of liquidity. As of April 30, 2021, the Company had approximately $48.1 million in cash and cash equivalents. The actual amount of cash that the Company will need to continue operating is subject to many factors. The Company based this estimate on assumptions that may prove to be wrong, and we could use available capital resources sooner than currently expected.

The Company recognizes that it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to it or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

On May 8, 2020, the Company entered into a sales agreement related to an at-the-market equity offering program pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners, as sales agent, for general corporate purposes.

On July 30, 2020, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Over the 36-month term of the purchase agreement, the Company has the right, but not the obligation, from time to time, in its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to an aggregate amount of $20,000,000 of its common stock, subject to certain limitations.

The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. The Company believes it has sufficient capital to fund its obligations, as they become due, in the ordinary course of business into the 3rd fiscal quarter of 2023. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.

Cash Flows

Operating Activities

Net cash used in operating activities includes reduced spending associated with our clinical trial programs and general and administrative activities. Net cash used in operating activities was approximately $8.9 million for the six months ended April 30, 2021 compared to $13.4 million for the six months ended April 30, 2020. The decrease was due to measures to control costs for non-essential items in areas that did not support our strategic direction, and as a result, we have continued to reduce non-strategic operating expenditures over the past several quarters.

Investing Activities

Net cash used in investing activities was approximately $0.1 million for the six months ended April 30, 2021 compared to $0.4 million for the six months ended April 30, 2020. The decrease is a result of proceeds on disposal of property and equipment and reduction in purchases for intangible assets.

Financing Activities

Net cash provided by financing activities was approximately $31.9 million for the six months ended April 30, 2021, as compared to $9.6 million for the six months ended April 30, 2020. On April 12, 2021, the Company completed an offering of (i) 17,577,400 shares of common stock, (ii) 7,671,937 pre-funded warrants to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock (the “Registered Direct Offering”) with two healthcare focused, institutional investors. The Company also issued to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock (the “Private Placement” and together with the Registered Direct Offering, the “April 2021 Offering”). We received gross proceeds of approximately $20 million, before deducting the fees and expenses payable by us in connection with the April 2021 Offering. On November 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stock warrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”).

On November 24, 2020, the underwriters notified us that they had exercised their option to purchase an additional 3,999,999 shares of common stock and 1,999,999 warrants in full. After giving effect to the full exercise of the underwriters’ option, we issued and sold an aggregate 30,666,665 shares of common stock and warrants to purchase up to 15,333,332 shares of common stock. We received gross proceeds of approximately $9.2 million, before deducting the underwriting discounts and commissions and fees and expenses payable by us in connection with the November 2020 Offering. In January 2020, we completed a public offering of 10,000,000 shares of our common stock, which resulted in net proceeds of approximately $9.7 million. In January 2020, we completed a public offering of 10,000,000 shares of our common stock, which resulted in net proceeds of approximately $9.7 million.

Off-Balance Sheet Arrangements

As of April 30, 2021, we had no off-balance sheet arrangements.

Critical Accounting Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

	●	it requires assumptions to be made that were uncertain at the time the estimate was made, and

	●	changes in the estimate or different estimates that could have been selected could have material impact in our results of operations or financial condition.

While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results could differ from those estimates and the differences could be material. The most significant estimates impact the following transactions or account balances: stock compensation, warrant liability valuation and impairment of intangibles.

See Note 2 to our condensed financial statements for a discussion of our significant accounting policies.

Recently Issued Accounting Standards Not Yet Effective or Adopted

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

At April 30, 2021, we had approximately $48.1 million in cash and cash equivalents, which consisted primarily of bank deposits and money market funds. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy and achieve our investment objectives. We typically invest in highly-rated securities, and our investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant.

We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our financial statements.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and interim principal financial officer of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“the Exchange Act”). Based upon this evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the quarter ended April 30, 2021, there were no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Limitations on Effectiveness of Controls

Our management, including our Principal Executive, Financial and Accounting Officers, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations. For more information regarding legal proceedings involving the Company, please see Note 9 – Commitments and Contingencies to our condensed financial statements.

Item 1A. Risk Factors

Our business and financial results are subject to numerous risks and uncertainties. As a result, the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our 2020 Form 10-K should be carefully considered. There has been no material change in this information. The risks described in the 2020 Annual Report on Form 10-K, and the information in the section of this Form 10-Q entitled “Cautionary Note Regarding Forward Looking Statements” are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business operations.

Item 6. Exhibits

Exhibit No.		Description

3.1		Second Amended and Restated By-Laws of Advaxis, Inc., incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 5, 2021.

4.1		For of Pre-Funded Warrant, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 12, 2021.

4.2		Form of Accompanying Warrant, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on April 12, 2021.

4.3		Form of Private Placement Warrant, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on April 12, 2021.

10.1		Lease Agreement, dated March 25, 2021, by and between the Company and Princeton Corporate Plaza, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 30, 2021.

10.2		Lease Termination and Surrender Agreement, dated March 26, 2021, by and between the Company and 300 CR LLC, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 30, 2021

10.3		Securities Purchase Agreement dated April 12, 2021, by and among Advaxis, Inc. and the purchasers identified on the signature pages thereto, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 12, 2021.

10.4		Form of Investor Agreement, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on April 12, 2021.

10.5		Amendment to the Advaxis, Inc. 2015 Incentive Plan, dated as of February 11, 2021, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 4, 2021.

31.1*		Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL INSTANCE DOCUMENT

101.SCH		XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

101.CAL		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

101.DEF		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

101.LAB		XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

101.PRE		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

* Filed herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Corporation has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 14, 2021

	ADVAXIS, INC.

	By:	/s/ Igor Gitelman
	Name:	Igor Gitelman
	Title:	Chief Accounting Officer, VP of Finance

	By:	/s/ Kenneth Berlin
	Name:	Kenneth Berlin
	Title:	President, Chief Executive Officer and Interim Chief Financial Officer

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18.U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

I, Kenneth Berlin, certify that:

1. I have reviewed this annual report on Form 10-Q for the quarter ended April 30, 2021 of Advaxis, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

June 14, 2021

By:	/s/ Kenneth Berlin
Name:	Kenneth Berlin
Title:	President & Chief Executive Officer

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18. U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

I, Kenneth Berlin, certify that:

1.	I have reviewed this annual report on Form 10-Q for the quarter ended April 30, 2021 of Advaxis, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

June 14, 2021

By:	/s/ Kenneth Berlin
Name:	Kenneth Berlin
Title:	President., Chief Executive Officer and Interim Chief Financial Officer

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended April 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Executive Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: June 14, 2021	By:	/s/ Kenneth Berlin
	Name:	Kenneth Berlin
	Title:	President., Chief Executive Officer and Interim Chief Financial Officer

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended April 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Financial Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: June 14, 2021

By:

/s/ Kenneth Berlin

Name:

Kenneth Berlin

Title:

President, Chief Executive Officer and Interim Chief

Financial Officer

EX-101.INS 6 adxs-20210430.xml XBRL INSTANCE FILE 0001100397 2020-11-01 2021-04-30 0001100397 2020-10-31 0001100397 2021-01-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2020-10-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2020-10-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2020-10-31 0001100397 srt:MinimumMember 2020-10-31 0001100397 srt:MaximumMember 2020-10-31 0001100397 ADXS:EquityWarrantsMember 2020-10-31 0001100397 ADXS:WarrantLiabilityMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2019-11-01 2020-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2019-11-01 2020-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2019-11-01 2020-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2020-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2020-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-10-31 0001100397 us-gaap:RestrictedStockUnitsRSUMember 2020-10-31 0001100397 us-gaap:IPOMember 2020-11-01 2020-11-30 0001100397 us-gaap:IPOMember 2020-11-30 0001100397 us-gaap:PrivatePlacementMember 2020-11-30 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-04-30 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-04-30 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-04-30 0001100397 2020-11-01 2020-11-30 0001100397 2019-11-01 2020-01-31 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2020-04-29 2020-04-30 0001100397 2020-01-31 0001100397 2021-06-07 0001100397 2019-10-31 0001100397 ADXS:OSTherapiesLLCMember ADXS:MileStoneSetForthInTheLicenseAgreementMember 2021-01-01 2021-01-31 0001100397 ADXS:OSTherapiesLLCMember ADXS:MileStoneSetForthInTheLicenseAgreementMember 2020-12-01 2020-12-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2019-10-31 0001100397 us-gaap:PreferredStockMember 2020-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2019-10-31 0001100397 us-gaap:CommonStockMember 2020-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2019-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-01-31 0001100397 us-gaap:PreferredStockMember 2019-11-01 2020-01-31 0001100397 us-gaap:CommonStockMember 2019-11-01 2020-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-01-31 0001100397 us-gaap:RetainedEarningsMember 2019-11-01 2020-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-04-30 0001100397 us-gaap:WarrantMember 2020-11-01 2021-04-30 0001100397 ADXS:StockOptionsMember 2020-11-01 2021-04-30 0001100397 ADXS:RestrictedStockUnitsMember 2020-11-01 2021-04-30 0001100397 srt:MinimumMember 2021-04-30 0001100397 srt:MaximumMember 2021-04-30 0001100397 ADXS:EquityWarrantsMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember srt:MaximumMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember srt:MinimumMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeOneMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-04-30 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-04-30 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-04-30 0001100397 ADXS:ExercisePriceRangeFourMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-04-30 0001100397 us-gaap:RestrictedStockUnitsRSUMember 2021-04-30 0001100397 us-gaap:RestrictedStockUnitsRSUMember 2020-11-01 2021-04-30 0001100397 ADXS:EmployeeStockAwardsMember 2020-11-01 2021-04-30 0001100397 ADXS:EmployeeStockAwardsMember 2019-11-01 2020-04-30 0001100397 ADXS:TwoThousandEighteenEmployeeStockPurchasePlanMember 2020-11-01 2021-04-30 0001100397 ADXS:TwoThousandEighteenEmployeeStockPurchasePlanMember 2019-11-01 2020-04-30 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-04-30 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-02-01 2020-04-30 0001100397 2021-04-30 0001100397 2019-11-01 2020-04-30 0001100397 2021-02-01 2021-04-30 0001100397 2020-02-01 2020-04-30 0001100397 2020-04-30 0001100397 2020-11-01 2021-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-04-30 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2019-11-01 2020-04-30 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-02-01 2020-04-30 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-02-01 2021-04-30 0001100397 us-gaap:WarrantMember 2019-11-01 2020-04-30 0001100397 ADXS:StockOptionsMember 2019-11-01 2020-04-30 0001100397 ADXS:RestrictedStockUnitsMember 2019-11-01 2020-04-30 0001100397 us-gaap:WarrantMember 2020-11-01 2021-04-30 0001100397 us-gaap:WarrantMember 2019-11-01 2020-04-30 0001100397 us-gaap:PrivatePlacementMember 2020-11-01 2021-04-30 0001100397 ADXS:DefinitiveAgreementsMember us-gaap:InvestorMember 2021-04-11 2021-04-12 0001100397 ADXS:DefinitiveAgreementsMember us-gaap:InvestorMember 2021-04-12 0001100397 ADXS:DefinitiveAgreementsMember 2021-04-12 0001100397 ADXS:DefinitiveAgreementsMember ADXS:AprilTwoThousandTwentyOneOfferingMember 2021-04-12 0001100397 ADXS:DefinitiveAgreementsMember ADXS:AprilTwoThousandTwentyOneOfferingMember 2021-04-11 2021-04-12 0001100397 us-gaap:IPOMember 2020-11-26 2020-11-27 0001100397 ADXS:NovemberTwoThousandTwentyofferingMember 2020-11-27 0001100397 ADXS:UnderwritersMember 2020-11-23 2020-11-24 0001100397 ADXS:NovemberTwoThousandTwentyofferingMember 2020-11-23 2020-11-24 0001100397 us-gaap:IPOMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeFiveMember 2020-11-01 2021-04-30 0001100397 ADXS:ExercisePriceRangeSixMember 2021-04-30 0001100397 ADXS:ExercisePriceRangeSixMember 2020-11-01 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember us-gaap:PrivatePlacementMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:PrivatePlacementMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:PrivatePlacementMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-04-14 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember us-gaap:PrivatePlacementMember 2021-04-14 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:PrivatePlacementMember 2021-04-14 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:PrivatePlacementMember 2021-04-14 0001100397 ADXS:EmployeeStockAwardsMember 2021-02-01 2021-04-30 0001100397 ADXS:EmployeeStockAwardsMember 2020-02-01 2020-04-30 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-02-01 2021-04-30 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2019-11-01 2020-04-30 0001100397 ADXS:SecondMileStoneLicenseAgreementMember ADXS:OSTherapiesMember 2021-04-30 0001100397 ADXS:NewLeaseAgreementMember 2021-03-24 2021-03-25 0001100397 ADXS:SecuritiesPurchaseAgreementsMember ADXS:PreFundedWarrantMember 2021-04-12 0001100397 us-gaap:IPOMember 2020-11-01 2021-04-30 0001100397 us-gaap:PreferredStockMember 2020-02-01 2020-04-30 0001100397 us-gaap:PreferredStockMember 2021-02-01 2021-04-30 0001100397 us-gaap:CommonStockMember 2020-02-01 2020-04-30 0001100397 us-gaap:CommonStockMember 2021-02-01 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2020-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-04-30 0001100397 us-gaap:RetainedEarningsMember 2020-02-01 2020-04-30 0001100397 us-gaap:RetainedEarningsMember 2021-02-01 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001100397 us-gaap:RetainedEarningsMember 2020-04-30 0001100397 us-gaap:PreferredStockMember 2020-04-30 0001100397 us-gaap:CommonStockMember 2020-04-30 0001100397 us-gaap:PreferredStockMember 2021-04-30 0001100397 us-gaap:CommonStockMember 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001100397 us-gaap:RetainedEarningsMember 2021-04-30 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughAprilTwoThousandTwentySixMember 2021-04-30 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughAprilTwoThousandTwentySixMember 2021-04-30 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughAprilTwoThousandTwentySixMember 2021-04-30 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-04-30 0001100397 ADXS:ThroughFiveYearsMember 2021-04-30 0001100397 ADXS:WarrantLiabilityMember 2020-11-01 2021-04-30 0001100397 us-gaap:FairValueInputsLevel1Member 2021-04-30 0001100397 us-gaap:FairValueInputsLevel2Member 2021-04-30 0001100397 us-gaap:FairValueInputsLevel3Member 2021-04-30 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2020-10-31 0001100397 us-gaap:IPOMember ADXS:SecuritiesPurchaseAgreementsMember 2021-04-11 2021-04-12 0001100397 us-gaap:IPOMember ADXS:SecuritiesPurchaseAgreementsMember 2021-04-12 0001100397 us-gaap:IPOMember ADXS:SecuritiesPurchaseAgreementsMember srt:MaximumMember 2021-04-12 0001100397 ADXS:PurchaseAgreementMember us-gaap:PrivatePlacementMember 2021-04-12 0001100397 ADXS:AmendedAndRestatedCertificateOfIncorporationMember 2021-04-12 0001100397 ADXS:AmendedAndRestatedCertificateOfIncorporationMember srt:MinimumMember 2021-04-12 0001100397 ADXS:AmendedAndRestatedCertificateOfIncorporationMember srt:MaximumMember 2021-04-12 0001100397 ADXS:ATMMember 2021-03-01 2021-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

170000000

300000000

170000000

300000000

451000

100000

113000

62000

452000

215000

210000

338000

299000

148000

159000

30000

40000

56000

153000

Advaxis, Inc. 0001100397 10-Q 2021-04-30 false --10-31

0.001

5000000

0.001

78074023

145638459

78074023

145638459

50000

281.25

0.37

281.25

0.372

0.35

0.30

281.25

22.50

0.30

281.25

0.30

2.80

0.35

0.70

0.30

0.70

0.372

0.70

30180000

37575000

35437000

39531000

50000

60000

423750000

433614000

-384269000

-392126000

78000

116000

440840000

452174000

-410738000

-414715000

47551000

-398449000

433826000

-398449000

60000

146000

467227000

-419822000

Q2 true false 17000 17000 17000 29000 4931000 4931000 4902000 29000 4902000 4931000 17000

-968000

2990000

25000

253000

1375000

250000

8500000

3800000

2957

5888

8608

5888

5561

5651

5888

5555

1000

8249

2694

1000

-9084000

-7857000

-3977000

-7857000

-14180000

-5107000

-6323000

-3977000

-6323000

-5107000

25178000

32363000

48110000

28217000

2000

28115000

9628000

2000

9628000

31000

8519000

10000

9618000

13683000

8550000

19000

13664000

30666665

10000000

17577400

26666666

18463448

2000 7000 2579000 2000 1185000 2586000 1999999000 11000 1174000 Yes false Yes

4839000

962000

Non-accelerated Filer 2021

398226

327363

70863

327338

70863

15333332

11314432

18910965

70297

327338

4578400

30225397

7671937

11244135

14005202

13333333

10754932

11244135

14005202

11244135

14005202

30666665

17577400

886048

2337500

2025-11-30

2022-03-31

29000

1363000

611000

1039000

311000

0.30

0.7911

0.7921

9200000

20000000

9200000

700000

38526000

55771000

-410738000

-419822000

440840000

467227000

78000

146000

8346000

8220000

5055000

3291000

8220000

1737000

2133000

410000

1156000

38526000

55771000

182000

3261000

3325000

2393000

333000

27851000

52113000

865000

1295000

1808000

1333000

25178000

48110000

111895403

56107657

123145051

60572632

-0.08

-0.25

-0.04

-0.10

50000

-9084000

-14130000

-5107000

-6273000

968000

-23000

995000

14000

3000

101000

2000

35000

-10284000

-14207000

-6321000

13274000

14460000

7696000

6571000

6360000

5679000

3352000

2649000

6914000

8781000

4344000

3922000

22932000

-4146000

31886000

9632000

4000

3771000

-54000

-358000

268000

358000

-8900000

-13420000

-389000 -397000

-165000

1142000

-1161000

-182000

-1000

-45000

-235000

327000

365000

135000

181000

100000

200000

100000

316000

457000

100000

200000

603000

100000

600000

100000

400000

-1530000

-1500000

-530000

-970000

The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.

50201671

60236599

78074023

116130688

60252444

145638459

242000

236000

242000

215000

210000

236000

210000

215000

7390000 26416 7500 11037435

0.34

0.49

0.57

31256720

30225397

1031323

5946322

5398226

252296

5818

343838

2335000

1218000

413000

744000

409000

19000

4725000

822000

2332000

489000

The expiration dates of the existing patents range from 2021 to 2040.

4479000

4674000

777000

117000 117000

5373000

5568000

2112000

2243000

136000

273000

2097000

3325000

737000

445000

671000

1357000

329000

331000

2024-07-31

2024-09-30

2024-07-31

2024-09-30

2025-11-30

2026-04-30

July 2019 Public Offering Other Warrants September 2018 Public Offering Other warrants September 2018 Public Offering July 2019 Public Offering November 2020 Public Offering April 2021 Registered Direct Offering (Accompanying Warrants) April 2021 Private Placement (Private Placement Warrants)

398226

30225397

48254606

18427435

0.08 0.67 0.48 0.20 P3Y9M3D P5Y P4Y10M21D 110640000 809752000

P3Y10M14D

P3Y4M13D

P5Y

106

0.29

120

0.35

106

0.86

106

0.85

300000

P1Y9M

50000

P8Y0M15D

P3Y

33.43

32.51

400000

200000

4000

28000

5556

5555

24.32

1011768

1031323

30112

0.39

P7Y7M13D

P4Y10M14D

0.30

10.01

100.01

200.01

10.00

100.00

200.00

277.50

P8Y3M8D

P6Y9M29D

P2Y3M4D

P1Y1M2D

P6Y

1.0327

0.00

0.0053

273000

P10Y

777.385

91700

92847

69391

100404

90105

92847

69391

P8Y11M12D

P6Y8M9D

P2Y3M4D

P1Y1M2D

1.04

29.17

166.04

210.79

3.02

29.35

166.04

210.79

145638459

1375000

214000

1116000 69000 1000 7671937 7671937 7671937

333

3999999

30225397

5 years after the date such warrants become exercisable, if ever

8000

352747

0.30

10.57

93.53

8000

1375000

1000000 817000 4500000 5600000

100000

The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one year term upon six months written notice to the landlord. This new lease is accounted for as a short-term lease and the Company has elected to not recognize the right-of-use asset and lease liability.

182000

1476000

1018000

503000

1088000

159000

270000

129000

61000

16000

169000

85000

16000

1301000

579000

289000

1011000

5882000

1375000

Leases   At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. In accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases “ASC 842”), The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.   Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

165000

229000

-1000

217000

-1000

Net Income (Loss) per Share   Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">As of April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">30,225,397</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">5,398,226</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">1,031,323</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">252,296</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Restricted stock units</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,818</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">31,256,720</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,946,322</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Recent Accounting Standards   Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">As of April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">30,225,397</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">5,398,226</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">1,031,323</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">252,296</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Restricted stock units</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,818</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">31,256,720</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,946,322</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Property and equipment, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Leasehold improvements</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">2,335</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Laboratory equipment</td> <td> </td> <td> </td> <td style="text-align: right">413</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,218</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Furniture and fixtures</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">744</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer equipment</td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Construction in progress</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total property and equipment</td> <td> </td> <td> </td> <td style="text-align: right">822</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,725</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(489</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,332</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net property and equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">333</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fiscal year ending October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">136</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Thereafter</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,097</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,325</td> <td> </td></tr> </table>

Intangible assets, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,674</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,479</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Licenses</td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Software</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total intangibles</td> <td> </td> <td> </td> <td style="text-align: right">5,568</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,373</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,243</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,112</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Intangible assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,325</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,261</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Salaries and other compensation</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">445</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">737</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vendors</td> <td> </td> <td> </td> <td style="text-align: right">1,357</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">671</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Professional fees</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">331</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">329</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total accrued expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,133</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,737</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Six Months Ended April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Research and development</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">56</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">62</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">113</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">153</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">159</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">148</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">338</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">299</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">215</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">210</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">451</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">452</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Restricted Stock Units (RSUs)   A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center">Number of RSUs</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted-Average Grant Date Fair Value</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 61%">Balance at October 31, 2020</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 16%; text-align: right">5,556</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 16%; text-align: right">24.32</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top">Vested</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(5,555</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt">Cancelled</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: right">(1</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">)</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 2.5pt">Balance at April 30, 2021</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt">$</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: right">-</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td></tr> </table>

A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life In Years</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value (in thousands)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Outstanding as of October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,011,768</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">33.43</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.39</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(333</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled or expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(30,112</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">10.57</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of April 30, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,031,323</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">32.51</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.62</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">28</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vested and exercisable at April 30, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">352,747</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">93.53</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.87</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Price Range</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercisable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">.30-$10.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">777.385</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.95</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">100,404</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">8.27</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">3.02</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">10.01-$100.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">91,700</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">90,105</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.68</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.35</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">100.01-$200.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.26</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.26</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">200.01-$277.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.09</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.09</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td></tr> </table>

In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">6 years </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%">Expected Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">103.27</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Dividends</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk Free Interest Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.53</td> <td>%</td></tr> </table>

Supplemental lease expense related to leases was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Lease Cost (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Statements of Operations Classification</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%; text-align: justify">Operating lease cost</td> <td style="width: 1%"> </td> <td style="width: 24%; text-align: center">General and administrative</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,011</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,301</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Short-term lease cost</td> <td> </td> <td style="text-align: center">General and administrative</td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Variable lease cost</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">61</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">159</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total lease expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,088</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,476</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Lease Cost (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Statements of Operations Classification</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%; text-align: justify">Operating lease cost</td> <td style="width: 1%"> </td> <td style="width: 24%; text-align: center">General and administrative</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">289</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">579</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Short-term lease cost</td> <td> </td> <td style="text-align: center">General and administrative</td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">169</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Variable lease cost</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">129</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">270</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total lease expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">503</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,018</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

Supplemental cash flow information related to operating leases was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt; text-align: justify">Cash paid for operating lease liabilities</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">1,039</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">1,363</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt; text-align: justify">Cash paid for operating lease liabilities</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">311</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">611</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> </table>

A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center">Additional Paid-In</td> <td> </td> <td colspan="3" style="text-align: center">Accumulated</td> <td> </td> <td colspan="3" style="text-align: center">Total Shareholders’</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%">Balance at November 1, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">50,201,671</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">423,750</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">(384,269</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">39,531</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,957</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,618</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,628</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">26,416</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,555</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at January 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,236,599</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">60</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">433,614</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(392,126</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">41,548</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,651</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">210</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">210</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,694</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(6,323</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(6,323</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance at April 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">60,252,444</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">60</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">433,826</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(398,449</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">35,437</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Additional Paid-In</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Total Shareholders’</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%">Balance at November 1, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">78,074,023</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">78</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">440,840</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">(410,738</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">30,180</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">30,666,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,519</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,550</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,390,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,579</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,586</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net Loss</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance at January 31, 2021</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">116,130,688</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">116</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">452,174</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(414,715</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">37,575</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,888</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">215</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">215</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,463,448</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13,664</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13,683</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,037,435</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,174</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,185</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net Loss</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(5,107</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(5,107</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance at April 30, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">145,638,459</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">146</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">467,227</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(419,822</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">47,551</td> <td> </td></tr> </table>

Basis of Presentation/Estimates   The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.   Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.   These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-K/A filed on February 26, 2021. The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.

0.0999

12. FAIR VALUE   The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:   ● Level 1 — Quoted prices in active markets for identical assets or liabilities.   ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.   ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.   The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.30 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">29</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">29</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,902</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,902</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,931</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,931</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.372 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; text-align: justify">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued</td> <td> </td> <td> </td> <td style="text-align: right">5,882</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Change in fair value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(968</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify">Ending Balance</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,931</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

10. LEASES   Operating Leases   The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $817,000. During the three months ended April 30, 2021, the Company wrote off of the remaining right-of-use asset of $4.5 million and lease liability of $5.6 million. After consideration of the termination payment and write off of remaining right-of-use asset and lease liability, the Company recorded a net gain of $0.1 million.   On March 25, 2021, the Company entered into a new lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one year term upon six months written notice to the landlord. This new lease is accounted for as a short-term lease and the Company has elected to not recognize the right-of-use asset and lease liability.   As a result of the termination of the Company's prior lease agreement pursuant to the Lease Termination and Surrender Agreement, the Company does not have an outstanding lease liability or operating right-of-use asset recorded as of April 30, 2021.   Supplemental lease expense related to leases was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Lease Cost (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Statements of Operations Classification</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%; text-align: justify">Operating lease cost</td> <td style="width: 1%"> </td> <td style="width: 24%; text-align: center">General and administrative</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,011</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,301</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Short-term lease cost</td> <td> </td> <td style="text-align: center">General and administrative</td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">16</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Variable lease cost</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">61</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">159</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total lease expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,088</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,476</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Lease Cost (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Statements of Operations Classification</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%; text-align: justify">Operating lease cost</td> <td style="width: 1%"> </td> <td style="width: 24%; text-align: center">General and administrative</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">289</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">579</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Short-term lease cost</td> <td> </td> <td style="text-align: center">General and administrative</td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">169</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Variable lease cost</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">129</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">270</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total lease expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">503</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,018</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Supplemental cash flow information related to operating leases was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt; text-align: justify">Cash paid for operating lease liabilities</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">1,039</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">1,363</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt; text-align: justify">Cash paid for operating lease liabilities</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">311</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">611</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

9. COMMITMENTS AND CONTINGENCIES   Legal Proceedings   The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.

8. COLLABORATION AND LICENSING AGREEMENTS   OS Therapies LLC   On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.   In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.   On April 26, 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans. The Company has a receivable due from OS Therapies of $1.375 million at April 30, 2021.

7. SHARE BASED COMPENSATION   The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Six Months Ended April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Research and development</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">56</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">62</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">113</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">153</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">159</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">148</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">338</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">299</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">215</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">210</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">451</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">452</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Restricted Stock Units (RSUs)   A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center">Number of RSUs</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted-Average Grant Date Fair Value</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 61%">Balance at October 31, 2020</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 16%; text-align: right">5,556</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 16%; text-align: right">24.32</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top">Vested</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">(5,555</td> <td style="vertical-align: bottom">)</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt">Cancelled</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: right">(1</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">)</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 2.5pt">Balance at April 30, 2021</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt">$</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: right">-</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td></tr> </table>   As of April 30, 2021, there was no unrecognized compensation cost related to non-vested RSUs.   Employee Stock Awards   Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 5,561 shares during the three months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the three months ended April 30, 2021 and 2020 was approximately $30,000 and $40,000, respectively.   Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 8,608 shares during the six months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the six months ended April 30, 2021 and 2020 was approximately $0.1 million and $0.1 million, respectively.   Stock Options   A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life In Years</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value (in thousands)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Outstanding as of October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,011,768</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">33.43</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">4</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.39</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(333</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled or expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(30,112</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">10.57</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of April 30, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,031,323</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">32.51</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.62</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">28</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vested and exercisable at April 30, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">352,747</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">93.53</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.87</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Price Range</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercisable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">.30-$10.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">777.385</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.95</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">100,404</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8.27</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3.02</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">10.01-$100.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">91,700</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">90,105</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.68</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.35</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">100.01-$200.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.26</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.26</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">200.01-$277.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.09</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.09</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td></tr> </table>   During the six months ended April 30, 2021, the Company granted options to purchase 50,000 shares of its common stock to an employee. The stock options have a ten-year term, vest over three years from the date of grant, and have an exercise price of $0.39.   Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended April 30, 2021 and 2020 was approximately $0.2 million and $0.2 million, respectively. For the six months ended April 30, 2021 and 2020, compensation cost related to the Company’s outstanding stock options was approximately $0.4 million and $0.4 million, respectively   As of April 30, 2021, there was approximately $0.3 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.75 years.   As of April 30, 2021, the aggregate intrinsic value of vested and exercisable options was $8 thousand and the aggregate intrinsic value of non-vested options was approximately $28 thousand.   In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">6 years </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%">Expected Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">103.27</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Dividends</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk Free Interest Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.53</td> <td>%</td></tr> </table>   Employee Stock Purchase Plan   During the six months ended April 30, 2021 and 2020, the Company issued 1,000 and 8,249 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

5. ACCRUED EXPENSES:   The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Salaries and other compensation</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">445</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">737</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vendors</td> <td> </td> <td> </td> <td style="text-align: right">1,357</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">671</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Professional fees</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">331</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">329</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total accrued expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,133</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,737</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

4. INTANGIBLE ASSETS   Intangible assets, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,674</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,479</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Licenses</td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Software</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total intangibles</td> <td> </td> <td> </td> <td style="text-align: right">5,568</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,373</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,243</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,112</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Intangible assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,325</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,261</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The expiration dates of the existing patents range from 2021 to 2040 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of $0.1 million and $0.4 million were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended April 30, 2021 and 2020, respectively. Patent applications having a net book value of $0.1 million and $0.6 million were abandoned and were charged to general and administrative expenses in the statement of operations for the six months ended April 30, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $0.1 million for each of the three months ended April 30, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $0.1 and $0.2 million for each of the six months ended April 30, 2021 and 2020, respectively.   Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.   As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fiscal year ending October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">136</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Thereafter</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,097</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,325</td> <td> </td></tr> </table>

1. NATURE OF OPERATIONS   Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;</td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Attacking the tumor by generating a strong, cancer-specific T cell response; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.</td></tr> </table>   Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.   Liquidity and Capital Resources   Liquidity and Management’s Plans   Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.   As of April 30, 2021, the Company had approximately $48.1 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least July 2022, the actual amount of cash that it will need to operate is subject to many factors. Over the past year, the Company has taken steps to obtain additional financing, including conducting sales of its common stock through its at-the-market (“ATM”) program through A.G.P./Alliance Global Partners, an equity line financing arrangement with Lincoln Park Capital and the completion of a registered direct offering and concurrent private placement with two healthcare-focused, institutional investors in April 2021, as further described below. The Company received aggregate proceeds of about $3.8 million during the six months ended April 30, 2021 upon the exercise of outstanding warrants, which were payable upon exercise.   On April 12, 2021, the Company entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock, (ii) 7,671,937 pre-funded warrants to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock ("Accompanying Warrants") in a registered direct offering (the “April 2021 Registered Direct Offering”). The Company also issued to the investors, in a concurrent private placement (the “April 2021 Private Placement” and together with the April 2021 Registered Direct Offering, the “April 2021 Offering”), unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock (the “Private Placement Warrants”).. The Company received gross proceeds of approximately $20 million, before deducting the fees and expenses payable by us in connection with the April 2021 Offering.    On November 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stock warrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”). On November 24, 2020, the underwriters notified us that they had exercised their option to purchase an additional 3,999,999 shares of common stock and 1,999,999 warrants in full. The Company received gross proceeds of approximately $9.2 million, before deducting the fees and expenses payable by us in connection with the November 2020 Offering. With these funds raised and a reduction in the operating expenses the Company believes that it has enough cash to fund its operations for one year from the date of filing.   The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.   The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.

A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Remaining Contractual Life In Years</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Aggregate Intrinsic Value</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Outstanding and exercisable warrants at October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">398,226</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.08</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">3.76</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">110,640</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">48,254,606</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.48</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Exercised</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(18,427,435</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">0.20</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable warrants at April 30, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">30,225,397</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">0.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">4.89</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">809,752</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at April 30, 2021 and April 14, 2021 (issuance date), the Company used the following inputs in its Black Scholes model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 14, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Exercise Price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.70</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.70</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.49</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.57</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">5.00 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.00 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility %</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk Free Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.86</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.85</td> <td>%</td></tr> </table>

In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Exercise Price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.37</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.49</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.34</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">3.37 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.87 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility %</td> <td> </td> <td> </td> <td style="text-align: right">120</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk Free Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.35</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.29</td> <td>%</td></tr> </table>

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.30 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">29</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">29</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,902</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,902</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,931</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,931</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.372 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Six Months Ended April 30, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; text-align: justify">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrants issued</td> <td> </td> <td> </td> <td style="text-align: right">5,882</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Change in fair value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(968</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify">Ending Balance</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,931</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

11. STOCKHOLDERS’ EQUITY   Public Offerings   On April 12, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors. The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 17,577,400 shares (the “Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”), at an offering price of $0.7921 per Share and 7,671,937 pre-funded warrants to certain purchasers whose purchase of additional Shares would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the Company’s outstanding Common Stock immediately following the consummation of the offering (the “Pre-Funded Warrants”). The Shares and Pre-Funded Warrants were sold together with warrants to purchase up to 11,244,135 shares of Common Stock (the “Accompanying Warrants” and together with the Shares and the Pre-Funded Warrants, the “Securities”). The Pre-Funded Warrants were sold for a purchase price of $0.7911 per share and have an exercise price of $0.001 per share. The Pre-Funded Warrants were immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Each Accompanying Warrant has an exercise price per share of $0.70, became exercisable immediately and will expire on the fifth anniversary of the original issuance date.   The Purchase Agreement also provided for a concurrent private placement (the “Private Placement”) of 14,005,202 warrants to purchase the Company’s Common Stock (the “Private Placement Warrants”) with the purchasers in the Registered Offering. The Private Placement Warrants will be exercisable for an aggregate of 14,005,202 shares of Common Stock at any time on or after such date, if ever, that is fourteen (14) days after the Company files an amendment (the “Authorized Shares Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares with the Delaware Secretary of State and on or prior to the date that is five years after such date. The Private Placement Warrants have an exercise price of $0.70 per share.    In March 2021, the Company sold 886,048 shares of its common stock via the at-the-market (“ATM”) program through A.G.P./Alliance Global Partners netting about $0.7 million in proceeds.   In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million.   During the six months ended April 30, 2021, warrant holders from the Company’s November 2020 offering exercised 10,754,932 warrants in exchange for 10,754,932 shares of the Company’s common stock and warrant holders from the Company’s April 2021 Offering exercised 7,671,937 pre-funded warrants in exchange for 7,671,937 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $3.8 million which were payable upon exercise.   A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center">Additional Paid-In</td> <td> </td> <td colspan="3" style="text-align: center">Accumulated</td> <td> </td> <td colspan="3" style="text-align: center">Total Shareholders’</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%">Balance at November 1, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">50,201,671</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">423,750</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">(384,269</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">39,531</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,957</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,618</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,628</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">26,416</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,555</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at January 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,236,599</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">60</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">433,614</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(392,126</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">41,548</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,651</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">210</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">210</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,694</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(6,323</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(6,323</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance at April 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">60,252,444</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">60</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">433,826</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(398,449</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">35,437</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Additional Paid-In</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Total Shareholders’</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%">Balance at November 1, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 6%; text-align: right">78,074,023</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">78</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">440,840</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">(410,738</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">30,180</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">30,666,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,519</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,550</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,390,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,579</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,586</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net Loss</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance at January 31, 2021</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">116,130,688</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">116</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">452,174</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(414,715</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">37,575</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,888</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">215</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">215</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,463,448</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13,664</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13,683</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,037,435</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,174</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,185</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net Loss</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(5,107</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(5,107</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance at April 30, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">145,638,459</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">146</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">467,227</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(419,822</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">47,551</td> <td> </td></tr> </table>

3. PROPERTY AND EQUIPMENT   Property and equipment, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Leasehold improvements</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">2,335</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Laboratory equipment</td> <td> </td> <td> </td> <td style="text-align: right">413</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,218</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Furniture and fixtures</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">744</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer equipment</td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Construction in progress</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total property and equipment</td> <td> </td> <td> </td> <td style="text-align: right">822</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,725</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(489</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,332</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net property and equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">333</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the three months ended April 30, 2021 and 2020 was $0.1 million and $0.2 million, respectively. Depreciation expense for the six months ended April 30, 2021 and 2020 was $0.3 million and $0.5 million, respectively. During the three months ended April 30, 2021, the Company incurred a loss on disposal of equipment of $1.5 million, $0.97 million of which is reflected in the research and development expenses and $0.53 million of which is reflected in the general and administrative expenses in the statement of operations.

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY   Warrants   As of April 30, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 and 16,220,195 shares, respectively, of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Shares Underlying Warrants</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 22%; text-align: right">281.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 23%; text-align: right">25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%">N/A</td> <td style="width: 1%"> </td> <td style="width: 26%">Other warrants</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,297</td> <td> </td> <td> </td> <td>July 2024</td> <td> </td> <td>September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">2.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">327,338</td> <td> </td> <td> </td> <td>September 2024</td> <td> </td> <td>July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,578,400</td> <td> </td> <td> </td> <td>November 2025</td> <td> </td> <td>November 2020 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">0.70</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,244,135</td> <td> </td> <td> </td> <td>April 2026</td> <td> </td> <td>April 2021 Registered Direct Offering (Accompanying Warrants)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">0.70</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">14,005,202</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">5 years after the date such warrants become exercisable, if ever</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">April 2021 Private Placement (Private Placement Warrants)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">Grand Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">30,225,397</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Shares Underlying Warrants</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 22%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 23%; text-align: right">327,338</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%">July 2024</td> <td style="width: 1%"> </td> <td style="width: 26%">July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">281.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25</td> <td> </td> <td> </td> <td>N/A</td> <td> </td> <td>Other Warrants</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">0.372</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">70,863</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">September 2024</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">Grand Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">398,226</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>    A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Remaining Contractual Life In Years</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Aggregate Intrinsic Value</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Outstanding and exercisable warrants at October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">398,226</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.08</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">3.76</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">110,640</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">48,254,606</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.48</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Exercised</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(18,427,435</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">0.20</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable warrants at April 30, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">30,225,397</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">0.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">4.89</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">809,752</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of April 30, 2021, the Company had 18,910,965 of its total 30,225,397 outstanding warrants classified as equity (equity warrants). At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the condensed balance sheets.   Warrant Liability   As of April 30, 2021, the Company had 11,314,432 of its total 30,225,397 outstanding warrants from April 2021 Private Placement Offering and September 2018 Public Offering classified as liabilities (liability warrants). At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants).   The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is fourteen (14) days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As a result, liability classification is warranted. For these liability warrants, the Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.   In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at April 30, 2021 and April 14, 2021 (issuance date), the Company used the following inputs in its Black Scholes model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 14, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Exercise Price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.70</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.70</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.49</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.57</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">5.00 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.00 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility %</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk Free Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.86</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.85</td> <td>%</td></tr> </table>   The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of April 30, 2021, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.30. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.   In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">April 30, 2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Exercise Price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.37</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.49</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.34</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">3.37 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.87 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility %</td> <td> </td> <td> </td> <td style="text-align: right">120</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk Free Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.35</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.29</td> <td>%</td></tr> </table> As of April 30, 2021, there were outstanding and exercisable warrants to purchase 30,225,397 and 16,220,195 shares, respectively, of our common stock with exercise prices ranging from $0.30 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Shares Underlying Warrants</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 22%; text-align: right">281.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 23%; text-align: right">25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%">N/A</td> <td style="width: 1%"> </td> <td style="width: 26%">Other warrants</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,297</td> <td> </td> <td> </td> <td>July 2024</td> <td> </td> <td>September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">2.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">327,338</td> <td> </td> <td> </td> <td>September 2024</td> <td> </td> <td>July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,578,400</td> <td> </td> <td> </td> <td>November 2025</td> <td> </td> <td>November 2020 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">0.70</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,244,135</td> <td> </td> <td> </td> <td>April 2026</td> <td> </td> <td>April 2021 Registered Direct Offering (Accompanying Warrants)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">0.70</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">14,005,202</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">5 years after the date such warrants become exercisable, if ever</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">April 2021 Private Placement (Private Placement Warrants)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">Grand Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">30,225,397</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Shares Underlying Warrants</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 22%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 23%; text-align: right">327,338</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%">July 2024</td> <td style="width: 1%"> </td> <td style="width: 26%">July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">281.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25</td> <td> </td> <td> </td> <td>N/A</td> <td> </td> <td>Other Warrants</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">0.372</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">70,863</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">September 2024</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">Grand Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">398,226</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

13. Subsequent Events   None.

Sequencing Policy   The Company adopted a sequencing policy under ASC 815-40-35, if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. Certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION   Basis of Presentation/Estimates   The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of April 30, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.   Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.   These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-K/A filed on February 26, 2021.   Net Income (Loss) per Share   Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">As of April 30,</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">30,225,397</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">5,398,226</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">1,031,323</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">252,296</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Restricted stock units</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,818</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">31,256,720</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,946,322</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Sequencing Policy   The Company adopted a sequencing policy under ASC 815-40-35, if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. Certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.   Leases   At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. In accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases “ASC 842”), The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.   Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.   Recent Accounting Standards   Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

EX-101.SCH 7 adxs-20210430.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock Purchase Warrants and Warrant Liability link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Share Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Collaboration and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Share Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Nature of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Share Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Share Based Compensation - Summary of Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Share Based Compensation - Summary of RSU Activity and Related Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Share Based Compensation - Summary of Changes in Stock Option Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Collaboration and Licensing Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Leases - Schedule of Lease Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Stockholders' Equity - Summary of Stockholders Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 adxs-20210430_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 adxs-20210430_def.xml XBRL DEFINITION FILE EX-101.LAB 10 adxs-20210430_lab.xml XBRL LABEL FILE Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Award Type [Axis] Through September 2024 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Range [Axis] Minimum [Member] Maximum [Member] Equity Components [Axis] Equity Warrants [Member] Warrant Liability [Member] Derivative Instrument [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Measurement Input Type [Axis] Expected Term [Member] Volatility [Member] Risk Free Rate [Member] Restricted Stock Units (RSUs) [Member] Sale of Stock [Axis] Public Offering [Member] Private Placement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Development, License and Supply Agreement [Member] Scenario [Axis] OS Therapies [Member] Legal Entity [Axis] OS Therapies LLC [Member] Milestone Set forth in the License Agreement [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Antidilutive Securities [Axis] Warrants [Member] Stock Options [Member] Restricted Stock Units [Member] Exercise Price Range Four [Member] Employee Stock Awards [Member] Plan Name [Axis] 2018 Employee Stock Purchase Plan [Member] Income Statement Location [Axis] Research and Development [Member] General and Administrative [Member] Definitive Agreements [Member] Title of Individual [Axis] Investor [Member] April 2021 Offering [Member] November 2020 Offering [Member] Underwriters [Member] Exercise Price Range Five [Member] Exercise Price Range Six [Member] Second Mile Stone License Agreement [Member] New Lease Agreement [Member] Securities Purchase Agreements [Member] Pre-Funded Warrants [Member] Through April 2026 [Member] Through 5 Years [Member] Purchase Agreement [Member] Amended and Restated Certificate of Incorporation [Member] ATM [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Deferred expenses Accounts receivable Prepaid expenses and other current assets Total current assets Property and equipment (net of accumulated depreciation) Intangible assets (net of accumulated amortization) Operating right-of-use asset (net of accumulated amortization) Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Common stock warrant liability Current portion of operating lease liability Deferred revenue Total current liabilities Operating lease liability, net of current portion Total liabilities Commitments and contingencies - Note 9 Stockholders' equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at April 30, 2021 and October 31, 2020; Liquidation preference of $0 at April 30, 2021 and October 31, 2020 Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 and 78,074,023 shares issued and outstanding at April 30, 2021 and October 31, 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference value Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Research and development expenses General and administrative expenses Total operating expenses Loss from operations Other income (expense): Interest income, net Net changes in fair value of derivative liabilities Other income (expense) Net loss before income taxes Income tax expense Net loss Net loss per common share, basic and diluted Weighted average number of common shares, basic and diluted Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock compensation Employee stock purchase plan expense Loss (gain) on change in value of warrants Loss on disposal of property and equipment Loss on write-down of intangible assets Abandonment of intangible assets Depreciation expense Amortization expense of intangible assets Amortization of right-of-use asset Net gain on write off of right-of-use asset and lease liability Change in operating assets and liabilities: Accounts receivable Prepaid expenses, other current assets and deferred expenses Other assets Accounts payable and accrued expenses Deferred revenue Operating lease liabilities Net cash used in operating activities INVESTING ACTIVITIES Proceeds from disposal of property and equipment Cost of intangible assets Net cash used in investing activities FINANCING ACTIVITIES Net proceeds of issuance of common stock and warrants Warrant exercises Proceeds from employee stock purchase plan Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for taxes SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES Warrant liability reclassified into equity Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies and Basis of Presentation Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Common Stock Purchase Warrants And Warrant Liability Common Stock Purchase Warrants and Warrant Liability Share-based Payment Arrangement [Abstract] Share Based Compensation Business Combinations [Abstract] Collaboration and Licensing Agreements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases [Abstract] EX-101.PRE 11 adxs-20210430_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Apr. 30, 2021	Jun. 07, 2021
Cover [Abstract]
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Apr. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		145,638,459
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Current Assets:
Cash and cash equivalents	$ 48,110	$ 25,178
Deferred expenses	1,333	1,808
Accounts receivable	1,375
Prepaid expenses and other current assets	1,295	865
Total current assets	52,113	27,851
Property and equipment (net of accumulated depreciation)	333	2,393
Intangible assets (net of accumulated amortization)	3,325	3,261
Operating right-of-use asset (net of accumulated amortization)		4,839
Other assets		182
Total assets	55,771	38,526
Current liabilities:
Accounts payable	1,156	410
Accrued expenses	2,133	1,737
Common stock warrant liability	4,931	17
Current portion of operating lease liability		962
Deferred revenue		165
Total current liabilities	8,220	3,291
Operating lease liability, net of current portion		5,055
Total liabilities	8,220	8,346
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at April 30, 2021 and October 31, 2020; Liquidation preference of $0 at April 30, 2021 and October 31, 2020
Common stock - $0.001 par value; 170,000,000 shares authorized, 145,638,459 and 78,074,023 shares issued and outstanding at April 30, 2021 and October 31, 2020, respectively	146	78
Additional paid-in capital	467,227	440,840
Accumulated deficit	(419,822)	(410,738)
Total stockholders' equity	47,551	30,180
Total liabilities and stockholders' equity	$ 55,771	$ 38,526

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	145,638,459	78,074,023
Common stock, shares outstanding	145,638,459	78,074,023

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Income Statement [Abstract]
Revenue	$ 1,375	$ 250	$ 2,990	$ 253
Operating expenses:
Research and development expenses	4,344	3,922	6,914	8,781
General and administrative expenses	3,352	2,649	6,360	5,679
Total operating expenses	7,696	6,571	13,274	14,460
Loss from operations	(6,321)	(6,321)	(10,284)	(14,207)
Other income (expense):
Interest income, net	2	35	3	101
Net changes in fair value of derivative liabilities	995	14	968	(23)
Other income (expense)	217	(1)	229	(1)
Net loss before income taxes	(5,107)	(6,273)	(9,084)	(14,130)
Income tax expense		50		50
Net loss	$ (5,107)	$ (6,323)	$ (9,084)	$ (14,180)
Net loss per common share, basic and diluted	$ (0.04)	$ (0.10)	$ (0.08)	$ (0.25)
Weighted average number of common shares, basic and diluted	123,145,051	60,572,632	111,895,403	56,107,657

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
OPERATING ACTIVITIES
Net loss	$ (9,084)	$ (14,180)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	451	452
Employee stock purchase plan expense		1
Loss (gain) on change in value of warrants	(968)	23
Loss on disposal of property and equipment	1,530
Loss on write-down of intangible assets	69
Abandonment of intangible assets		603
Depreciation expense	316	457
Amortization expense of intangible assets	135	181
Amortization of right-of-use asset	327	365
Net gain on write off of right-of-use asset and lease liability	(1,116)
Change in operating assets and liabilities:
Accounts receivable	(1,375)
Prepaid expenses, other current assets and deferred expenses	45	235
Other assets	182	1
Accounts payable and accrued expenses	1,142	(1,161)
Deferred revenue	(165)
Operating lease liabilities	(389)	(397)
Net cash used in operating activities	(8,900)	(13,420)
INVESTING ACTIVITIES
Proceeds from disposal of property and equipment	214
Cost of intangible assets	(268)	(358)
Net cash used in investing activities	(54)	(358)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock and warrants	28,115	9,628
Warrant exercises	3,771
Proceeds from employee stock purchase plan		4
Net cash provided by financing activities	31,886	9,632
Net increase in cash and cash equivalents	22,932	(4,146)
Cash and cash equivalents at beginning of period	25,178	32,363
Cash and cash equivalents at end of period	48,110	28,217
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes		50
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Warrant liability reclassified into equity		$ 2

XML 17 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations

6 Months Ended

Apr. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

1. NATURE OF OPERATIONS

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and
	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Liquidity and Capital Resources

Liquidity and Management’s Plans

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation

6 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

Net Income (Loss) per Share

	As of April 30,
	2021		2020
Warrants		30,225,397		5,398,226
Stock options		1,031,323		252,296
Restricted stock units		-		5,818
Total		31,256,720		5,946,322

Sequencing Policy

Leases

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Apr. 30, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

	April 30, 2021			October 31, 2020

Leasehold improvements	$	-		$	2,335
Laboratory equipment		413			1,218
Furniture and fixtures		-			744
Computer equipment		409			409
Construction in progress		-			19
Total property and equipment		822			4,725
Accumulated depreciation and amortization		(489	)		(2,332	)
Net property and equipment	$	333		$	2,393

XML 20 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Apr. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

	April 30, 2021			October 31, 2020

Patents	$	4,674		$	4,479
Licenses		777			777
Software		117			117
Total intangibles		5,568			5,373
Accumulated amortization		(2,243	)		(2,112	)
Intangible assets	$	3,325		$	3,261

As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2021 (Remaining)	$	136
2022		273
2023		273
2024		273
2025		273
Thereafter		2,097
Total	$	3,325

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

6 Months Ended

Apr. 30, 2021

Payables and Accruals [Abstract]

Accrued Expenses

5. ACCRUED EXPENSES:

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):

	April 30, 2021		October 31, 2020

Salaries and other compensation	$	445	$	737
Vendors		1,357		671
Professional fees		331		329
Total accrued expenses	$	2,133	$	1,737

XML 22 R11.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability

6 Months Ended

Apr. 30, 2021

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.30		70,297	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		4,578,400	November 2025	November 2020 Public Offering
$	0.70		11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70		14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		30,225,397

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data):

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		48,254,606			0.48		5.00
Exercised		(18,427,435	)		0.20
Outstanding and exercisable warrants at April 30, 2021		30,225,397		$	0.67		4.89	$	809,752

Warrant Liability

	April 30, 2021			April 14, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.49		$	0.57
Expected Term		5.00 years			5.00 years
Volatility %		106	%		106	%
Risk Free Rate		0.86	%		0.85	%

In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	April 30, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.49		$	0.34
Expected Term		3.37 years			3.87 years
Volatility %		120	%		106	%
Risk Free Rate		0.35	%		0.29	%

XML 23 R12.htm IDEA: XBRL DOCUMENT

Share Based Compensation

6 Months Ended

Apr. 30, 2021

Share-based Payment Arrangement [Abstract]

Share Based Compensation

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):

	Three Months Ended April 30,				Six Months Ended April 30,
		2021		2020		2021		2020
Research and development	$	56	$	62	$	113	$	153
General and administrative		159		148		338		299
Total	$	215	$	210	$	451	$	452

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows:

	Number of RSUs			Weighted-Average Grant Date Fair Value

Balance at October 31, 2020		5,556		$	24.32
Vested		(5,555	)
Cancelled		(1	)
Balance at April 30, 2021		-		$	-

As of April 30, 2021, there was no unrecognized compensation cost related to non-vested RSUs.

Employee Stock Awards

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 5,888 shares and 8,608 shares during the six months ended April 30, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the six months ended April 30, 2021 and 2020 was approximately $0.1 million and $0.1 million, respectively.

Stock Options

A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Exercised		(333	)		0.30
Cancelled or expired		(30,112	)		10.57
Outstanding as of April 30, 2021		1,031,323		$	32.51		7.62	$	28
Vested and exercisable at April 30, 2021		352,747		$	93.53		4.87	$	8

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	.30-$10.00		777.385		8.95	$	1.04		100,404		8.27	$	3.02
$	10.01-$100.00		91,700		6.69	$	29.17		90,105		6.68	$	29.35
$	100.01-$200.00		92,847		2.26	$	166.04		92,847		2.26	$	166.04
$	200.01-$277.50		69,391		1.09	$	210.79		69,391		1.09	$	210.79

As of April 30, 2021, the aggregate intrinsic value of vested and exercisable options was $8 thousand and the aggregate intrinsic value of non-vested options was approximately $28 thousand.

In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model:

	Six Months Ended April 30, 2021

Expected Term		6 years
Expected Volatility		103.27	%
Expected Dividends		0	%
Risk Free Interest Rate		0.53	%

Employee Stock Purchase Plan

During the six months ended April 30, 2021 and 2020, the Company issued 1,000 and 8,249 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

XML 24 R13.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Agreements

6 Months Ended

Apr. 30, 2021

Business Combinations [Abstract]

Collaboration and Licensing Agreements

8. COLLABORATION AND LICENSING AGREEMENTS

OS Therapies LLC

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Apr. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

XML 26 R15.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Apr. 30, 2021

Leases [Abstract]

Leases

10. LEASES

Operating Leases

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended April 30, 2021		For the Six Months Ended April 30, 2021
Operating lease cost	General and administrative		1,011		1,301
Short-term lease cost	General and administrative		16		16
Variable lease cost	General and administrative	$	61		159
Total lease expense		$	1,088		1,476

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended April 30, 2020		For the Six Months Ended April 30, 2020
Operating lease cost	General and administrative		289		579
Short-term lease cost	General and administrative		85		169
Variable lease cost	General and administrative	$	129		270
Total lease expense		$	503		1,018

Supplemental cash flow information related to operating leases was as follows:

	For the Three Months Ended April 30, 2021		For the Six Months Ended April 30, 2021
Cash paid for operating lease liabilities	$	1,039		1,363

	For the Three Months Ended April 30, 2020		For the Six Months Ended April 30, 2020
Cash paid for operating lease liabilities	$	311		611

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Apr. 30, 2021

Equity [Abstract]

Stockholders' Equity

11. STOCKHOLDERS’ EQUITY

Public Offerings

In March 2021, the Company sold 886,048 shares of its common stock via the at-the-market (“ATM”) program through A.G.P./Alliance Global Partners netting about $0.7 million in proceeds.

A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2019		-	$	-		50,201,671	$	50	$	423,750	$	(384,269	)	$	39,531
Stock-based compensation		-		-		2,957		-		242		-			242
Advaxis public offerings, net of offering costs		-		-		10,000,000		10		9,618		-			9,628
Warrant exercises		-		-		26,416		-		2		-			2
Issuance of shares to employees under ESPP Plan		-		-		5,555		-		2		-			2
Net Loss		-		-		-		-		-		(7,857	)		(7,857	)
Balance at January 31, 2020		-	$	-		60,236,599	$	60	$	433,614	$	(392,126	)	$	41,548
Stock-based compensation		-		-		5,651		-		210		-			210
Warrant exercises		-		-		7,500		-		-		-			-
Issuance of shares to employees under ESPP Plan		-		-		2,694		-		2		-			2
Net Loss		-		-		-		-		-		(6,323	)		(6,323	)
Balance at April 30, 2020		-	$	-		60,252,444	$	60	$	433,826	$	(398,449	)	$	35,437

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575
Stock-based compensation		-		-		5,888		-		215		-			215
Advaxis public offerings, net of offering costs		-		-		18,463,448		19		13,664		-			13,683
Warrant exercises		-		-		11,037,435		11		1,174		-			1,185
Issuance of shares to employees under ESPP Plan		-		-		1,000		-		-		-			-
Net Loss		-		-		-		-		-		(5,107	)		(5,107	)
Balance at April 30, 2021		-	$	-		145,638,459	$	146	$	467,227	$	(419,822	)	$	47,551

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value

6 Months Ended

Apr. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value

12. FAIR VALUE

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands):

April 30, 2021	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.30 through September 2024		-		-	$	29	$	29
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-	$	4,902	$	4,902
Total		-		-	$	4,931	$	4,931

October 31, 2020	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	17	$	17

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):

	For the Six Months Ended April 30, 2021
Beginning balance	$	17
Warrants issued		5,882
Warrant exercises		-
Change in fair value		(968	)
Ending Balance	$	4,931

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Apr. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

13. Subsequent Events

None.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

6 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation/Estimates

Basis of Presentation/Estimates

Net Income (Loss) Per Share

Net Income (Loss) per Share

	As of April 30,
	2021		2020
Warrants		30,225,397		5,398,226
Stock options		1,031,323		252,296
Restricted stock units		-		5,818
Total		31,256,720		5,946,322

Sequencing Policy

Leases

Leases

Recent Accounting Standards

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Tables)

6 Months Ended

Apr. 30, 2021

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share

The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of April 30, 2021 and April 30, 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.

	As of April 30,
	2021		2020
Warrants		30,225,397		5,398,226
Stock options		1,031,323		252,296
Restricted stock units		-		5,818
Total		31,256,720		5,946,322

XML 32 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

6 Months Ended

Apr. 30, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment, net consisted of the following (in thousands):

	April 30, 2021			October 31, 2020

Leasehold improvements	$	-		$	2,335
Laboratory equipment		413			1,218
Furniture and fixtures		-			744
Computer equipment		409			409
Construction in progress		-			19
Total property and equipment		822			4,725
Accumulated depreciation and amortization		(489	)		(2,332	)
Net property and equipment	$	333		$	2,393

XML 33 R22.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Apr. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

Intangible assets, net consisted of the following (in thousands):

	April 30, 2021			October 31, 2020

Patents	$	4,674		$	4,479
Licenses		777			777
Software		117			117
Total intangibles		5,568			5,373
Accumulated amortization		(2,243	)		(2,112	)
Intangible assets	$	3,325		$	3,261

Schedule of Carrying Value of Intangible Assets

As of April 30, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2021 (Remaining)	$	136
2022		273
2023		273
2024		273
2025		273
Thereafter		2,097
Total	$	3,325

XML 34 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

6 Months Ended

Apr. 30, 2021

Payables and Accruals [Abstract]

Summary of Accrued Expenses

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):

	April 30, 2021		October 31, 2020

Salaries and other compensation	$	445	$	737
Vendors		1,357		671
Professional fees		331		329
Total accrued expenses	$	2,133	$	1,737

XML 35 R24.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability (Tables)

6 Months Ended

Apr. 30, 2021

Schedule of Outstanding Warrants

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.30		70,297	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		4,578,400	November 2025	November 2020 Public Offering
$	0.70		11,244,135	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	0.70		14,005,202	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		30,225,397

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

Schedule of Warrants Activity

A summary of warrant activity for the six months ended April 30, 2021 is as follows (in thousands, except share and per share data):

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		48,254,606			0.48		5.00
Exercised		(18,427,435	)		0.20
Outstanding and exercisable warrants at April 30, 2021		30,225,397		$	0.67		4.89	$	809,752

Schedule of Assumptions Used in Warrant Liability

	April 30, 2021			April 14, 2021
Exercise Price	$	0.70		$	0.70
Stock Price	$	0.49		$	0.57
Expected Term		5.00 years			5.00 years
Volatility %		106	%		106	%
Risk Free Rate		0.86	%		0.85	%

Private Placement [Member]

Schedule of Assumptions Used in Warrant Liability

In measuring the warrant liability for the September 2018 Public Offering warrants at April 30, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	April 30, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.49		$	0.34
Expected Term		3.37 years			3.87 years
Volatility %		120	%		106	%
Risk Free Rate		0.35	%		0.29	%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Share Based Compensation (Tables)

6 Months Ended

Apr. 30, 2021

Share-based Payment Arrangement [Abstract]

Summary of Share Based Compensation Expense

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):

	Three Months Ended April 30,				Six Months Ended April 30,
		2021		2020		2021		2020
Research and development	$	56	$	62	$	113	$	153
General and administrative		159		148		338		299
Total	$	215	$	210	$	451	$	452

Summary of RSU Activity and Related Information

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the six months ended April 30, 2021 is as follows:

	Number of RSUs			Weighted-Average Grant Date Fair Value

Balance at October 31, 2020		5,556		$	24.32
Vested		(5,555	)
Cancelled		(1	)
Balance at April 30, 2021		-		$	-

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the six months ended April 30, 2021 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Exercised		(333	)		0.30
Cancelled or expired		(30,112	)		10.57
Outstanding as of April 30, 2021		1,031,323		$	32.51		7.62	$	28
Vested and exercisable at April 30, 2021		352,747		$	93.53		4.87	$	8

Summary of Outstanding and Exercisable Options

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	.30-$10.00		777.385		8.95	$	1.04		100,404		8.27	$	3.02
$	10.01-$100.00		91,700		6.69	$	29.17		90,105		6.68	$	29.35
$	100.01-$200.00		92,847		2.26	$	166.04		92,847		2.26	$	166.04
$	200.01-$277.50		69,391		1.09	$	210.79		69,391		1.09	$	210.79

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the six months ended April 30, 2021, the Company used the following inputs in its Black Scholes Merton model:

	Six Months Ended April 30, 2021

Expected Term		6 years
Expected Volatility		103.27	%
Expected Dividends		0	%
Risk Free Interest Rate		0.53	%

XML 37 R26.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Apr. 30, 2021

Leases [Abstract]

Schedule of Lease Expenses

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended April 30, 2021		For the Six Months Ended April 30, 2021
Operating lease cost	General and administrative		1,011		1,301
Short-term lease cost	General and administrative		16		16
Variable lease cost	General and administrative	$	61		159
Total lease expense		$	1,088		1,476

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended April 30, 2020		For the Six Months Ended April 30, 2020
Operating lease cost	General and administrative		289		579
Short-term lease cost	General and administrative		85		169
Variable lease cost	General and administrative	$	129		270
Total lease expense		$	503		1,018

Schedule of Cash Flow Information Related to Leases

Supplemental cash flow information related to operating leases was as follows:

	For the Three Months Ended April 30, 2021		For the Six Months Ended April 30, 2021
Cash paid for operating lease liabilities	$	1,039		1,363

		For the Three Months Ended April 30, 2020				For the Six Months Ended April 30, 2020
Cash paid for operating lease liabilities		$	311				611

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Apr. 30, 2021

Equity [Abstract]

Summary of Stockholders Equity

A summary of the changes in stockholders’ equity for the three and six months ended April 30, 2021 and 2020 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2019		-	$	-		50,201,671	$	50	$	423,750	$	(384,269	)	$	39,531
Stock-based compensation		-		-		2,957		-		242		-			242
Advaxis public offerings, net of offering costs		-		-		10,000,000		10		9,618		-			9,628
Warrant exercises		-		-		26,416		-		2		-			2
Issuance of shares to employees under ESPP Plan		-		-		5,555		-		2		-			2
Net Loss		-		-		-		-		-		(7,857	)		(7,857	)
Balance at January 31, 2020		-	$	-		60,236,599	$	60	$	433,614	$	(392,126	)	$	41,548
Stock-based compensation		-		-		5,651		-		210		-			210
Warrant exercises		-		-		7,500		-		-		-			-
Issuance of shares to employees under ESPP Plan		-		-		2,694		-		2		-			2
Net Loss		-		-		-		-		-		(6,323	)		(6,323	)
Balance at April 30, 2020		-	$	-		60,252,444	$	60	$	433,826	$	(398,449	)	$	35,437

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575
Stock-based compensation		-		-		5,888		-		215		-			215
Advaxis public offerings, net of offering costs		-		-		18,463,448		19		13,664		-			13,683
Warrant exercises		-		-		11,037,435		11		1,174		-			1,185
Issuance of shares to employees under ESPP Plan		-		-		1,000		-		-		-			-
Net Loss		-		-		-		-		-		(5,107	)		(5,107	)
Balance at April 30, 2021		-	$	-		145,638,459	$	146	$	467,227	$	(419,822	)	$	47,551

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value (Tables)

6 Months Ended

Apr. 30, 2021

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of April 30, 2021 and October 31, 2020 (in thousands):

April 30, 2021	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.30 through September 2024		-		-	$	29	$	29
Common stock warrant liability, warrants exercisable at $0.70 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-	$	4,902	$	4,902
Total		-		-	$	4,931	$	4,931

October 31, 2020	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	17	$	17

Schedule of Changes in Fair Value of Warrant Liabilities

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):

	For the Six Months Ended April 30, 2021
Beginning balance	$	17
Warrants issued		5,882
Warrant exercises		-
Change in fair value		(968	)
Ending Balance	$	4,931

XML 40 R29.htm IDEA: XBRL DOCUMENT

Nature of Operations (Details Narrative) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended				6 Months Ended
	Apr. 12, 2021	Nov. 27, 2020	Nov. 24, 2020	Nov. 30, 2020	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Cash and cash equivalents					$ 48,110				$ 48,110		$ 25,178
Proceeds from warrant exercise									$ 3,771
Number of shares issued
Number of warrants to purchase common stock					30,225,397				30,225,397		398,226
Options exercised									333
Warrant exercises					$ 1,185	$ 2,586		$ 2
Capital description									The Company does not have any current plans to raise capital in the near term, absent an extraordinary change in circumstances, such as unforeseen liabilities or if we acquire new assets that require additional investment. We do not believe we will need to raise additional capital in the near term because we have a) built a strong balance sheet (including the proceeds from the financing completed in April 2021) and b) executed on our cost reduction plans that have reduced our annual cash burn by greater than 75% over the past few years, securing a cash runway through potential future clinical and corporate milestones.
Public Offering [Member]
Number of shares issued		26,666,666
Pre-funded warrants to purchase common shares					7,671,937				7,671,937
Number of warrants to purchase common stock					10,754,932				10,754,932
Proceeds from sale of common shares				$ 9,200
November 2020 Offering [Member]
Number of warrants to purchase common stock		13,333,333
Proceeds from sale of common shares			$ 9,200
Underwriters [Member]
Options exercised			3,999,999
Warrant exercises			$ 1,999,999
Definitive Agreements [Member]
Number of warrants to purchase common stock	11,244,135
Definitive Agreements [Member] \| April 2021 Offering [Member]
Number of warrants to purchase common stock	14,005,202
Proceeds from sale of common shares	$ 20,000
Definitive Agreements [Member] \| Investor [Member]
Number of shares issued	17,577,400
Pre-funded warrants to purchase common shares	7,671,937
Number of warrants to purchase common stock	7,671,937

XML 41 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - $ / shares	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Number of securities included in computation of basic earnings per share	31,256,720	5,946,322
Exercise price	$ 0	$ 0
Warrants [Member]
Number of securities included in computation of basic earnings per share	0	343,838

XML 42 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Total	31,256,720	5,946,322
Warrants [Member]
Total	30,225,397	5,398,226
Stock Options [Member]
Total	1,031,323	252,296
Restricted Stock Units [Member]
Total		5,818

XML 43 R32.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Depreciation expense	$ 100	$ 200	$ 316	$ 457
Loss on disposal of equipment	1,500		$ 1,530
Research and Development [Member]
Loss on disposal of equipment	970
General and Administrative [Member]
Loss on disposal of equipment	$ 530

XML 44 R33.htm IDEA: XBRL DOCUMENT

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Leasehold improvements		$ 2,335
Laboratory equipment	413	1,218
Furniture and fixtures		744
Computer equipment	409	409
Construction in progress		19
Total property and equipment	822	4,725
Accumulated depreciation and amortization	(489)	(2,332)
Net property and equipment	$ 333	$ 2,393

XML 45 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Expiration of patents description			The expiration dates of the existing patents range from 2021 to 2040.
Book value patent applications, net				$ 603
Intangible asset amortization expense			135	181
General and Administrative [Member]
Book value patent applications, net	$ 400	$ 100	100	600
Intangible asset amortization expense	$ 100	$ 100	$ 100	$ 200

XML 46 R35.htm IDEA: XBRL DOCUMENT

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,674	$ 4,479
Licenses	777	777
Software	117	117
Total intangibles	5,568	5,373
Accumulated amortization	(2,243)	(2,112)
Intangible assets	$ 3,325	$ 3,261

XML 47 R36.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Apr. 30, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021 (Remaining)	$ 136
2022	273
2023	273
2024	273
2025	273
Thereafter	2,097
Total	$ 3,325

XML 48 R37.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Payables and Accruals [Abstract]
Salaries and other compensation	$ 445	$ 737
Vendors	1,357	671
Professional fees	331	329
Total accrued expenses	$ 2,133	$ 1,737

XML 49 R38.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - $ / shares	Apr. 30, 2021	Oct. 31, 2020
Class of Warrant or Right [Line Items]
Warrants outstanding	30,225,397
Number of warrants to purchase common stock	30,225,397	398,226
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Public Offering [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	10,754,932
Common stock, shares authorized	300,000,000
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	18,910,965	327,363
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	11,314,432	70,863
Warrant exercise price per share	$ 0.30	$ 0.37
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.30	0
Minimum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.30
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	281.25	$ 281.25
Maximum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 22.50

XML 50 R39.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Apr. 30, 2021	Oct. 31, 2020
Class of Warrant or Right [Line Items]
Number of Shares Underlying Warrants	30,225,397	398,226
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25
Number of Shares Underlying Warrants	25	327,338
Expiration Date		Jul. 31, 2024
Type of Financing	Other warrants	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.30	$ 281.25
Number of Shares Underlying Warrants	70,297	25
Expiration Date	Jul. 31, 2024
Type of Financing	September 2018 Public Offering	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.80	$ 0.372
Number of Shares Underlying Warrants	327,338	70,863
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Type of Financing	July 2019 Public Offering	September 2018 Public Offering
Exercise Price Range Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.35
Number of Shares Underlying Warrants	4,578,400
Expiration Date	Nov. 30, 2025
Type of Financing	November 2020 Public Offering
Exercise Price Range Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.70
Number of Shares Underlying Warrants	11,244,135
Expiration Date	Apr. 30, 2026
Type of Financing	April 2021 Registered Direct Offering (Accompanying Warrants)
Exercise Price Range Six [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.70
Number of Shares Underlying Warrants	14,005,202
Type of Financing	April 2021 Private Placement (Private Placement Warrants)
Expiration date description	5 years after the date such warrants become exercisable, if ever

XML 51 R40.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Apr. 30, 2021 USD ($) $ / shares shares
Common Stock Purchase Warrants And Warrant Liability
Warrants, Outstanding and exercisable warrants, Beginning balance \| shares	398,226
Warrants, Issued \| shares	48,254,606
Warrants, Exercised \| shares	(18,427,435)
Warrants, Outstanding and exercisable warrants, Ending balance \| shares	30,225,397
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning \| $ / shares	$ 0.08
Weighted Average Exercise Price, Issued \| $ / shares	0.48
Weighted Average Exercise Price, Exercised \| $ / shares	0.20
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending \| $ / shares	$ 0.67
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	3 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Issued	5 years
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	4 years 10 months 21 days
Aggregate Intrinsic Value, Beginning \| $	$ 110,640
Aggregate Intrinsic Value, Ending \| $	$ 809,752

XML 52 R41.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details)	Apr. 30, 2021 $ / shares	Apr. 14, 2021 $ / shares	Nov. 30, 2020 $ / shares	Oct. 31, 2020 $ / shares	Apr. 30, 2020 $ / shares
Class of Warrant or Right [Line Items]
Stock Price	$ 0				$ 0
Private Placement [Member]
Class of Warrant or Right [Line Items]
Exercise Price			$ 0.35
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise Price	0.30			$ 0.37
Stock Price	$ 0.49			$ 0.34
Warrant Liability [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term	3 years 4 months 13 days			3 years 10 months 14 days
Warrant Liability [Member] \| Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	120			106
Warrant Liability [Member] \| Risk Free Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	0.35			0.29
Warrant Liability [Member] \| Private Placement [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.70	$ 0.70
Stock Price	$ 0.49	$ 0.57
Warrant Liability [Member] \| Private Placement [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term	5 years	5 years
Warrant Liability [Member] \| Private Placement [Member] \| Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	106	106
Warrant Liability [Member] \| Private Placement [Member] \| Risk Free Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	0.86	0.85

XML 53 R42.htm IDEA: XBRL DOCUMENT

Share Based Compensation (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
Share Based Compensation (Details Narrative) - USD ($)	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Unrecognized compensation cost related to non-vested stock option awards	$ 300,000				$ 300,000
Share-based compensation, common stock, shares
Stock compensation expense	$ 215,000		$ 210,000		$ 451,000	$ 452,000
Stock granted options to purchase					50,000
Stock option term					P10Y
Stock option vesting period					3 years
Stock option exercise price	$ 32.51				$ 32.51		$ 33.43
Compensation cost related to outstanding stock options	$ 200,000		$ 200,000		$ 400,000	$ 400,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period					1 year 9 months
Aggregate intrinsic value of vested and exercisable options	8,000				$ 8,000
Aggregate intrinsic value of non-vested options	$ 28,000				28,000		$ 4,000
Number of shares issued under employee stock purchase plan
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	5,888		5,561		5,888	8,608
Stock compensation expense	$ 30,000		$ 40,000		$ 100,000	$ 100,000
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan					1,000	8,249

XML 54 R43.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Share-based compensation expense	$ 215	$ 210	$ 451	$ 452
Research and Development [Member]
Share-based compensation expense	56	62	113	153
General and Administrative [Member]
Share-based compensation expense	$ 159	$ 148	$ 338	$ 299

XML 55 R44.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Apr. 30, 2021 $ / shares shares
Number of RSUs, Unvested Beginning Balance \| shares	5,556
Number of RSUs, Vested \| shares	(5,555)
Number of RSUs, Cancelled \| shares	(1)
Number of RSUs, Unvested Ending Balance \| shares
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance \| $ / shares	$ 24.32
Weighted-Average Grant Date Fair Value, Vested \| $ / shares
Weighted-Average Grant Date Fair Value, Cancelled \| $ / shares
Weighted-Average Grant Date Fair Value, Unvested Ending Balance \| $ / shares

XML 56 R45.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	6 Months Ended
	Apr. 30, 2021 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Shares, Outstanding, Beginning Balance \| shares	1,011,768
Shares, Granted \| shares	50,000
Shares, Exercised \| shares	(333)
Shares, Cancelled or Expired \| shares	(30,112)
Shares, Outstanding, Ending Balance \| shares	1,031,323
Shares, Vested and Exercisable \| shares	352,747
Weighted Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 33.43
Weighted Average Exercise Price, Granted \| $ / shares	0.39
Weighted average exercise price, Exercised \| $ / shares	0.30
Weighted Average Exercise Price, Cancelled or Expired \| $ / shares	10.57
Weighted Average Exercise Price, Outstanding, Ending \| $ / shares	32.51
Weighted Average Exercise Price, Vested and Exercisable \| $ / shares	$ 93.53
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	8 years 15 days
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	7 years 7 months 13 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	4 years 10 months 14 days
Aggregate Intrinsic Value, Beginning \| $	$ 4,000
Aggregate Intrinsic Value, Ending \| $	28,000
Aggregate Intrinsic Value, Vested and Exercisable \| $	$ 8,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details)	6 Months Ended
	Apr. 30, 2021 $ / shares shares
Exercise Price Range One [Member]
Exercise Price Range, lower limit	$ 0.30
Exercise Price Range, upper limit	$ 10.00
Number Outstanding, Options Outstanding \| shares	777.385
Weighted Average Remaining Contractual, Options Outstanding	8 years 11 months 12 days
Weighted Average Exercise Price, Options Outstanding	$ 1.04
Number Outstanding, Options Exercisable \| shares	100,404
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	8 years 3 months 8 days
Weighted Average Exercise Price, Options Exercisable	$ 3.02
Exercise Price Range Two [Member]
Exercise Price Range, lower limit	10.01
Exercise Price Range, upper limit	$ 100.00
Number Outstanding, Options Outstanding \| shares	91,700
Weighted Average Remaining Contractual, Options Outstanding	6 years 8 months 9 days
Weighted Average Exercise Price, Options Outstanding	$ 29.17
Number Outstanding, Options Exercisable \| shares	90,105
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	6 years 9 months 29 days
Weighted Average Exercise Price, Options Exercisable	$ 29.35
Exercise Price Range Three [Member]
Exercise Price Range, lower limit	100.01
Exercise Price Range, upper limit	$ 200.00
Number Outstanding, Options Outstanding \| shares	92,847
Weighted Average Remaining Contractual, Options Outstanding	2 years 3 months 4 days
Weighted Average Exercise Price, Options Outstanding	$ 166.04
Number Outstanding, Options Exercisable \| shares	92,847
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	2 years 3 months 4 days
Weighted Average Exercise Price, Options Exercisable	$ 166.04
Exercise Price Range Four [Member]
Exercise Price Range, lower limit	200.01
Exercise Price Range, upper limit	$ 277.50
Number Outstanding, Options Outstanding \| shares	69,391
Weighted Average Remaining Contractual, Options Outstanding	1 year 1 month 2 days
Weighted Average Exercise Price, Options Outstanding	$ 210.79
Number Outstanding, Options Exercisable \| shares	69,391
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	1 year 1 month 2 days
Weighted Average Exercise Price, Options Exercisable	$ 210.79

XML 58 R47.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	6 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement [Abstract]
Expected Term	6 years
Expected Volatility	103.27%
Expected Dividends	0.00%
Risk Free Interest Rate	0.53%

XML 59 R48.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Agreements (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2020	Jan. 31, 2021	Dec. 31, 2020	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Revenue				$ 1,375,000	$ 250,000	$ 2,990,000	$ 253,000
Development, License and Supply Agreement [Member] \| OS Therapies [Member]
Revenue	$ 25,000
Funding milestone payment	$ 2,337,500
Milestone Set forth in the License Agreement [Member] \| OS Therapies LLC [Member]
Milestone achievement, description		The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.	The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.
Second Mile Stone License Agreement [Member] \| OS Therapies [Member]
Due from affiliate				$ 1,375,000		$ 1,375,000

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 60 R49.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
Leases (Details Narrative) - USD ($) $ in Thousands	Mar. 25, 2021	Apr. 30, 2021	Apr. 30, 2021
Operating lease expiration			Nov. 30, 2025
Early termination of lease payment			$ 1,000
Security deposit		$ 182	182
Net payment of lease termination fee			$ 817
Write off of the remaining right of use asset		4,500
write off of lease liability		5,600
Gain on termination of lease		$ 100
New Lease Agreement [Member]
Operating lease expiration	Mar. 31, 2022
Rent expense	$ 29
Lease description	The lease expires on March 25, 2022 and the Company has the option to renew the lease for one additional successive one year term upon six months written notice to the landlord. This new lease is accounted for as a short-term lease and the Company has elected to not recognize the right-of-use asset and lease liability.

XML 61 R50.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Operating lease cost	$ 1,011	$ 289	$ 1,301	$ 579
Short-term lease cost	16	85	16	169
Variable lease cost	61	129	159	270
Total lease expense	$ 1,088	$ 503	$ 1,476	$ 1,018

XML 62 R51.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Leases [Abstract]
Cash paid for operating lease liabilities	$ 1,039	$ 311	$ 1,363	$ 611

XML 63 R52.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		6 Months Ended
	Apr. 12, 2021	Mar. 31, 2021	Nov. 30, 2020	Apr. 30, 2021	Oct. 31, 2020
Common stock, par value				$ 0.001	$ 0.001
Number of warrants to purchase common stock				30,225,397	398,226
Common stock, authorized				170,000,000	170,000,000
Net proceeds from offering			$ 8,500
Amended and Restated Certificate of Incorporation [Member]
Common stock, par value	$ 0.001
Maximum [Member]
Warrants exercise price				$ 281.25	$ 281.25
Maximum [Member] \| Amended and Restated Certificate of Incorporation [Member]
Common stock, authorized	300,000,000
Minimum [Member]
Warrants exercise price				$ 0.30	$ 0
Minimum [Member] \| Amended and Restated Certificate of Incorporation [Member]
Common stock, authorized	170,000,000
Securities Purchase Agreements [Member] \| Pre-Funded Warrants [Member]
Share price per share	$ 0.7911
Warrants exercise price	$ 0.70
ATM [Member]
Number of common stock shares sold		886,048
Proceeds from sale of common shares		$ 700
Public Offering [Member]
Number of common stock shares sold			30,666,665
Share price per share			$ 0.30
Pre-funded warrants to purchase common shares				7,671,937
Number of warrants to purchase common stock				10,754,932
Common stock, authorized				300,000,000
Proceeds from sale of common shares			$ 9,200
Net proceeds from offering				$ 3,800
Public Offering [Member] \| Securities Purchase Agreements [Member]
Number of common stock shares sold	17,577,400
Common stock, par value	$ 0.001
Share price per share	$ 0.7921
Pre-funded warrants to purchase common shares	7,671,937
Ownership percentage	9.99%
Public Offering [Member] \| Securities Purchase Agreements [Member] \| Maximum [Member]
Number of warrants to purchase common stock	11,244,135
Private Placement [Member]
Number of warrants to purchase common stock			15,333,332
Warrants exercise price			$ 0.35
Private Placement [Member] \| Purchase Agreement [Member]
Number of warrants to purchase common stock	14,005,202
Warrants exercise price	$ 0.70

XML 64 R53.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021	Apr. 30, 2020
Beginning balance	$ 37,575	$ 30,180	$ 35,437	$ 39,531	$ 30,180	$ 39,531
Stock-based compensation	$ 215	236	$ 210	242
Stock-based compensation, shares
Advaxis public offerings, net of offering costs	$ 13,683	8,550		9,628
Advaxis public offerings, net of offering costs, shares
Warrant exercises	$ 1,185	2,586		$ 2
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan			$ 2	$ 2
Issuance of shares to employees under ESPP Plan, shares
Net Loss	$ (5,107)	$ (3,977)	$ (6,323)	$ (7,857)	(9,084)	(14,180)
Ending balance	47,551	37,575	(398,449)	35,437	47,551	(398,449)
Preferred Stock [Member]
Beginning balance
Beginning balance, shares
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Net Loss
Ending balance
Ending balance, shares
Common Stock [Member]
Beginning balance	$ 116	$ 78	$ 60	$ 50	$ 78	$ 50
Beginning balance, shares	116,130,688	78,074,023	60,236,599	50,201,671	78,074,023	50,201,671
Stock-based compensation
Stock-based compensation, shares	5,888		5,651	2,957
Advaxis public offerings, net of offering costs	$ 19	$ 31		$ 10
Advaxis public offerings, net of offering costs, shares	18,463,448	30,666,665		10,000,000
Warrant exercises	$ 11	$ 7
Warrant exercises, shares	11,037,435	7,390,000	7,500	26,416
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	1,000		2,694	5,555
Net Loss
Ending balance	$ 146	$ 116	$ 60	$ 60	$ 146	$ 60
Ending balance, shares	145,638,459	116,130,688	60,252,444	60,236,599	145,638,459	60,252,444
Additional Paid-In Capital [Member]
Beginning balance	$ 452,174	$ 440,840	$ 433,614	$ 423,750	$ 440,840	$ 423,750
Stock-based compensation	$ 215	236	$ 210	242
Stock-based compensation, shares
Advaxis public offerings, net of offering costs	$ 13,664	8,519		9,618
Advaxis public offerings, net of offering costs, shares
Warrant exercises	$ 1,174	2,579		2
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan			$ 2	2
Issuance of shares to employees under ESPP Plan, shares
Net Loss
Ending balance	467,227	452,174	433,826	433,614	467,227	433,826
Accumulated Deficit [Member]
Beginning balance	(414,715)	(410,738)	(392,126)	(384,269)	(410,738)	(384,269)
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Net Loss	$ (5,107)	$ (3,977)	$ (6,323)	(7,857)
Ending balance	$ (419,822)	$ (414,715)	$ (398,449)	$ (392,126)	$ (419,822)	$ (398,449)

XML 65 R54.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Oct. 31, 2020
Common stock warrant liability, warrants exercisable	$ 4,931	$ 17
Through September 2024 [Member]
Common stock warrant liability, warrants exercisable	29	17
Through 5 Years [Member]
Common stock warrant liability, warrants exercisable	4,902
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 1 [Member] \| Through September 2024 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 1 [Member] \| Through April 2026 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member] \| Through September 2024 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member] \| Through April 2026 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	4,931
Fair Value, Inputs, Level 3 [Member] \| Through September 2024 [Member]
Common stock warrant liability, warrants exercisable	29	$ 17
Fair Value, Inputs, Level 3 [Member] \| Through April 2026 [Member]
Common stock warrant liability, warrants exercisable	$ 4,902

XML 66 R55.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Apr. 30, 2021	Oct. 31, 2020
Through September 2024 [Member]
Warrant exercise price per share	$ 0.30	$ 0.372
Through 5 Years [Member]
Warrant exercise price per share	$ 0.70

XML 67 R56.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2020	Jan. 31, 2020	Apr. 30, 2021
Beginning balance		$ 17			$ 17
Warrant exercises	$ 1,185	2,586		$ 2
Ending Balance	4,931				4,931
Warrant Liability [Member]
Beginning balance		$ 17			17
Warrants issued					5,882
Warrant exercises
Change in fair value					(968)
Ending Balance	$ 4,931				$ 4,931

EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 166 326 1 false 50 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://advaxis.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://advaxis.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://advaxis.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://advaxis.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://advaxis.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Nature of Operations Sheet http://advaxis.com/role/NatureOfOperations Nature of Operations Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of Significant Accounting Policies and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Property and Equipment Sheet http://advaxis.com/role/PropertyAndEquipment Property and Equipment Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://advaxis.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Accrued Expenses Sheet http://advaxis.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Common Stock Purchase Warrants and Warrant Liability Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability Common Stock Purchase Warrants and Warrant Liability Notes 11 false false R12.htm 00000012 - Disclosure - Share Based Compensation Sheet http://advaxis.com/role/ShareBasedCompensation Share Based Compensation Notes 12 false false R13.htm 00000013 - Disclosure - Collaboration and Licensing Agreements Sheet http://advaxis.com/role/CollaborationAndLicensingAgreements Collaboration and Licensing Agreements Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://advaxis.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://advaxis.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders' Equity Sheet http://advaxis.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 00000017 - Disclosure - Fair Value Sheet http://advaxis.com/role/FairValue Fair Value Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://advaxis.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of Significant Accounting Policies and Basis of Presentation (Policies) Policies http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Tables) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of Significant Accounting Policies and Basis of Presentation (Tables) Tables http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 20 false false R21.htm 00000021 - Disclosure - Property and Equipment (Tables) Sheet http://advaxis.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://advaxis.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Tables) Sheet http://advaxis.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://advaxis.com/role/IntangibleAssets 22 false false R23.htm 00000023 - Disclosure - Accrued Expenses (Tables) Sheet http://advaxis.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://advaxis.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Tables) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables Common Stock Purchase Warrants and Warrant Liability (Tables) Tables http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability 24 false false R25.htm 00000025 - Disclosure - Share Based Compensation (Tables) Sheet http://advaxis.com/role/ShareBasedCompensationTables Share Based Compensation (Tables) Tables http://advaxis.com/role/ShareBasedCompensation 25 false false R26.htm 00000026 - Disclosure - Leases (Tables) Sheet http://advaxis.com/role/LeasesTables Leases (Tables) Tables http://advaxis.com/role/Leases 26 false false R27.htm 00000027 - Disclosure - Stockholders' Equity (Tables) Sheet http://advaxis.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://advaxis.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - Fair Value (Tables) Sheet http://advaxis.com/role/FairValueTables Fair Value (Tables) Tables http://advaxis.com/role/FairValue 28 false false R29.htm 00000029 - Disclosure - Nature of Operations (Details Narrative) Sheet http://advaxis.com/role/NatureOfOperationsDetailsNarrative Nature of Operations (Details Narrative) Details http://advaxis.com/role/NatureOfOperations 29 false false R30.htm 00000030 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) Details http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 30 false false R31.htm 00000031 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation-ScheduleOfAnti-dilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) Details 31 false false R32.htm 00000032 - Disclosure - Property and Equipment (Details Narrative) Sheet http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://advaxis.com/role/PropertyAndEquipmentTables 32 false false R33.htm 00000033 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://advaxis.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 33 false false R34.htm 00000034 - Disclosure - Intangible Assets (Details Narrative) Sheet http://advaxis.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://advaxis.com/role/IntangibleAssetsTables 34 false false R35.htm 00000035 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://advaxis.com/role/IntangibleAssets-SummaryOfIntangibleAssetsDetails Intangible Assets - Summary of Intangible Assets (Details) Details 35 false false R36.htm 00000036 - Disclosure - Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) Sheet http://advaxis.com/role/IntangibleAssets-ScheduleOfCarryingValueOfIntangibleAssetsDetails Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) Details 36 false false R37.htm 00000037 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://advaxis.com/role/AccruedExpenses-SummaryOfAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 37 false false R38.htm 00000038 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Details Narrative) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative Common Stock Purchase Warrants and Warrant Liability (Details Narrative) Details http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables 38 false false R39.htm 00000039 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability-ScheduleOfOutstandingWarrantsDetails Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) Details 39 false false R40.htm 00000040 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability-ScheduleOfWarrantsActivityDetails Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) Details 40 false false R41.htm 00000041 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability-ScheduleOfAssumptionsUsedInWarrantLiabilityDetails Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) Details 41 false false R42.htm 00000042 - Disclosure - Share Based Compensation (Details Narrative) Sheet http://advaxis.com/role/ShareBasedCompensationDetailsNarrative Share Based Compensation (Details Narrative) Details http://advaxis.com/role/ShareBasedCompensationTables 42 false false R43.htm 00000043 - Disclosure - Share Based Compensation - Summary of Share Based Compensation Expense (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfShareBasedCompensationExpenseDetails Share Based Compensation - Summary of Share Based Compensation Expense (Details) Details 43 false false R44.htm 00000044 - Disclosure - Share Based Compensation - Summary of RSU Activity and Related Information (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfRsuActivityAndRelatedInformationDetails Share Based Compensation - Summary of RSU Activity and Related Information (Details) Details 44 false false R45.htm 00000045 - Disclosure - Share Based Compensation - Summary of Changes in Stock Option Plan (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfChangesInStockOptionPlanDetails Share Based Compensation - Summary of Changes in Stock Option Plan (Details) Details 45 false false R46.htm 00000046 - Disclosure - Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfOutstandingAndExercisableOptionsDetails Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) Details 46 false false R47.htm 00000047 - Disclosure - Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfFairValueOfStockOptionsGrantedOfBsmDetails Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) Details 47 false false R48.htm 00000048 - Disclosure - Collaboration and Licensing Agreements (Details Narrative) Sheet http://advaxis.com/role/CollaborationAndLicensingAgreementsDetailsNarrative Collaboration and Licensing Agreements (Details Narrative) Details http://advaxis.com/role/CollaborationAndLicensingAgreements 48 false false R49.htm 00000049 - Disclosure - Leases (Details Narrative) Sheet http://advaxis.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://advaxis.com/role/LeasesTables 49 false false R50.htm 00000050 - Disclosure - Leases - Schedule of Lease Expenses (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfLeaseExpensesDetails Leases - Schedule of Lease Expenses (Details) Details 50 false false R51.htm 00000051 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfCashFlowInformationRelatedToLeasesDetails Leases - Schedule of Cash Flow Information Related to Leases (Details) Details 51 false false R52.htm 00000052 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://advaxis.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://advaxis.com/role/StockholdersEquityTables 52 false false R53.htm 00000053 - Disclosure - Stockholders' Equity - Summary of Stockholders Equity (Details) Sheet http://advaxis.com/role/StockholdersEquity-SummaryOfStockholdersEquityDetails Stockholders' Equity - Summary of Stockholders Equity (Details) Details 53 false false R54.htm 00000054 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://advaxis.com/role/FairValue-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 54 false false R55.htm 00000055 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) Sheet http://advaxis.com/role/FairValue-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) Details 55 false false R56.htm 00000056 - Disclosure - Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) Sheet http://advaxis.com/role/FairValue-ScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) Details 56 false false All Reports Book All Reports adxs-20210430.xml adxs-20210430.xsd adxs-20210430_cal.xml adxs-20210430_def.xml adxs-20210430_lab.xml adxs-20210430_pre.xml http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true ZIP 73 0001493152-21-014308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-014308-xbrl.zip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
5BU?G?=VV^&N?5O>\'7)Y@W7E+[UNC\? M+GF%)3_[3-@JZQT#',(YI%V Z9P=JL"KY$%*>7"T=D?&BGV[7"/0BSDBW+/2:K&)(.R7E1SSOC*V]&/> MZR,W*$UB)KK$5P*QJZL#;;$L:E/13T:L8=SH!P@7B"[8#W2K9F1/'P. R0*N MJ&[-V*TP]Y*9I-V%Q>)L1HJEH=ICWR5D.D^TF0) M,VW6F+CQKG08T44.PW^MSQ=*3=M-H '(4(6\2%*&+S?+F7?'*"#0 S@YO#H# M\ %XT]JNIKH;^Z79@!R1?#^;E>\E1C, /,+>>&&.LAO,P(2QV?4OHSL?SJ;S M.< PN!?+5KL+^^5:DQ213+\8.7->/G.]?1TMERY^3E2UZCQV1D3A&/9[_6/8 M]%L\"#N GF^V>4Y[/)T]GLY^U:>SQ^(AW>(AP^&YL7C(ZDSJ6#RD*4*KSUBS M<"3 &'C<)E"?\"VW-G2:2:O42(&VI0M?S@E5":34M/?7CQN(HQIIH3!,O_;F M>9QUU+=PH3<)CMT5#%U?>:13!M9[=7T#*:D)$.Y,QA^OIIY, +Q3%[/7-)2G M;ZO;6UU#J<9T M%<5L^:8#$$8URI;N^UQUXC*8DXB%KRX!AB@NJ*BNP/J.$9$ZK8TZ'(!<7T*8 M<-NR4OJQ"K!*?0$>^9>&DST#'ZQHJ\@0R=%P)854 M.9L+<@-^L)*LI$,DRJ:%#Z+7[>+T>YJ4%U6:;3:SF-=B=$4L;5I3H,E2:0E? M=>.!L3>/M(C)ILL!)(OHZ7+EHV< XEK0I/20E>8WVUJ$W5DLU9>3)9*[X3(! MZ9(K)*GI7B3N<+"RUR-,)/TO9J5_ <+X19=SJ5M0:&:_I"K0E26<#51TG+D0 M\T4C]Y! ]AM_P9==/96^,@L!^0%<5K#A35DE4H29^E%_!"#!P>%(C)4@8R7(FZ@$R:;HT7/VY_]" M@"GBB^=S\ !\>4F(+KS=M2'UN&!=S#3#.5G1^&'4,B&JZH2:W9@I*JDI*H&< MZS#*OJH3$_*VN4JE/YVPNHPE0WH2K**0<,+W5'E?"9"AHI9FDU0@U&JJ;%_' M%[LU4R7F\[^#OYEH MO.7*%BMY^+IDL\W])FZYNEE@%-TOKL$JY+O6S2.Z6:"(N(%W\TAQ?3Y#$99> M;U6C!U.O=_5TK55-3K2]0_@M7A@DBHC9\. MDTOU##Z OP,7R]^JJ6Y\^^E-2*V*:F$^O^5W4W)'()+R@C0[4U4.S4 D$+=[ MI@2F53^AQ%S$]->1S;ND"AN$"Q#"F>M7I_8^])[:0"D+3MGC@1\OV"0@DR#[F-&2AFJ#GQYTDM6_V4/!@S5T\B*9B]TM'&7KC9J^,0R>_L?^Y< N@O_P]0 M2P,$% @ .8#.4D5E!(@Y4P 4O4$ !4 !A9'AS+3(P,C$P-#,P7VQA M8BYX;6SM??MSY#:2YN\7K9V)FQ59G@E\"'1.*5^)=_>WZ(T"-. MLS")__+-V^]/OD$X]I,@C.__\LWGF^/9S>E\_@W*O/F MZ>GI^SAY])Z2]+?L>S]Y,"OO)MFF/JX+FYW]U\W_?7?V[N3=VY,?WI^@MR?_ MB?[S'3J[N/K^>45,.?-R(D5_)E(G?R#_]?:'V[=__.GDAY_>_O#_##^9>_DV MJS]Y\ORGD[K_$H7Q;S_1_[KS,HQ( \793\]9^)=O6I8^O?\^2>_? MO#LY>?OFOSY=WOAK_. =AS%M*!]_4VG14D1Z;W_\\<SD%+OF_)OZQ2OQ&"B-'U#]=_$^)ZT>$ _ M]"/]T-L_T _]4_GG2^\.1]\@*DD8*;7KQTY9I=(;VV"7. V3X#P>A[JO[0@^ MZ3MIOH,!;7WK)MPFN1>- M_6M [["H^K\4;/?DV3@06/J^F6YB2PTC"B=1?OUSB1QS-GL.L^C2S^R_?#%5^TS>0%C-+*RN)N*:J2HDW?D(&NDU^ M'!6-4JBOTN1A.*:R@I.AFK]&=_67B^8AOTM,[(BE.&,!T"!VM.T<5?DEW(>( MJ-- $\?'GV^^^5>J441%J-9!)/!$5[,OZ!>J^-__\J;Y*@2"SN/--L^886\_ MX8<[G.HJ1J3AA(IRZ$+^\>+P2"?%*&?:$2J4CA!30V_1+X4F%*K-GKPTN"6? M4;B\GHQ-.@GAM0G4$0!#&1&J/DF8#*)">W(^7O"<'5=32];(=+KYZ^TZ3;;W MZQM2TXQYMT_)[3K99L3SW3[A.'^Y(*8+G>$&@FXS[6R M!%070=<8?H#FBT2.]MW@8>\=E&'OW;!A[QT0RIEC-!_VWAT"U=X/IMI[*%1[ M/XQJ[P^ :N]'4NW]Q%3+TKQ%,_)O?8J1/_UZ3;"*(JK>;S9H(X1#"=+YP3D5 M1&CZC"! M$EN?":4PJJ6A#3IG. T?O3Q\)#.C+$^WU--=A]EOBC%'K6)SR#$!WQYQ5/+. MR34 9)]EC0IJ="8>3]C+MBF;V+'57>)UO2&*+HDF-T1%.5X++/FD M4'D/5P@B*@G=J3$O_"6)R-1 NBXP4-A5*""J@:@H-*)>$Q-( MCR,^_29/_-\^QV&>7=]\5G)3HV.3CD;PVPQ4*H AG0E*CF>U#F)*B&FA;XE> M]ATTVMUL[[(P"+WTY<:+\&+%$*MV^N3R5G?Y=+ [.WPR83 TTR'L4XQ*H615 M\@O4Y&.^7"A]5NMWFX3A8+4)4O\(AA!]1'T"++=W4>BCQ6J%TS"^A^95EFPC M "\CSV<#MI(1,F&;]% #;G-%+ F&.$IX'(L*851+0^,175M9K&9T\_*> 52, M3!)9FRQ2PFV32"@(AD,J=-R!>[KZ14:BEG1QU2R)C[W6WV[)/V:>3^^M3WP, MY8R>CDTV]*N79 8;9W@6!S?;S29ZF=V3Z%_JCP9K6UO4'VY2O<)OKNJI)7*V#E\J85:',(5"SDFE M0\9%UJ7(M#YJ<7.[QJFW";'BG)Q R)K'D0*L'0LGX;RIE;#Z[;RX0;7@-)X@ MP_[W]\GCFP"'A2,@_\"HP&A _N772WSO1>=Q'N8O@GXOE+!! 4TVOJ"GYTW MO1Q3O]V9%"K$K/7QR\M3HV[>DG/1TSF8HLY>"SEO=!TR99HMJ+2$2LY>(73M%S_UJSCB$3MKN+(P7;7<'@YYVPS ,>OWY2B MU4(P+.Z<)@\/2:PGCD#.)FND,-N4X83 \$6&K$^60@XF4V9!$-*E(2]:>F$P MCT_)()U[D9(U&AVKR5M,X'>2N:@4P##+!"67[*76053I>!ZC4@T:YZYQ[H4Q M#LZ]- [C>_%$7"=L=XM=!;B[MRZ2!,,K)3R.4+Z_?=A&-*<@.L.KT _!Q4@S M,IL,PFA+;[[<8'^;DAZ L_-G/]H&.+@@C4BO8&YSEK5UL:K,7N+T9NVE^,.+ MN !5HJHIOVC573R>\?L\AVL6%;C/)5%9&4M;43.<1ZA807<=[8:ES<#@J; M8)224[>YZ'R>O.U5TM8XH(=<=A$R0O&Q3E,FK]4E<]$+FR/*SK #5%DDD!8HH''4:24 M+_U)H0%M@K@DD.F;)8H975?$ZJ*Y %QGL;SUNW..*$!QB^/DW]A+,1-G'6YR MU)Z']^L^UE]$1F+/K1(84+4VI8/>NOA]XY_2\7=TY"S.&B=W*37F^-,?3'32-/R%3A34WH7X71J8&AHCE4P M\V.:["AN2Q>:VRN>VXN(@;/@(8Q#,E]E&:U,&&FH:Y.3@\QIL])($0POAZ#M M,[/49<3L:D\]RZ3;67%(OU0?_U%,,U72%F\BZ""W;A[(1)W3Q@P??[.@4FB. M:TT]U32Z17 ;YO32Z#P.PL/]$BB>!%4)F0WAAT5G M$>/JXK!\N#%6M3;V##2F'H@,]9PS: 18;B>>:K-GE?=_-5Q"L:ODD97/84ZT M%#-6M4:Q@<;4%#/4@T&Q86#[%*NT*M&O;DG>Y:\O!5NW:UL(PJ&& T&S7UL)\FL=Z M$SX/(4Q+W"%?.- *NM2R4-G2!VA$%J(T^6$Q3!HFJ"]WF=_*,U2T=Z1LB"'- M*3,3+1B<&@*5.XO&=!%51DQ[P@MWLO@8/UUBSXA:4E%[\:\:;!/OBN5@$$8- MCHMG\1-BXO8HT1R1KG: 3=9_3;1L>AU#$]HN1Z,"@S[&. 7.ICKY7N_L3[!0 M+"'5,L476Q*>!ZJ#[DI):^110ZT)(Q:#01(E-L$UW>-"VMI;7.4[V.+5)&54 M;*II^P5T0U/ZCY]KU&"P:1!6V9/G]=K?'RR1BT[I_HH]U8*,3-(V>210^V3I MB8$BAQB;C R_1TQV\D&G/T(J1AV9J+UA1PVV&7?$WGY2T+'YT1[+^H :\E2_ .%$#P[7 MU+>?7"78.TT><3J[H^>Y_+R'7?"[K>1Z0EA5:KW.C\Y;6(:(3RY#9- OE93M MAB[R^5WC>W9V+\[IM0^!)6(Q6\VN EFUOD@&! D4P+@E_2*Y8B/+;N$X8<0I MB7A2+YJ3L>;Y/_"+U"Y.SBXG)#"[I.@) 6*%&)F$%J4P8M*(B%LFQEGBLW>) M:>)R@47=GVW10 2J:OWV;R :70"(.RI;BK#'$1TU\!*G81*Y$&:_[3M"H$@@0B9E0R&,SND5$")NF1ALSD%Q7$3>O<"DWN^VB""$51&@ M\R.(AAV5B=NED!ITET)B64 44@*44*BE M0[V/5W'*"84NP@BGI\0'WB>I?*;:D[)+&"'$+D\Z(H#H(<(E8043196L$R[< M/'A1]&&;A3'.Y -13\HN%X00NUSHB #B@@B7A M,%%6R+L+9 LCY T[OR1CW M,4V>\C5-X.G%*VE) "*& );,D5!)IRQHO1/ $OUFBVV>Y5X<$);* W.EDN49CX$! MO7F/0@,0BPQ@RN9 K3<=CE"AC%K:CI9>BYE]L=IW0?XF"F$4LK:78*5P^\NP MG" ($NG029=CRP68FHPE;I]L_ M2<;GL*A3FRU6%V'LQ7Y(V)]D[/D1R:&/8:HV\UT,,::=!<-$SSGY1H#ELXI7 M>>R2%:J54:4]U=&3'1X%R3*<9QH>]H6L/KTA!-AY+:,C 89%0EC<%M3-S?GM M#2@NE(N+1I3@9.TS0P*7)TA/$!A/Q.AD>U*%SD] >'/J9335(OV?\[]MPTD+">^_>-&VOZ\Y4-?J0WM#S.D\OF>B"(9W0]!R/"1*[%"T3_\! M-^I &'E6/CAYFF1UUY)4@UC4)M]48-OT$LF!89,"G"!!8?$:*"[27D(AS'S782O<*XFCUK%ZF!H +XS)BKDP9#* *3@'3ZF@M):!PB]EBG> M>&%0YGHEGG>1KW':&?TEU6"D:?D!8U-3>N\9Z]3 4,\=A66%@*3& T?Z'O/N2D M"] PD65#)UY8VFU4*G9]E!Y\USG)Y0%Y)2U(WAT5*LP-X4H>?1MCMD;EM=ZM M#?"&C)HAN\CX'1 .SN.<6!.28;SH3,30XHU0NL^=),%3&,DJRTS5;K9@F X.@ LGV^X4BT=H9"FW@,]2/EW4#1=D#[FT=.=+$?3-7V#9['ZG!55 M(*DHC8Y-8AK!;S-2J0"&BB8H^QRL=5!*Y8^3U?$V*_EX.'1L@M4KTOK*V$XB M:Y5^*K@=VHD$X=!-@8ZC&9L0@ KW"N3*4-9%Z"^/^2$&^\HH'U1S7X;>71@5 MCZ;'Q79^?7-[]#Y__Y>7[[5WA<-=N>5"DXXJ/!1J5<&B+G MAFU91HTBE'W+:JUXZ;W0=6*SI?Z^L(M%?C%@T?)^5Q(,BY3PI$OZFT(:#GO2 M+0[X#B&W629OF4-JV#T:B84A,4F)4$ F*K^WO4=)GJ[66>DREVJ%L'^U02]N M+9>7 >@ZNY="UCDW# 'RR:'8*?6,/7K\5.C4P]9^+T/L:Z&I-DGM>G1*[I:: M9 ;(UYKZ&L[9-@BF+#IB=\,)^9(52NH%J(CE>X?&P-,D9O'>SV&^/MV2WO* M4T,>FJE:/>LUP)C.42\#/3#,' !6>E8GQ8\XWD*)O8R#+M?1EEF8Y3B^TBYM M&4=7WP&4UKH MW1A**@[&%>DQBF:1I49Q0KZM@X[159)C]",0L@W>]8&RSS-L9^< ]G(&[]ZT M%7['#G;E+U 6UI=I.6U@(%77?X22EH\RRZ#VCB[WQG]&OS\Z.3FA_T%9D:;!V^;K) W_CH,_HQN<4B?V 34% ML6_^&=7B899MRP<3DB;! _)R5#S\\_[DJ'CXFTHL_#RA;S2_?\O^>/)G=!D2 M(@?%4PH;]A'B.-DS"_]\8E@(D#[06G]4WG_CQ&R/V"*0_6&Z+0.&]Q)@RF7= M8P'EW_[Q1$[Z(_3VA]\?_>']GXY^^/V/C&]__-/1R1]_.#IY]WXOG#]"I(@- M9MG](BAK?+,@8/?5O6CIA<$\/O4V(0F797LP,FFK^UIJR)U=+;$H&&*K\7$[ M6K4THO=.CL,8^84"$#)=X]P+8QR<>VE,^D4V:PY/GN%5Z(>R8--$T2;%S UI MLTVO!89XQE %NZJM6P1,$@CY^+C:. !W/:,QF\G 6G>1XA,OOV2"20P0XN@. MU^D7GB1JD(Y#:M;TA#JP"&>(5KOZQV(SP'3L3O*67KI(6:ZA@(6^2YRRK'I& M,T2YLKN)M\X@^5Q=:!:,JQ8AD%,+_DF8B- MM5PS39*+V% %-.?TV8AEQ$LFRD2\+_:U%L67]9JX^:Z*2MT='_5&R8DIUP7* M4"U@+54C\<8(I%"PM1X_<'YBI.EH7V3(S,1 #0Q!S;&J-E3@34BX+/7:V8A2 MPQ'K3.8A"G&(+#.<@739!77ZP=FEG'M(I9VR2S[KD(C"995ROB%D%*C)QH W M3\Q4G/)*,\< _=K) )!&-(,WM9C'?O* ZSSUFO-^4FF[:;.4D+N9LH2B8'BE MQL?GPZ+2J'E4 -SS =?%M: +TEZB6T9UXB^:'(7\?W#K/4OWGD>49'?W?[2I MW>, @XL!P][QV/O,O@9UG:R^.%*F>]6]AZ&0=W(-2 9;>/VG+PR&73J$\NL^ MU65^*.>?KW&&2272]/IGA.A1PG)NEF9)^Y92QZZG,X#?]6D*!3#\,D')^ZE" MAQT/"!HM:+GK/^*8=(:(F#8+'L(XI!V'GBA5:=1 <,\,YQ] M[I5:C'I>1P\:^SC/;>KA'8^71N,DK/-.,GCB TX)-T1"8TPQQ;E,N/?#E9). M6,-#%?*F$0/*' X@EQB0_(1H)53\26(HO+E*XJ1K1_5"@SIB-]"SR2EC,]H, MTRJ!&>],D8J3XH;%JL>WI>7[ M8F X),1'_ J27$A=^L]X^S\F40$21J$L9>^ MS'/\P'+GT]7E)(I8G13>7;FA,M$7[6]R35IU_$;9))^#U;^F-U0T+$1T"G7' M"J[Z:DZ+!M5/B;&EK_F 8[R2WL.52MOO'U+(/+I-3\9JL"""UPD0V@*PG)8(FLS- &%#=6>\.CSZPH#XTM5J=>MKZ(DB?=L1:UBMUD&'KPW;08)1)<2TX)T#I.^R$WC+-'D, QQ\>/FUWM.,YK?JLC2H-FH&5&0 MY:ARI*&]T'-@*6!8/!HZMY"U/+^>WW\"WN'3,5F.%.%=Y :0X + M^$QA%OS/-BLRY-XFUYBV3QCACBFWR7Z\R32?LIO6;KK*ZN;$V_]WP'23"8WC ML_'5GT)Y@M+J8RP#/9M+D;_2?_;I:+XE7Z%;1\TY':_^$)1M[VJ^B(/3Y(&N M/[%54UF,(Q&V&CPJ 7?"1J$D&-HJX0GS0=/)22TXT=-FYP^;*'G!N+@Z3.Q= M$X1+@D6\A6BH8^V1,U/X]4MG.@7G=!F"LL^:2JU,C[LI%=&&2)DL-Q_>H0-+ MP=N/17O%^)Y>JU>M]9I#%I[3^_:>:'V'DK@\BD"'D_H00OF*'93(KS'PQHOP M8D6&6S+PY2^4ISG-U\?.UDOJR539ZIGU009UCJX;:4+CZB#40KH2G@9AMDDR M>CIYA39E 6P!#5<%3#1R%Q M ?7@I=6 ,7J9PI11ZHEJ'E-52JJP5D8>TP;B_N8/&R],BQ7 OH'UW8U]FW'U* <^+N@IJ;-=X1_Y?$U4HO5 *?X0V9T(:J"6!7 MQ.XA51Y<-S1L?@=#'@$H_@G.1@38"9#9 WU'[^\,FG8T-56RNKIF9$!GG4RI M 8971C Y+]12JI@&V1UUWXF\ICNVB]7GK#"R;8SZ8C\?/83RFP M,US\;VLKI7S-2)]XRK@ R\>0!QK6.YELJ W&!0^&S.5%JY#XH+'H%9$(5$Z0[ MMJ4D6#8N4TQ?>CLK4T17=ZOC@-T-4TZ^QA;FEK%##%9SV*0D^*P>8(4@L3A5 MK?.!'*&$72CTMZ2D.&][YJ!*00XL=XA@1*(F-&$&C" M)[0"M?C^*ZAU"/FPL_1>Z$A"$S_Y?KHEU=)$.X/','5A,&(*$X/-H@Q528"# MXP'PI2'(IM M$G\5VO!]L"@AJ&Q18W0I;DEN9**:W?^="1@>4;8[JH8 MH,0KQK"D+ L!E M T,-.*THQ;D;WADZE[OBZLOYS8 [7E:?V$M\C .6%49PF)$$[KH#J8-*L/O0 MWF#3NF_M&:N#8>QPS/S"6%%"D?AT^C.J^Z*Q]U+>:YKY!!K-8V1T"L= SRIE M3K!1+47 M8>S%_AZB6F5! +AL8*@!IQ6E@(D11D/OT_MB?C6[.@4?U=)'$8EE)!9JO69G M$#])]%Q%L$HS9'&K4 D,$TV1BOSJIHI3:3Q0ZK;3$K%[G#12!7;WKVWSSP6T M\V><^J'\N1"UBBL^RL#+J-B7!\E""4@N+58AAG E!Y!&4>,NP<A%F)V$)+%MZ.Y%Z:3^81QMG/+=;+^C_R)6D#\Q278)K4VVKZ0J' MF=3)7VBF"F:Q8!A>+L/AY^7R\OS3^=7M[!*=SF[^'5U<+GY&\ZN+Q?6GV>U\ M<06$I*VGA)9>&,B?^1,).GE3AP,J?$ZGE@)#*"DTH:-C%Y\(VT ]Q42?EB+@ MFLW5.*C7(]C;4_J7;4WU+3_5-\RLWM-]9LI@B#@4L=*WG/\U]B,OR$52-?,\H2&(^)T%:::UH[1 M#S.E/D%OIN:<@\.QRK9UZBP2]!9TK4Z/'24L. 237F*1WGMQF=#EE 2X210& M10@1!TM2KS3"*%(?E;W0B^JG-'0.=4]E6\T1M,_JZ"0.VD?!SCO(%-9P5T]: M91^A3NEL@M4NG\ZJZB^@YA/PGG79J<;H7#1*LFV*;_%S_B&2GS[9_V<.IO-_@41.%@M7DB5K@ MG<2)4FDP7-1"E-S8ILNYE08\'TX?O,OH?8BF,Y&^=1/>QR2Z\^GE",YLG;_> MK4B;'-V'\6T6[U(>&)[OP0AN_KI]>/#2%^I@6^4@40>AT1!#0(7;&(#T%^G% M(8U;-M"S?,+,S(S>83.U$A@.FR(5'$%C>D>(:3(VUKKPG+?43//@>E@1("AJ M&!0/T8=/7/-@=MF^D%CK V%LE>F>F-:_W=98J'&E \NP^N++&/,Z#[\,*0 , M:\>@[M.V*H/1MBD%%<6@IAQX;EANL\[[&FG:W?,S-J6[":A5 T-6G6R8.AE]ZC-R(76HPUU?IP'-S)LGK MS%W?Z-(<+&*--5FPPC6T*#"TW@V_8&V,)2X\WU/B0O4NM-"Z/%L!J8V(@_[NN,QU M[5:4-5;M:&Q-OI'EP.#H;N '4MF;@LK[>I6M]LGL#GG]_O,UCFA"&IH\)F-/ M2=_1IZ2K'#2:^''70JV^_+:7"NB\%;=3B<[[QU[-X);ZJ<(QTT"E"IK1GG&/ M8:ZA&M?"AW8MZ*+;G4L%V4/453"JBXB+/+P^HK1#V$D04T'M4H%TB0_;+(QQ MEA%H=V%<'(?0# AJ%:M[N@;@.WNV"GDP-#0 V>=8I8+:.O#/8[ZQX:!SDP#*LWDH>8U[GLN:0 L#P=PQJT;RP+(.1N%,*Z#TK(^MU M_G=H(>!8K?3'PTHX+%Z;+'A(B0V$PNS9!UU@VA>R24$QP#;%NA)@*"2$U:=( M(03/LQ6X%JM+$IM@;.[,#/3LD\? #)Y/"B5@%-,C%;,."-6*:W,:#]07LDDB M,< V8[H28.@AA-7G0B$$SP.Q;8)U$@4XS0J,5TD^P!,-T+>:BF*H69UD%*;* M8"@X%#&WR-?2_QTZAW1!]L(+TR]>M&U9HXNCU"HV:6@"OLT\E3P8LAF Y/*, M$Q7$=%H338#QF,@TG0?4Z+BFF]+3*15 $T[GT1K& :'6S?8NPW_;DEGJ^:/! MKK5^ MO4RR[#M$]!$K8")_=\.R@K$<7R;[&H:^:AE!IV%^BUT+M+\U)QJ\1ZQ.E=DN%+Y=J\#BKH5?DK_-1* M49$F,?E'OSA08N+$QA=C]XF6<49V'VH95H9S![@C\#YKK[&/NVE(;G(O#KPT M@$+E&W^-@RU]L'A& 9AM,W#1WR#_6W*+ER=/]-,WSB@[RO1@Z3;*AU6/[[0 MSF(G^)#5Z>]D%=69-^_]*V"ZU&2F<9%(^2$Z@:*?.JZ^A9J/H>IKQ5-@9U2" M_ L-?VG8N[^H=^H\+*.SKT#+N3(NTPH\FAM#5=$6=(:5IB-?A'&8XTO2M;BL M'+?T"J_YF#"@)#=.?["I8J]N7 P8/H_'KLC1!C7/165LHC+V8DMS>DC0O M$X>6=\P'<7X_GW#1&?99.:)>LH_RP76?/1JE&CA.O31]H?.,8MO^ +H:"0<- M\CX,'$[&%.EH,C':>,FT87!YX+K*#D8HAIQ]YP/9VTF^,IDTLT=Z4*PK9/=, MG@A@]^!=6P(.G42P^"-TI1#ZA8F!.2-0X;H,8\P><-%9V1)T0@\.J) BM10\ MFO2A*:A"11&3W9DOLEVQVAV6#3>JV3DSUW5. MK9& 57%=JXPZ*0P45U4;*C[/7,%=I-?A_=K@N-/X\MR$<"/-%L=O PMSSO5] M6: B?Y/0JWC?'LK6*F/SFH;G'OM @$8%^W;[WJJ1))EJ9JD0*A*-NA+7.U MH=9;XC"[+N>\6&4LBMAEEPXZJF"'W7"'BE!TMA&E0NU2XTU1=)S3-1U7,QH? M%XENB_+84TB'TF'H7[/9-E\G:?AW''R.R3RW53?4%!(-G#_CU \SO"0^!U]3 MJW?N4'OX,*@.M[>*'-0A=_[JX738?9FJZ-#M94EV5*DHC+J%LF\#7*7DPOTG M+PW:[HWNG1>O$C83^]X?<=U?=Z\@7=\<_P70_7!GLQ1]KI65@4XA6^-H MAC[2-2<2B)(?/MQ\ M+UV-4-.DLVZD-2:>NIL>20N818O"@8>JKQJ98UF2:X M\Q+-2HZ7K2^BY.EFN]E$;+'&B]JI)@:N0 XKS=$:XAB3):N 0XH"0^;=\*L/ MSF5K1 ML3^+KB7V>(% 7T%2[;4,C%6T!4'95!T48&FV C#:$K%I.;I4 *QU8 MZQ!YE16H.(PZB]MG^CZ1/D9Z;["(K^E-G91,*U@JA*&7"?;Q#4?7#/97/9(+ M"+M_ &#?V9]5JC&BB;R/JD=CB[SR]:=0]2W$!H_R:\5S\Y.?%"M7U^9Q71N+ M5>\9*MU)ZKV4Z. \V2ZF"XZ8C2G.>:_8GPW*.*E9PNU.1/L''C19O"?TIK>D M6A>KUB;N[#D4GDH5"O[Z#EJR!#5,Q;L7C[CS,!9[^[7U[XM\C5.4DP9%7:5? MZ >4)ULG;+UEFO@8!QF]!EQRJEJB%#:B2AY>6QJAY5[O+96*N\I/94?#I1Z4 M$(\&G_,LV^+@;$M'O25.PR0H5J&O\!/[27Z*W4S9>C)B8X.X3,1:3><#QBBX M7,*H[<,=\2)D ,B8/ I901,%.TORXS8.<% ?I$ZJMS++YS@9"-'(:*QJ+7P9 M:$P=IQCJ.>?7"+"\Y\/'A7KE]C*Z%K.IWD?UBU=3"^H!<82GD9=E=:Q5GG*?5LB]\?* M#D-=/I#^E%_$ML2/S?/I'V1 VK RK8<08\SK1 MQ) "P/![#&IUW)MYQ0P4HL]7AE#M#> JV _&Q&*2@L $Q4I#C0-D82EP>#T6 M>I_\LAUBW.BSCO_6I4!19]W@1>;K+D;I/"N^7GG#U0,V45N9^R MK5)^G]71Z0K[*!A.%]FC-8I5YB:%:QB7*5S#F$X*JZ*IU)V7A3["Y2?0ANAF M@+*Y%@\RT /WLEE&2\#J](X#UIFVU;^"(1T'B7O!LPRYT88*.=K3!.Y!P(2! MTYC5I\1M0H)S1TSXZ(4Q33"]B(L%LDZVX#K1KZBIS31MM>6/15O&^)Z>C[W% MJ;I!!X+G'G^@*;F)9P_";)-D)/HG+AX#RXK,S@?3PY?SATV:/!;1X,>4()?4 MB4K!^ET')7#NNH-0&LR8H(4H?%N$*J"PI0&$5Y\\?QW&.'UIYQ)7\4JE8)-7 M>N!M7LFEP?!*"Y'C57&D*DE?P'FKBRT9,EG2X3BX")_I/RF=E4+>ZE.Y.MB= M9W)EPF 8I4/(/8];R;.S?*M2 PBERE5/>M6XB,Y(-):L\B<2D*F8I5>S>FK! MT(C.H02-#ABZ&0+E3Y06LN"<&-U8SM,MVT*>QR2FO"^Y4CJ+:'LJV\7*BW(5;;]V";:SJN)1T"J?=2JO5;"[BR1B>ZZPD 8J>\_*H9&>D11A4WN#6BV>EPU$N,A3RD]NT^Q?D_-0,\1F]1F2'@E5H+(,"52;E^D$)[J%'0+EFH! M6B-K+=34P:V#3)F@PW1 MBE?]PEH#X##7-Z>UNM*.%(?7B[0@(,S4&&K(54DIT);D1EN@6GP#L-;6-^8* MYV:S< ,]:&MO@S#KIF^'X(GX9ZFO\8,7TG3B]%'XS/>BOV(O'4%YXY*A^*J! M56'JO R+=1[H[=^6?O^@]$3?%AJD/WUWD-WC"C_GMT\X>L2?DCA?CP@>C0J% MVRED%3"^/_1+/-"N(#%#T O>'23S:<^^?4KV4E=U67!YWC-W/+W+@@Z4U5WT M C*_/UPRD^_++FF-+@TXH=LF[TAI6M0AD[J%7T#K'PZ6UA>D8O=62T5AL$G= M-G@W3M.2#IC2+?@"1O_^(!D]6^4X9<81A;W45*]$N-P6FCZ>X)WB#I3E(ANX M!>$U3K%'!>$3OG5F!(0VDK.VZDU8*WY&6$=?,_8(K_.'S91\H)Q^:!- M*TG[Z39-Y:>%#?1LLLS8C#;1M$I@')TI4FXSU8N\E*;$H*=($-2*=4LDPW P-Z1%-H0**8'J8@,6PMC5;8V4LC)7BS M84@J#&V#4P]4?+["*_2J0ZA0^KXPTS9[]T9BOTK!>0;U#G!M:G0F#::O:R%R M%T2I0OMQH21%3 G]PM2@),P3&G89QGB>XP?I762-DG.J<09HZ59KP*9<'^8 MVE%5Q'1!>?P @M ULZL#G( Y4DC29$;$0AR\=4_ M9N6OV=LAM:,ORSD[3&Z+7940OTC.:)>I\O2T-[I+:;F9(;B!/HNT6$T_2B3Y,E\BUS&_>*]FQ0.>3@]C+_;W,(51/W.4-5U( MDVI$HV#[ 20U\/YK2&)I&$0R@:AP?.PY#'<)1CHFS.ZR//7\7-H,E0"<\$T- M3Y#:D;ZEQ]XM0]6[K'40AF9QP+WK_H*.4?T@_&+5$O;S\)'\#B1T8['E!V(. MRW59;86WWC__\-*(++T7]K#ZDY<&5TEM]MQ-\5I@[J6Y:O)ET6[9LN,1:FD4Z<*:^+5^7/8( M?<#W84SO:J$[CQ2DGM1?_WL(@%)[2S.RTK@KOS MV#;9Y';O&MR=%P)[BNPD2S?3U@C-CMO8]C.F"U/.UM9HIDT'&S6 M%J3@F-Q;=($"#-*$$6+%<$ZG5$&E#NKN P^>:!Z.&RK#= !.QPC)(;N8 54] MI4,Q@.%\7NK>]L$>8C_S6'L=OP[J 71]0RR'W/D'5?>4W=\(R*MU $.L'^P" M7,V30458<&-B0#-MF!4S451\OI=SX:J1\4Y?B7?22C2NM#KEWVD2LSWKK1?= MXO2ACOJEC0P&G]T1%(S9(H\$!!R@D196C6B=45T0:I6$+L,51O,8T>PJPS>( M7Z^3*J8G0-N^ O5/:."^)I?4 M;1!(+ND\!#JV M$9RL)$DP?=4;J^HZX=Y_J:11+8Z8O.%\ZQ_,MMN*7_/RJ*Y.!G!;O]HY]4DY M;AF>_Q7.92 %-BZ%9'$%2']DV95YQ'F^VLG21PXJ 0D*9<::$[.L?!#DE MH/M$;8FAD,K1_#0^^3%#.J"4U;.G;+O)+6ZE.48[J23\,IF_:M+;? MJ3_':2W>R9)-_B7+45KD.$9Y@N(D/BX0H(Q%1PDK&'D,#Q 'P"PN%K//MB18 MOE\6\UJ664=." MS$J7-<67#N)JI[ZJ]G+A3OX9.#YP,MO$'>^^..I>1@09C18V9?:40^]_=%*> M+5;LG_==V]VR#Z*/B:IC+[VJ7?#A]R.!->*>4\;0.9REG]%;SJ7O^%),4NB2 M=[&N=9O0/[66&PPWGF49DB$!M-YG@=@MZ?@@T,'R'I"J1.F"Z-2>GK.J=)\AM^&G83D :_8J>W XI\MVYVO<9"X\& \;?N*X!^3G+L#YG^4CE:;[^TM/T;RO BDWV M.-^PXC<4WSLDOZ"MMHGFP*^T7^LL'-1O6U$"L+ZJ.J90AV)4J'J'8$FL'G5. M154:F&,J>I.-3ZG(BX+31W;"+W]!K#B%@D)6,MK2A\00+HLKI]/5QBS:D#(. M];S*>[M/A.-TU&F5]P//%+V6,RO\79A\C=/;M5?=2:UGD=.\&S+\^P<1;HRM MUKV$'T,_#NGRHBOCY7[Z^N9S=H0^ETK-'47TX74\&J*ML&+R5ITPLMY>_<^_ MCOXOKE0[W;_[[5?SI,$XNW4=OU!Z]9W\(DE7.'39SP4(7D=7EU:MG=[.??[K MZ? RTW5]_I2.Z_1Q:%!SKE<7=@+*+.#.>./ L\RQ\[5$G75]]8[3L//N[+%J M+TPG6?'>*[37,80-;PS+'D6+ZRN=XYK6BRQ9V'&5+(QILJ?=$=6MLIK\8UI< M1A;PO-1@?*_#58UL%A3BV8^1,E*5CV>Z8H\R MAU0KJ5K]"M_@0XK"4FRU_8!]M/$VR)K6Z.7" QJ@6^%]<1DA3%D)V52[WN;? M/:0!W+@:]^E_M1\%UQ\M&2SKO/4$$R4I8NJ'-]=T&S&^IEF@UDBCF/%53MM: MU] FG;8)OG-(7E]:3?OLA-Q'7E\7E)DHZX!?FON,+=7#]^104]*X\/HV5PHF M?_-YCP^GVAHALD'SXBGR4^T3 :A19?]5.\@I[._SA[/]M7>;!WL#@S6A0^K^ ME7E./5@>T'4R/3=)L;Z5T /:!B4/U!N8\ S M_OHA#6T#JW2BE5HVZ -0J 5V&*_J4./HK]E+I\;U=78D7/&?,/YS\\/Z$>8?F MG76KE54$1[VV^]SLXJ-M*LLVZI[NOMK,6=F\6J-8DH(Q4;#:/Z^L%V87V5 M3M:;Y9]^G1U;:Z\DGW!G2Z#4:/\14D_G)ALCZXJOHTG.*#A YWYF[:Q)]--P MZ]!@>1HP]3%N[^$?WDEX^JQ>#"^OW@];SW,%\?7Z*;/&<>>LU/B^4H]E5"G# M#WC#]E?[CCQ;"Z\.YDVBKQ_\O$E>I9//F_A/P_(-UNP=,F\"NO>P+S_*UQ&D M>=,NZ XV'MF]228+1<9#@^5IP-3'R#-;M(BV9_J'NQ*&?58F3H,AO5[')*Y\ M=]ZHB^.>;8IZH2OB01*28*\Y=K+]_[7?,A7W:_ M##%)5>[EE++Y9V&-R%9LE?;=1OHU]^"S\#$,YL:DY7);W5;\W8/MMJIJG*S;BC[Z.KNM MPM)^MZ6BB,JB2AA1:?0U:D=AK4QR@QZ/42IQ9V3Q1PC MMP) E5#>:*%D5=)G3Q'.OE8$L+]-2:A^AC=))K^QV)>R.ML60^S,C;LBSHFC MQL7/A HI$K\PL8GSPCO'-1(*_4QHBA>KU6)5'SVZIF<#%JO/&5UTP<+1R43+&I', M3:BYI%>!02=CG-P!#ZI(N+2B?,K7&*7UP;*4%D#_O"4D\V@9DU.+]83+T+MC M&UYJ0_NR#F@DABL@3U<0&F6$Z/I$>6H3I7 \4:4")*#Y2(A[F639(N9C-LDH MK5:Q&>J8@&_'/2IYYP0; ++/,ZJ"R$@F"J"!\(S!G\7!-1F&O8CN^,52@DED MK4_:97"Y67M?$ R75.BX[1P:(.%"! QILBQ)ZP4%9HU\_=E8RRZ1C$SH4DJI M HA<)CC[-&-B )>>NW:<)IEL7+UX:TF/^.K8(Y&R2 M10JSS15." Q59,CZ3*GDX/%$QP]'O%#RP0T/\H0$M*(S-3)8?1+MT<8+ [1* M4I3T8I]JW2C$8 ['>A%>K-BENBI)0''M;IYE6QS,X]O4BS//5\S4AA5A-6P: M85PGH!J@#X:^(T!+LC\D*S*J/CPD,D]^*A]$1S;/** 6$3.=_VX;YRR> M8#F-O"Q;K'[VZ"6 ?)&R?2AM5D.6G4\B47WV)>#B!L3[DXG&L10\!R470K[#A"7JT 9*18IHF/ M<9#1\[N]:+F]BT)_L5KAE'_-E@JLGNVAW69/HG+C28A@4AI2<%-#7V.0X^RU1)[.$^,YG^[TN MZ>HX)V?]9J<()G<3LRT$DC,2D%K"')636RC$H=POYNMG6^I1ELQ^=LU3?%'T M8YIDTE2D8TNS2L+=3.8\W/"BP Q,N^'GIMRTM&.66HWH*GGJRDN-:YH%Y(![WCLVZ+SK]PRS1.$RU(RM*5I M;-'YS7*):"D01SBIR<.'/'E1!S8&&ABR(Q-,/.&$C+C">7G.13+=Z@A8WAXR M:#TQ/-&J+14XM#5:N]5M]C:Z'"67&J!(>62P/ MOG=/%ZKC)J_1"D.J*=^1A M6)38V@=BK4^C=E#)7"#\ YEPIK<[&Z( M] A-R,H#TAV:=*C!_VS+PU\K#=.-,8J"2<_[&<$E*S>SFX_+=/D/O4>/F%Z$%T$GI>QMF(K M@U>3H"_P:Y#XUMJ=?&M+NYSA'L>S^Q2S MC*:*-A?*V6MW!SD/$@],IWU3)@@D;3'!274A@U" M,6!\4&'D&%$(#^3$5*WPPY>$#S8:[3*+0?[G%S_D'PL'? MN*89H NKO88#YV:RM 2Z)MTNXTU="/JE* ;1ZB[%@B+!WNRAKM131!3;ER$,0GQB.#WCF/N:JNELJ69F-;AJKR7 MCRP'6$OO9(1D]9$5AZKR4#V9)^RH_@759:)?7/N"/FO$RUH(R&;R&&3T!8'00H^,X4(LYC;W.\"..D@VU MZ#+T:>(-XHMNMIM-]**+BLU583708-S<4PQ- 4>H+((YW*(0(%%UYZ #>V(J MDS2D5!)6N^E@,QW$E!#5 M8^BU@63RID MH;=.'ZA1XQ E8&US2[RZ>>NTI*&W#P_5J(68&K0V>DK,6ZB2!=\^/:!FK?.4 M.&Z;ZA&OQ6KIY32-G>HM1;4XM!8RP"IXLKI4HBN>FT*MG=7:R=KG11B'.;X, M'W%PDZQR,OO W U8I2"LEM&@Y%Y'9>+'$95'6:EPA.ZIRE3K6C3H6&_C(,4! M&>)^HV?QY7&_0MC>J[DZP U'9)+ 2**!V6?)#R=OO_WM.W9KPJE'W?7Y8EB- MH 1I_(SQ5+WTXW)YC1]QO%6L/O,RUOJD#%[-@;X K,:7H.,>J5DN42DW]9K, MQRBY\Z(/8;)<>^F#-X]]1;M+9>VUOP9NPP.)(# ^J%%RO&#BJ)8_0D3#J6LF MWT^+QTR*_YW'O<3.32YFKHD&Z,)JM>' =<]UM%)63^78+[V[)*72+W35=Z,^ M^J40MM;5M8!K(DDE8=%&!Y-[_J>61[7"U,/!91C[210OO?2W4V\3YEY$(Y#+ MRU,%5W0J]AAC!K[AC5H>&'N,P'(<*K0054.E'J**1XBH3LVF3SCU?S,X:2J6 ML\8;%W3\GM.MEF7AS(4G?,=2#U7+#0',9$$IM M1+SB":J2W#J-U1/+%--0!U>G=R75+A:#5?=*C/T&(,+'A;2UHSU]?)D\V).*6HOW-&"E MQ #9*]4@05 C?/1R?/[LLZO&!M,!G89%HIA ;_%%)0Z--@98>?8P)51I 3E+ M6]VOT+:/6 Y8PRA!IK?X'(=2YRH7A=4>6IS\X_"5 M0GFTF:DX;98;?XV#+;VS5J1[R.9QG2NBOMS66K6^I1]=BL.5O/NQ18N M+WA9*'OFE=9ZQ"!F-^:'6ADL$4 MN*KE6V6T@BT8K2M,=C^C&._9*/+AI1$I3RBP&QI72;Q@ZT_%U8%Y3'P=J].L M.HL7_(SI+5@=T[U\51Q! 08[]S6@OC]2/Y9 ^0UB-#=2Y'FL)0K MCZ4@C\)",3WLQX A7-PQ"1MHJ,I*':"G$ASR"G2H^U"S+-G,YHV%D1R"OI!?LIQ;V M3GHWG*9[JF6%2+:6>1%@/)#A$[XOC$K)J<_IL(_=;*)0<3*'E[%V%D<&K]OJ M+0& ; MH :[E9289:U6I]Y':4L=A3%]YIL5,%6$^7.8K\/X(GS$'[99&.,L._->%%>; MU/+68DL3V VM%,+ R*1'RE&(J2"J@RHE1+7@Y'YOQU+GSW15D#\8HE. U4Z& M:*4)X8N'-S95F+BA82(N5%VT%GW'?A'_G(8Y#I*G>+$BCHO@#NDIJ"S#.1_$ M:#5@M9J.8Q5:6GWL-:&7E,VTVF IQ_],*X-&NQ6BU6['&F M9+7-"JO(Q+23K(D?<$>4 :MAQQO 93/ .;HG1=7-35IZ15L[I>4=)ZOC;5:V M-]L)ZV:U4H_/4U& OK3):&NS>G:/V_)3?ALW#ZU+/3FZ0,U:AVBY+9Q MJM"F>5! E25.*0VK@4R@*EY5".C%&M>IX*P MFL<(*]<^5 GEC1:=+173(I,,[A/.BTO<6[/VZF >F[XO5I_+Z3OO]+0JL%K,&"^WL-M>A*!Y-=+Z["); MDJ!_KI>9IE))@BUI8P6C#J+1!!6@Z[P$P.NRQ$ED8/5&&J0O(-[0DQ\ M:,+?'7;./L=Z 4J^=Z;3L+9[9@:]-4M6B/)S@"ZL%AP.O-^<90FH+H(N2OW@=%FDA"1> M8)-/P,W40+:?&699T]5KB7]PVFPT2?D-35)^@_.+),W7\_AVC:M'VW7I] K(>1S_$&$XF@MMBP;8VT8#7J$,C*;Y^6U1/G+A>#BM=-5W19O?FU$-83PQ6W2LQRH:H MWQ?7!5T[KVW*U*K#:QABOP&>5BHA/(>QX4YE "#"].$(SZ7HY MF:K@- ]7(9E]8GHXR4_235*L?\S:_%:,\[. MG_/42](@C+WT99[CAXP8YM/D9TD4LA\WIP+WI MGX\=IOGK>S!4&0BXW^I4O6KS)$9G8;9)LK Z.EL5QK+&Y*@N[FNZ7.J^J7>& M+CA\.[0L=Z-+2G&)_Y_',]Y-MG&?7V,?A(YTQ288)K1XL?V\.5^"XF1+Z MME+_CIYKJ$I 31%@&G&9XHT7!F=XA=,4!V4(0TBWR-> :JGF8,:7>1)NAV5@(V;->B#9MI&;#6K/(7T_PO MI]LL)^%A*AR+1Q8!NGW-D!LV=%48>B*EH:JX(^1Z.":!PZF7K4E8^!@&./CP M\CFC*:4:6OMY^"A=)3?7!M32(T"+[CK1,E!5"'V9Z%M:#FGK[]K]N2[+4?N6 M%[FRVV3FDUB?3C#E67>,E0"UICE6+EM'J4G7YTM=U"B[=<42CL[C1S(%']LM M!=J &G($Z('=LB[*?;>4&'L1QAX[I3*J?07:\-M7!7I@^]9%N6]?BI+^AZZO M/'H19O.^ZCU[^D-Y)JWY0TMRB=,P"?B Q(^V =M?*=Y"O_9R?+Y:85^X[&47 M 2">.3*+Q6L<-$O7>V?^P.\#6$MT:O9DK&^872%"#!+3 M;(-J[6.X.EZ!2:2(V>)JICAJ:R .R(N:H.3.4S"=H^*2= ;EA.WP[/3N^[0: MER3!B[Z)4>TNDXXH/5J@U /4&0Z!\/LA"[:C<;:L.&3'5(\24 M71W?]?WMPS:B%QG.\";%?E@F3-I$F+VF%@>SAR3-P[^SOTLK0-2L^RH;$ 'V M;A)W"+GY &I_X0C5WV#T:7_E"/4(=M1EF"-J7=#LFO@R?&2YZ3MK,5)/H-,! M1 5CJ/TF+A2/F2:_T.36'2B,:C&S3;Z!K2@IY3#:50=^:$NW.WN[0'B-?X6% M'EZM<1B-V@8ZM &)KJNS]31CS ?]VZKT7MSZ/6]^G*9UNNQ( 8"'9X[[C 4=U(:"'I/#Y+ M9!F:U\/G:AX46.)Q_3U ?L^*F?9Y6V-P]@KX9#Y!^1A[)_4PMX !!1B ^ULP MZT/840 ?.V]:'9_G^)[$F:3$"X-XRSTOWC1UFT'DF#Z&ON.KBI<=AL)MD.+ MDGB#Z8'#V[575@B]4D(/1>!@@M!_Z,=?0_P_VN8)@BD^@BK/F^8$#BKQL)BK M0'2H4P%MG7]AYLWC8BO=+L>[WWX-4X2Q)KMC> &(G:-GD%X=P2^2=(5#9QSG M/O]5T%QNM3NFUYA>,=GK\:HWM?E(-\'/2,AVX84I%^A#PO5U!3KFU0$B!JK@ MHA(O8H 118PH9'20$X'2TFG7^F4?>0U\U]HV 7EK>KZ"]?KNH+E-6;*>YO6M M;)+(Q?2CKR%>&6SKE(1MH2C.I#0X#C MN \=L4]D^=.ODZQ&%ENC,!>G=E\;=SJ#$U6D]99UFV?:BJ=X/I)1;Z2.9^2:K]VFL@J;F1$Y"TF<^CUN>/ M4 4 403.KA41Q*>).&E>_2,@"O"8^ M"1.((41F7/;\]B9=VV+80M/4+(39A M]^BN'0@JO?VG2_)/Y,_5G\A_T4Y#_O+_ 5!+ P04 " Y@,Y2ISXQH?@[ M !K,P0 %0 &%D>',M,C R,3 T,S!?<')E+GAM;.U]:7/C.);@]XW8_\"M MB9VHC5A7GG5D=?=.R%>.8IV6QW96=>^7"EJ$+'13I)J'C_[U"X"D1)$$\$"1 M>J"2'3/=3AL WP7@W?CS?[RL?.>)1#$-@[]\]^Z'M]\Y))B''@T>__+=U[N3 MR=W9=/J=$R=NX+E^&)"_?!>$W_W'__GO_\UA__GS_S@Y<2XI\;U?G?-P?C(- M%N&?G&MW17YU/I. 1&X21G]R?G/]E/\FO*0^B9RS<+7V24+8'[(/_^K\^,,O MKG-R ECV-Q)X8?3U=KI9=IDDZU_?O'E^?OXA")_%@R5O?Q_MW/O[[]^.N[C_\/^,G$3=)X\\FW+[^\?7?ZEOTGF_YGGP;_^)7_ MUX,;$XGSS_NW;=V_^^N7J;KXD*_>$!IQ1<_)= M,8NOTC3OW:=/G]Z(OQ9#:R-?'B*_^,:'-P4XFY797ZEB? F2F/X:"_"NPKF; M"#G3?L:1CN#_.BF&G?!?G;Q[?_+AW0\OL?==07Q!P2CTR2U9./Q_F;QLONIZ M3^X+%2+RAO_M#>-/NB)!,@F\BR"AR2MG5K02L#+XQ6++B"S^\IWKO<0GA6SP M+_X;9&[RNF;;)J9"J3>H$K&MV%D7$ MA%;R&=W0*5VMW.AUMKBCCP%=, %ANVL^#U.VO8+'F]"G?3.(8<,K( MQG<"#&-+E!+OXF5-@IAH89$,[P04IJ^LPN N">?_N&'*PI)=/+^[4<1DAXM* M_N,5=1^HSRX ':3M5NMF:RW9L,"E=T MSK[#MN3D,2+9^:ED%3.T$Q"OB G;.[JB. MKCHFW,O0]YAZSX\J_::0S^@$H$N71D+;UL%1&]C1E?80DW^FC.$73Q!9EHU' MOU^+O_9YSU:_@8[TOU,43.7*9(W>@"X16 %/&U3, M5NY%.S+E"'1^+\">;/:)! Q3Z,$+]H3.AOUGC'ZO;*N+VZM#]%I^H ]]=TOK MRA^ R+5<#D%'-MU3W:R.@&A)OF9I(D*Y3,2*"4"^]OA)7))L1LT9F[:,ZXT> MFN_A$H,=,^EJ+;3>K\RRF@82L>Z-.J8 ]&B&&FO71JOT"/CVS&W^>WX$0Y7> M#K]Q$*1OX[386TS6;HGO)ER0-F'YCO V_,Q!4#];,G6!Q--LY\W$/KKQW:Y0 M!BY_$%1+UPI7QE](-*+/%:;SJ M"'OS+QTJ'&BNO+5>LD,GHBG4ZED= E:Z@<4O#)5^HT7Z ;O(CBF=P/F9?!_N MD-$8%^.5>W+X&NLCX!5Z KBD(\A ,4Q%^8 M2*01.QV9E,S3*&)GC' ' C'NZWM6$L,H@? @'^^-3!O=J72G5FP;"CZC.ON M"MUUR7M]Q7ZQ,X6\)"3PB%+\.6_9HO\3;[SSOGQ"EFE7]DJIB3+>&4 MU\@!+T#WP_D.M#[// ZC7;)R8&,&K<@OCLG\A\?PZ8U'Z!M.:OZ#H+F@-_O' M'V?A$XDF#W$2N?--WAW3*8@OUO^#C:D,>7, J#):W))'RK\:)#S#O!FXYI%5 M&,M,GT1S)XS8\YW,E]3?2,DB"E@ZY-N""1\X9$-&1GK\?K5]1TK0P%$O@#)H$;L3LPI2<,$(\#<^F[C\T4 MK@P!4O8C!F4;L3DP1<^8RL8AH#'3S_Y&W$@IOO+10#K_B$%G'8XX]UP&U"U9 MAQ%/;,CJU937G60&D/0_(=YZ2EQ1R#\-$L)A9@8Z$P4WAU!%?MD,(/E_QB._ M&E<4\HL:U3.V!Q_#2*GC508"B?T+'K$;,4.A\=W*]?W3-*8!B94'2V4@D,:? M\&C99, %LN>$17HHHCX$OB^P":[XZ# MDAK12FQ"#$=)V688B"A67(K4*545Y3PH!U#L23CB2%9FIL9FUM@E^YWD:%<, MA](?U=R4HHE*=FX]@(E>&@PE.8H=JD&Q@>!_?E/#XHK]HB_/=G.GA1U7]GOG MQ-G4\;.?ST*V?! 3S\DG._GLO45FX<8/@@EI?/+HNNM,;HB?Q,5OA "=O'V7 M-\SXM_S7?VS@FRTN:<" HDS PY@*(9#[O//IL-G[;XGV^.7A(2TFU7%8[G$C MPN[N&@DF/9Q0^[(CM_:@7*D-1_.IJTGS!S@=S54/XD38!B6KN'A.%H3AYIV%\09-.=.:1Z-Y^UOP2(6O)2S) MB\/B6S(G3(@>?')-$BUKU+/0P@8M6 3!WQ)6W41D[=*B/(7M_5FR9*II&5DY MQT"3T>(0+1AG0 U+^ ?D5#N>=!^@:+.9--1GL&<'XE6&M11" 5X2)JXO1F+O MNZRBDN>1)^6R2G92J#:<:A9:W,-$,80@;LG>JI8A,@BS8F7NY6T,@D>1JGQ+'Y?,F/P:9PC(F::9AA:(,>$6"'5;V+2] M7Z_#8*Z[QB3#\6(U1GQ1X6H)/W8[&LKT",R0C;D3XFATAE(^,[LXZW4 >H\2 M? 6\B-#^/D!3.EFR]TI@@UV$JCEX0:6V?)"RT6X_8F'NW[BOW-8'.SJJX_%" M4G"*-SLZFC&WASV\ T<=.26'9%.@3.K-G]&&26K\]^530S>4\[_>_5&*V,O: M^Y8HSZV$#I7:3Z.9!&=:;/\)XI\ H80G;> -E MCLOO-%F>I7$2KD@$9QYL-I2%O;DGC%EH0A5+&&ER,>US(_7FE3!F$N@J&J:- M)CE"0,X-_51P+-E2E1Y,'?NV)FA/PCG4FV.D.Z/K:/8DX.&!I@M2,0G*Y=Z\ M(WMR&?P4 _H.;./EZL"O]=Y6I\A@O%DWQ5$A(-:D4C4.AK*J-W>(,7,4.%O" ME9)5JLMNJXV$\J,WST>K8ZX)6TN8,?$\XM/@S%W3Q%6$E*43H*SI MS3=BS!H-[I9PZ):WC0F(=^%& ;LAX\E\GJY2T03KG"SHG"IN(3SAUO#9$8A M2^[97:"S$MU)FBS#B/YKN[UU[*S/PZYVZHR/,I)8S+]I'*>FO"OF8)<]=N8>WWW"NB*A5>4J6I>]AZH^ -A.HJ1[TRU G8) M56=,U9/)$NZ6WP,Q5G1 D[&KJ_;@J0%Q[&,G7,%13L(NQ.J&?9:K-C5(=7J- M= )VA567[+)2HS%L;R3#K8TNTZ,#KSNFP129 WME-@C&Y>=CFSTR'Z4>F>TJ M3KAPMNLXWW\-W-2C[&Y ]&#WUJWL-0 5+./:9! PYGX$Z\58T M$$\U\&Z^6IYI)V)[7DRY!J2$)7RK86=P"N([4$QY(\5V$'@#6;9AUC,^ RFA27GJ6AD3^(D@U5T M.% 91 V#L5TJ<(K7>J+(,+>$-^E>+8X%?$;V+3EFI8*@[\%MQ=[X6R@0&NRE"WQ>$RHXHG8NJIX^B=^4QNWH/P( C$5*&>[[[ M3IGQMU E04LGH#<0:B,<4L1MN2M( K&'*L/06_T8JLA-2 Y^9Q7Y]$7DF[_8 M.^>>,.JGB2I6J9V(W@;(C+U 0EBRXWXGO+T>\29/[))X)-?IZH%$LX6 O!2K M W.S[7KHK8/,F+P?V>R*>/)FZ9=^^"P)>/X(#'CR91RQCBT!SU+<>H.C40)Z MPRSDVY%#=!.%3Y1Q^O3U*^/"--BXUB;\/;ZL?D+O>&JQECT)Z5)VUJ_:EA2S MY'CN5R'JS4AN3W8S50FW^/7O:9RU(+@/;PFSFN94],G?0GP?=K9?^_D:=H2U M,T'IDQF6R%NA3/*',U;616"2- -7R5= R]6:S]$23+ M"TZC^9(!P)O%R]V>?)Y^&G;P]A",@U'"JGUI192BO\='#K=;VP0V@+Z23YG5 M$Y!'GJ%O@;=DB^&=ZY/98N=1B:C%;!COR?:A!Z0/ MR%X8#2UAN/+%HC(FVM07\Y70 ]$'%(JV=.[)U&Q]*K=N#SD=@*S)B1ARW=-!4"D?> WT>/LA M]4-CVEIRX]0!K[_9:R(.3;-MB,F;3[ZHT@]B(J*4DW)KC:7D7H] M].>9>KR>()2T5A-1/F%D(@>:A= ?=^I! $"T:YTL_$2BAY!92=T'+Q2DV#', MFD\"OH31"NA/1K5GO3&N5NUV>,9.%[F'%CP8U64NFR'E!E\3($%Y&CR1N*.$ M5>5:Z&]9=9>R"J"9)2<$@WQ.B">*T!HB\4RE >0W&"V"_IC5'CRK=@DUIITM M7'=?N M%RCI9"%?\\?C+UY(-*?*AF7J6>A/C?7"31EU+&1DEH_/]% @"\OCT1\AZX5Y M=8I8PC8XMEU\TI-WC-B^/+_Y^;ED_,Z!31<48D.F=F!/\#,SMW M?U$:>4,B&GIU?V:>6GOQ,E\R\X;<,MWF8K$@*JWMT'" "^$LTOAP>/5MB_B& M0.QZW^.PG0MNCK$\ZS+$O'J;>,[%G!C**#B;9/S$X-/K85[+;83PS)* M1A%'8. ?[^%"?HA7VFP4^(+?K%^2>!HLP6KG UT6A M"T %ZQ /R$$%RY ZEM@JI7:$_"5U9<%TTU@HI_I[%$/[PC) ML-KZG@-O8PV)EI&@+M?0):#2<.%P#\,.8C6?_R";N M/D2%V8MM%CVZ05Z<=<9@"?W\_4O&OIL2O4I/C&W;RP%>_.EF>=0:PGU0V/+^ MG@G8J:\,G73_)>3.<)T*5[7DL">VX)\M=^EJY4:OL\4=?0S8"3CG&299_C$[ M2F\8HG/N+PT\WL4RYJDHVT\WGT(_5T^A_!/\&"I]Q-E^Q2D^X[B!YX@/\<$[ MG\(LY*Z30]^I33$'\WQIX"+CK9+W@+-DOU61SPT]>RN'01E#4F%?X^ ME*;^[>S!3]4]N)WFY/,P&YGEO7,8T:OH;('6;T7#99!?C)+ !]B-H,G(F[ 5 M2^N/2T&)A+\/\Q*[VAN#Y6WX[FUU&^:SG,TTW.QK7BX8%_6"K@]05)634-LG M 8H@C79=ZP6QKT,]6ZM=D_8C'?Y>+.4T%JU?\5=]5MVJVJ"-6 M=8IEG6)=H5]SV/#)CICM[$S'[(.X 5"D/&]@NB4^+W0Y"^,D%G _<+"+ M AO]_;?ONJB](:&PGY9A!UR5>R^,?&5V(RS55I/=4!O_;#@+?<;R,"H\5U=T MSG#A0;3'B&0NZ^:#XD/]2BVM)&[0S5I.:3%,?V?*@"%QS!CV0(,L J8_%-2S M4/VW=R]W34PLQ#EJ)FX@PR70**'>N$&&TDP%3DO=/,D,KF %, ?S\(8WD9 M^HQH<26!:F=OU)*4RA/_W5V'\9^VK)-7R\DTU %+T-U%O8 '>->A;F5FJ" M#+!]--.0MPR$294-!*(#_J:Y2Q]B\L^4K7;Q)'=?U/)8MM.7K44E2[R/IWOBS&H MCXA;D0(J">DU,.HB3NC*34@LOJP-XQFM,)AL36/,I%L4Q0!QHX ARTL[$>WS?81D B6[)W,6Y+Y M3L#[1CD)_;ELTST#( %F__#..AP]ER@3A0'[<9X%':&;-5_*?"7TA[A-1:(M ML8:ML]Z+W+E&C?5]+9NS&XTU^^2HKW9E4,Z7Q$MY&^0)@\ZC?LI? K\C\S02 MF8S9"Z[$X[W8>%Y&6I3B5?4&B"7:P[<&HS#W2 -;3I*FHB?5"5%+(FTN?;)B MSW^#-5#[5#[9LT,[KW>R<.-52T%4FZZ6CUJK=;)BOWU[14_;F^&2!C0A5^Q> MJ $M.&-TU1HL=@1%47L0T1+SNL @5&%PF?+6(PVO,9O*1S=?P79Z=2DY7=(= M_V:HU-VI+H9:_G&U^LZ*>^&XRO!*U@"@JLS\\&^S*K:^9ER0UP41\7>J85&4 M8B,WIC*;UN;MM]FM*-+K+/$K;S5TKW[PNSI.MX]J@M?M=H(4XTD@WUS7;RVA M/-M:1/2= U"_-!:9 Q+JJEE0 K_\[B)VS@GUJ!N]9N^EB7-DP@XO=UNV(_WK/]'K.=SNMSPI5+ P6/ ',M899. *M\ V"VU6)P M?6_TB0GBC>]FL:(O9/5 (H4B*QF/'>^&RV'-RZ8B0%])!QN%<98F,;/P>+/O MXJ[4*MDB8F^R G:6G?06W)90Z37/YJ">D%$K/HECXN82F3[9?$=H7H MN;T_CI:R?Q+'Z6HMJEGYBT(MK&7U NB'K#EK023!MWV;^VFH;-Q:#:"LJX85 M3JNQO89JWY8AYR!?AE&MT\.$'T:/>3=A7\ EHN+-DB,0/Q6A._-3X*#@'&,K M#U3.6GQ59N>A;4_1MDI MD[6])="99=K"GI+7:FUL_>H0\K4'T8#2=_^S, W6[,"$)696FO'D4VQPB@=;,\:+H30_2F=,)C^-')L MK3MJB\?*9 V)K#@4!]F9 M2.');Z'':-<81&\B8YK@;ZQ-.QC5?JJU6=FV*+)B QU;KZ)20GD!8Y8*+%K[ M;K(*O["CGP'MS9BF/$^CB :/HGZQ1;Y^%Y\97B^D7NC<>_[ V9(;P?$TV ] M6U12-2%YN[L!^':+8BL_)CSO E];3NWZ\['G)'&I'U]S%'AQ9_-!7FOHT_2< MK/-]OIBS60WU=!^?F#W2;.%N&=!\PH]9QN@)K19G&=^S+\P6I6BP.L-8,GQ MS)!@8$EF\4Y8/O"NP\#=_J:4W1GK4E:-%[*#A4IQK+X(9HKBGLG'$K7TG"QX MY2+3$;:O@TBYPV>H)F"'P5K*7UG#U-.C'P]J'"6E?<;^5=UC[%=_W'-E<+:8 M!AY]HE[J^I+CCHV5#+5CGZB/.CGTI6 ^.NE_I\E2!+BX/"WI^CZ\")BR_BJM MH&A"2[<(,KODG-!S3(>:';44T^")Q&QQW854'8=VTK4A=>/]TXQY3\X/D1KP M'-&$1.K;I6D@V$EA(;%E.-D5C!MK]62U>A^P[K_KK\$E\IB8'(62'@&<#^?#)'CX8H6?5#N$Y)_PA./8_/!C^ MQ%#G!G9RQJSK5P;TSN,X#2_HP:9;7_%JAHY5'+R)PCDA7LP;A.91LB(M5Z'D MJ6=AQP[!#(,@?P2=M\59-(WCE'CG*3]+;MB)$GI9EO8U>19_4H8I8/.Q*R[@ M%:U&!.GI.KQA?TQY8'A3%A\6S93RYDT"',EU")Z-[7F%]0LP)(8EA^>9[\;Q M)KL@+VV_3OE%S32 31/F,]?WB7?Z>N'.E[MC%5?C_DMC)__#[\VNR&B)6)0T M0![UIEZ>?W%+YH2W@9P%)9409*5#E@&R^T=T=K: 'E(G[HZ:D6NW(7C^K5ED%G&9H_FC*F#J+'UPZ7 M.@A*XA#5Y_*MH0)!R&23]98<9LJ@"GB\Y+AEO&%I7(5=^$;4;(CCV4&TZZ M0&]E&':(0RE2%?(W8FB)/V7B_3V-$Y%+>QE&BE:X3*6;275"6>(F27) M27FZNQ<*VU>WMYI'V\&D5@+:7)I1P<^.XV_/9R,G*TX,Q<;L9OFA9 !T2DU+ MCNCL&7?>HDNA49;&8%^-J5P4P=[):55$[#35=M07$\ 2TSYT=DS!&=/%WE:!W9;W$3AFD0) MNYX]'IE8<_+!5WT*Q5+"8[!9S+;LGP)*WLD^*6,->#UV$.;/2JE-=^6D 3%&B8>"L:4'[/=C.PS!O#(CB+GU_"DS7 /RR!^BNB>1 MC29T*:*OL+";#>L/0,-Z-_RNL;Y'F[L7S,1+/_Q1D>EJ'?%&,#RA['/$Q%^. MDFH.\H'DE?^$^Z_:68@AT5:LLN+14LX59>/$I;P3(JAAFVZ>=ANF+:< M@]&C=> N"=E^MJ [V&0^3U>I>(^W;""SGWV2O]4R6851DK_C(J6*(B[P MO4!M1:EK&N]K[UH@=E(J!V.[C).M8UM6P. C2TMWX"V5NE;.[B8X[XVFB"V6F"U<[+TB&9.VYO"7?Z>OP]K$N&B.O_ MC;@*#WW761LPNF;'UOTS\9_(ES!(ENTT6M"Z1V9 [D';00H* ME_3[Y[ K^=@L-VA3=C_4ARX-[/N*?)[6"QZY80RAYF!EXC),.U,ZMNL=N_6K MI^4@!6*R2$@D,"DE<.XK%95%C\'F[8"J]LN',F=;-P\[J;]G+A])#O=D/H]2 MXN5R6@H95_Z@]&#\7/5@Y).=8O9NP+CV5RN<%3?N*\]YY%WX!8"N#WCZ43D) M]7&JU=H/7PFS?H6']HJZ#]3/WMM.HTA9UP.8BEV)KF=5]:TJ*#DL.93SMQ;B M'-,<[!LW G$0-AO;N#?GH@E5[&$D/^MNHG!!XIA1UO4O"8R%RGG8)G@KY@$H M81?;3(Y-Q11LZ[@ULT#GY.!TGK-PM0H#T=3Y)HWF2S>MR3J'\QP+U5UA5 MVR]5%2C[B".^XA2?<8KOB$8\^3^ZNC35'.0:CF8"-VY"%1:VU*,UPGBEKTW3S;.CTD8O>Q"678V/ M8?=+_/%A[#9D1G\8&T32+S2@JW2E(FIE")IJ7"5:C:2-N/2C\<)HR_0B'6UW MAZ!ILGK:-N%BB35QS ^Z&U^1X^/N:$7=Z(^[RVI+Q<<*K5CYR%#S4.P.,:!W MV^7@=W-8J8V^C9&I)*]L,)# G] )K,;6EOL@?8BI1]WH->N"+)P$FKM /L6. M0\;\'I!C9,ES]R6X^$MAL\4]0RUVYY!&$I"Y=C!.*XQ5O@$PLZ.AQ/1FIFL: M41H"#8?T5\0.%K=J_GT53TN.N<8C898F<>(&O#; T#NT,Q,Y @ES>T&<0PWT ML)E]URD7-":FFY?QSES?)][IZX4[7^Z.->2OV=+8T;/\;Y7^-WAF*A7PX[%MJ=*$!)9PO[2X$T-YI%PM#T1%52\1RF@MF0 MR=B1TW:LA9/%/D8*\.))FBS#B+I1;^W'JO5+]\_AX:$+\W -I[V)WP- M_<,1GI=VFI*^/ >[R*T#XM=)<##R\SI*0^J7IV#'@_]+NL%]L[ORS6?N5319]VAB^5T\>GMPR/ZEU8T==A,!,2FB4L;]V\Y?,C4U7D=^]AOHYE3!@$!0_)AM:ZX)H9O:%W ME[A18H$^V /)/G-6J1)!^OPFFH&"*Z85FEOB!>D!T<(3<%CQ*GT5S5#!%; : MW8^@7__QW]I_O$B]_9+ OZ:_-;S\#OAYA3Q)D\D M(PFS I9X<9GWJ M1W8('Q Q*M3LDC#8+F0N(-)ZT!$>S)PI5\:^C5_X&-B^HTCM-&MY(7V0M:XP1(^%/!!A1;'K6L9L8Y&-9X\/D;"&SUE>-(@IG-1 M=&V!5BR%#"JHW6=FV*@/:QCX[7B^CD?$#6R^=]^&CU=!J)[LO:'D1$V8%K7* M[K:O,7]RJ3I6F23UKH*J'&#L??8(=C["[W8X?C1KX-IL/QC:BW)C>^ M.Q?1;*9]BQHXR/0CE" MEO1Z;P)0=P*JYMC!)YWD ;ADUX%7A9 _(3U/B,?#&;K##S(7NVQ9+X8:ELD) M8NEA*')=?@M]1F*E[B[!5S(=NR9Y;SXJR6(I*WDKN\N(<+\V8?1.;MG-;,I/ MU1K81-E?15L-:MSOLH(A=]HI#E# ?0X_+,IRWQ.-]UK8@& M:L+JU7%V>"2ZX:@L)FA9O'T#5^U(4K#KRK:X>K/ R5AP9<=C]QMX[N8D<",: MRA^^EPP= O'ET/<3!X>1/@?D:Q"OR9PN*/&DGE2.@'PX,@ODU*US08Z$'8[3 M&]\->&A%'7?8'36$'= (N"71U0(H71RA.LX.NC=)C(3J_:9WW#^']\LPC9F& M?B'J&DAPL5K[X2LA.SFF'!IEZD>;A=![:C<+43DAI#U]^K%<09?$+4^LEM_) MI3_;L1NT]W )XGY"FG"R2C=! 294N/N_7VMB4*5H :H=MZA(^=>'[RO#AB#! MS9"7(BKH3F55=48L*\_8XA-XT.NXGZ_9(02- FS:O*L5_G9LX%L2)Q'E 7)Q M-7X-:!+?WGW512DUT["#&'WNCXIP@ C8UW,I9:U&0!ZK'TN1C\<.2!R"8QH2 M6!6\V,!)HB7H?)WTAR2^;A8\#?[16( MY_72\OU]H,\C![3E[LAJ]OXAN6&)! K0LC8.YVE$@\>;K&98O /=3('/41@K M/;IM5T2_3Z""LB_1;.%](Z2F&J(%MPJ8;TJ$CR"9H74]=WXXB9Z&\33(Y%FW MT?OX&'9H?4]9ZH345A\/ QYED@\6XB?>Q"?W>6QLR/[%Y@F2; MX+=,D^)](O+\[9#_JI29 NSIH\C"M E&[-=QS835$J+9)_%['/MR"N@ZFG9T M[X !0.OI?.B;V) EE@CBQ!>K$Z\9?;[O@E@A1]#YV&]*@\7 C""6<+$WET.F M5EZ&4?XK/DYQ21X:#K1VR-;XA)0,LD0Z]SU9)5I J[YN'1WV>X"$_<+[P2[$ MO=EV).);4@P.)9Z*3^(UTD94R.R6+Y4;6)J+U-9UKEH0/5VK&]>YGF:V%J2< MW*6KE1N]SA9*[5/9R/$#N%R%_2G['._5*!V5?W//-HUC22%AV[ MKL:2EH[9, W8.4RV$/)/<0HJTQ*5DP;$&"4>EC2 E,"HRSW43+.#20#A@W', MNMQ PNBP9/;>.7DB?K@632\SY0&0(:B?C)W7 1+*>L(?E"J66".?24 BUV< M3[P5#2B_9WDE,Y"3P.G8N1YM>&E$&4NX>>#<''R[L)_4G(1$M<0!,@_ZY2^.]J-H]TX MVHVCW7@,=N,W6L"&;0V.!6QC =M8P/;M%+!AQVWKCY$E2Q+=+]WBZO;0>FG.\C2*$@(,8:Y"@'Z@X@MS,U/,9?E3)LN! M2+/9ZR5[Z^7X,HP6A"*+<@,0V+Y."Z19RII1H >E9A@\1SO@TKHV5.E$UZB_ M/7ND ETID!!%C.>,K9P4NF%58*&3:]3$6RA]5FX28Q"/O_ZK+[8> MO1LEUPI3)A%6RKH9?(.I<+.%8-^(E!^+TF.@^^/7V]E"L)[, LMR3\Z6G*SQ M-"AUJ.+A!&7.R8_MF&MB;:Y)=[5^=2MO:#VP>HNB6"FVL'Y9@VWKH*2FP M+5&_Y>A&W23,.@'02*P0]QBD@W\:.Y9AY1$)9MDHWJAZJ8%!WEO;0BL%N)%2 M8X!N0Y]2!Y:^A;;A4]BA,RM%5LJ246"/L=MA;T$ *X6[?6?$HW8@2+.R&TW5 MG@2_2R"PHP,XPM\]&X<2$M-A7B"'+<.&<& WZ+-3C%LQB= *Y653GA])'(_%+W;P!/27^]"*Z79@("CO=EDC>/(/1@ J-0/+.)R6/X= MC\P_Z&GV8'Q2R-[4>*^1_T,# ]T+ W2&X_"UIX=(#X_1A1C<(*X<'CQPH ([ M$% ^^VB39W1@D WH,XY/6]MO"V%O:?P/==M;]:P!L4:-B"5-<;= %AX#WL=3U]Q6/2I[>@'H]Q0_J'_Y_CDT)'QI M!GH-T-Z$KZ%_.,*S\:8ROS,'O1A@?^+727 P\E^&:61(_?(4]&3UO8E?)X#5 M;O*L9'22)LLPXH]W?V56<53IF1'7L;P*GTF4_4175&&E]?O587>8[I;VQRAF M7]=K!#&K?15;$<*1,PGQCU'.L@*W'4=>[D,[D,BI ,#6!G&D3\\2FP2QYCYO MB74=V[XRWQ Q*X,-Q-D&RCV#0OZSI13\D@#3J)3ERTW-X__84&);4Q:*O(P MYMHD]UU?:_4@X8$UC28 L*UO7$U#SA*;!+&K/5K'UC)-8Q\ L6Q/^=F9? M!1N ;QYM*^->>70,K6';IE&KB/1;R-A&?9J\WC+V]9#V;O)Q[,"!7=GOYFRS M21_M&N-S^D0]IE$@B.GNIX^S0_*A6':,(LI3VRXCPM/Y"1.&Y( BVOQI[!"8 M_2*J8AF^-706^DQNPJQMT23PKIBQ%L2\7.*1P2R(E5L;UVX4B?R;9K/GEZK9 ML[.R*(38K.UL%]\8,\YF?52SYC1E )(X9HQ_H(& '6"TJ&=9D20_R'H&"#?& M:@7;4N)MKE;@28.S1>DH5Y)8X:0QBOV4,IR3)^*'ZVQ_\PN=,&#NTO7:?]U%?J$_NDC @=R2Y#*-D.0WNEZ2 "<0ZLR6PS=<. MF->&9GUUPB+S,/ V !GQ#3@7.PVL X894:D?#T$<):4+D/VK>OFQ7VW5P3L& MH!O14**'L+&2H79<8&H=1 Y]:>\?G/0Y(%^#>$WF=$&))ZV$Y C(AR.S0$[= M.A?D2/2C)ST7(G)_(?'\.F-1V@F MV^P'07!!;/://Z[(H^M?! E-7B6G"!M5&S2$\Z,)[I)'\1#$S3XM/2#8D-T1 MR&1MHEB-IKL0]WX 7%V=0<^ TE T[;%&(.7.KR%G2=CAEID=04HN&5I%3MGO M-%F>I7$2KDAT\3+W4]$6)XX)^S_OWGV16]>M%AM*"> >E.I)U;],188VUV)C MKL7F(0;)]I&.QC:>]1Q0@M^[,2P^-V$X, '@GSPG\3RB(FJCL'^5L[!-7AC) M@. V63; MXGP95/K(7G6<%2&D0<;RFBD^1N^L,;;&Z)U]S!BC=V/TKE.]]YH\BX,8%C>0 MCCZ"2(&&$I8HOP+$[<-RY^S,4!0#-(\>BB&NPK6O-EENY+_R[/T\NVBV$$"H M#6[=I&'8W3#4+=D&=V2>1MPE1]9AK&PW5!UHOT4N@[Q7P;\F2<[IG.\E2;@D M3<9%=F9J9MEO;8/0Z)7TOS,N,[5A,5MLJGYO>>7D;/$UYHG#1';N0"9B7\PP M!L!)T#L/!/^OJ/L@2ERTE*\.M[^-B!I^JT[YSTP4KL(XG@7U>TE^Y*MG 1G4 MV]-2X/,?@KPE?,KTYL"[Y83T>0U.H&*09/A@>IHHT;6&)7$<1K,UX;IS\"A M5L0!+:XTT_NYDOBI3[)]W@N5\HG27Y\*_&NGSC%:KQ)@/BE M4RQH1[^ T>$^.MQ'A[N2!5?V.=RG 3NUR!9"_BE.0:7;73EI0(Q1XF&)"UX" MH^YI#\TT.Y@$$#X8QSK*=.O*RB$!4U%\IE!./*;G4WX^\WAX?E_K8B7 Z=A. M2)!@5DT@$\I8HGCOZIN\WES.NJ:Q0W'.R_&TA!%WRS!*N.D,8$336.P-8]#& M38:H)9SXS8THOU8!C&@8.AB'O11-2]@ (+\YV?'SY%3D-NNWE82)Z^.^7UIS M!9RY\?+2#Y^GP2*,5N56)O?A3AI>LW_@'<@_P#_B\*\XI<\X^7><)*SF[(V. M@[V4 O%?F3Y4#K$J+"CH?&3E >1A,*,%OG=.M-Y 5;X! M,+/#0S>]F>F\<*4AZ(X#L+15O:55-"TQ7&_$2Y_DQG?GZA3E?()L/'IN3EO& MJ E@"9?&6HP^.YD8LV.LQ1A<+4:>\4M)?)-&\V6Y%D'=- 4R$?M6ZJ:7$Y ^ M/66)UCZKY(IT-/8]U $K-)3HB?Z3^R]*BI?^COT(3PMHVX6*)*;4YO3*_,']T( S$3:)VYZFG M#>%DAF%2*EK"9%,%.)TG3S+<,K:H1*[")0E"_1A'-Q'AG:&(][M0I#2JMV0P M=C6<4F)V]&LEMI8<4^*)$VYGJX^ERC#+Y%UU#%4@+]EE5C\@%,N>H]GB$WC\ M&4_NA=3&'WKYFAU"T"C IF__M,*_GS-RLA)Y#:(T+4[$>T(E73-!FG-2/RKVC\$2V%8C>$,9D\42=I[Y M;AS/%KD(SB+1^V5S_VZB?F>N[Q/O]/7"G2]WQRHNMOV7Q@[7P:^]KLAHLUA< MO# IIC$1-\;FCW'^UUC1#*_E**^I/-E5]8D9<=@ M1/^US?-7JKWU28/I1P- O35[GTCT$%K!X)*V>!8&,?5(E)=#S0E](M[,V&Z% M+#.8;C>MR&/)07\3A7-"O)CWN^>&MAO,R31@EY7KWZ0//IW/%DQD:? H9ZO! M$MBI(6"6&I/%QF*ID[MTM7*CUUPVFPJI-N#OU$]]@-=/L;]E'^'%C.5AU0*K ML:RJ;21Z+*M"(WWMF!C+JL9<#-MR,;!+K,9=13C>FU+O4FP9G[IHFKJ\M MRU%/PXX^F' (1 %+N'7+#8F >!=NQ+N4:ZNG9..Q8PHF_%'C; ECZM:E2CFK MCQU,AH(4S]8^OC6):,CN*C=*;/#S"1?F+$WBQ!4O@6IRTW:'8JL)!EW;)&@> M"QNYG&99,^>^2 M\X 5L;6@?5D/)MHQQ'<4TG]-GL5?6AX/I>G8>E)\OEBM M_?"5D"RU-4^GY)4%[:XOQ7+#24_8AUQVLSP33RD2;>\[U8*#26'8DV1'H-9> MDR1O;ZNT<2K#P&X,= XWXG<$?-O/G_C'>S@/+?!%-<+?B3OJ(O!L8.8>/D43 M5EK@0VH"OR=.'CBW[-*ED= 72NWQ-[\3C\3R3DO%6Z:4Q%^(RU/'O!E/@DPC M?OV\W:!*DK^[+7-A)U^KKY\3\IB1@5EJ]7 MY(GXZC0VZ/P!L0N*DB6);1L8\[M$=#*H ZY+>#-^749@^+N_(.A'GQ?US>+\, MT]@-O/MG!M;K99A&REYD1BM@:SN':D+6@JP]==/)(9FL(^K7H+BC+Q#>:B>C M)WPC<]9MC'3\>/-;A?+\#UAC[&&,?8^QCC'V, MOH#N? '8 8O1%S#Z D9?P+?L"SB(Y=A?JM516([?8@M.].2[KCIP6F2!GBVY MV,?38//'#0HEXT^94?<3V,K,/^;0H#R&_2'_XHZ].>;/C3;D:$..-N1AV#!V M?QN[OQV8+>C=W]25J!OWNU++EPW&-L[ +_&IL1T#/(,(\%C8&H?9B(4I("F+ MW>TB6!JONG?V71E[7YK5K'5 Q)YV<-^-$Q KS6QMG-"U23?Q_I[F+^@L]%M/ M,PT[#12\KT#H#^':,ZC;1.SV T"BD[O/I'HS_PO_KP&UL4$L! A0#% @ .8#.4D6DJ75>)@ Z9T" !4 M ( !8=8 &%D>',M,C R,3 T,S!?9&5F+GAM;%!+ 0(4 Q0 ( #F SE)% M902(.5, %+U! 5 " ?+\ !A9'AS+3(P,C$P-#,P7VQA M8BYX;6Q02P$"% ,4 " Y@,Y2ISXQH?@[ !K,P0 %0 M@ %>4 $ 861X&UL4$L%!@ & 8 B@$ (F, $ 0 $! end